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Over the last decades the importance of proteins in their application as therapeutics 
increased significantly. Especially, their benefit for the treatment of serious diseases 
such as cancer, auto immune diseases (e.g. multiple sclerosis), cardiovascular and 
metabolic diseases was discovered [1]. 
The developed protein therapeutics are potent and highly specific biomacromolecules 
with a molecular weight of more than 5 kDa or consisting of more than 50 amino acids 
[2]. In contrast to other drugs, proteins consist of complex and sensitive three-
dimensional structures of polypeptides (primary structure). These polypeptides are 
arranged in secondary, tertiary and sometimes quaternary structure.  
The secondary structure of a protein describes the arrangement and folding of the 
polypeptide. Due to this folding, the energetic level of the structure is reduced [3]. 
Drawn by forces, such as hydrogen bonding, electrostatic forces or van der Waals 
forces, the peptide strands form α-helices, ß-sheets, hinges, turns, and loops [3]. α-
Helices are right hand side coils stabilized by hydrogen bonding. For schematic 
drawing, see exemplarily the green coils in the tertiary structure of lysozyme (Figure 
1.1). ß-Sheets consist of extended, zigzag ß-strands associated by hydrogen bonding [4]. 
In Figure 1.1 the ß-strand domains are shown as blue arrows with the tip representing 
the C-terminal end. The different structural domains of α-helices and ß-sheets are 
connected via so called loops or shorter turns, respectively [4]. Turns, as shown 
schematically in magenta, purple and red in Figure 1.1, are 180° turns of different 
length [4]. 3-turns consist of three amino acid residues, 4-turns of four and so on. 
Within a turn, the carbonyl residue of the first amino acid is connected via hydrogen 
bonding with the amino group of the last one [4].  
The tertiary structure is the three-dimensional arrangement of secondary structure 
segments as shown exemplarily for lysozyme in Figure 1.1. These arrangements are 
stabilized by disulfide bridges (Figure 1.1), isopeptide bonds, hydrophobic interactions, 
hydrogen bonding, electrostatic interactions or van der Waals forces [3].  
In some proteins the tertiary structures aggregate to more complex structures or 
multimers called quaternary structure [3]. These structures are primarily stabilized by 
hydrophobic interactions [3].  
1.1 Challenges in Protein Formulations 
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This complex three-dimensional structure described above makes proteins more 
susceptible for instabilities than other common, small-molecule drugs.  
The tertiary structure forms the active site of a protein, which is essential for its activity 
and efficacy [3]. For this reason, the complex structure of proteins is closely related to 
their therapeutic effect, which makes formulation development very tricky [1, 7]. The 
activity of the protein drug at the site of action is the most important factor for an 
effective treatment. Furthermore, well-defined activity of the final formulation is 
desirable [8]. Damage to the fragile protein structures such as degradation, structural 
breakdown or aggregation is associated with loss of activity and immune reactions [1]. 
So, the challenge of protein formulations is to prevent degradation during the whole 
process of preparation, sterilization and subsequent release in order to maintain protein 
activity [2, 9].  
Aggregation is one of the most frequent complications, when working with proteins 
[10]. It has to be differentiated between physical and chemical (covalent) aggregation 
Figure 1.1: Tertiary structure of lysozyme. The shown structure model was created 
using the CCP4 Molecular Graphics software [5]. Structural information used to 
create this model is based on results from Diamond (PDB ID: 2 LYZ) [6]. 
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[10]. While physical aggregation is mostly reversible, chemical aggregation is 
irreversible in most of the cases. 
Aggregates can lead to B-cell activation and recruitment of T-cells [11]. This results in 
formation of antibodies and consequently product inactivation [11, 12]. Additionally, 
aggregates containing degraded epitopes can cause anaphylactic reactions [11]. In any 
case, the appearance of aggregates inhibits the release of the developed formulation to 
the market [10].  
Another important issue for every agent, but especially for biomacromolecular agents is 
to make it available at the desired target. The application of biomacromolecules can be 
performed via invasive (e.g. parenteral or subcutaneous injections, implants etc.) or 
non-invasive (e.g. oral, nasal, pulmonary, etc.) routes [2]. However, each route involves 
its own specific difficulties: the large size of the biomacromolecules leads to low 
transdermal availability and hampers crossing other anatomical barriers such as the 
blood brain barrier [1, 3]; oral availability is poor due to low absorption in the 
gastrointestinal tract [1, 13]; in addition, protein degradation by proteolytic enzymes in 
the gastrointestinal tract, the eye and the nasal mucosa hampers these ways of 
application [1]. So the right choice of the application route is very important for the 
success of the formulation.  
A further challenge is the stability of proteins inside the body after application. Many 
proteins show a very short half-life of few minutes to maximal hours [14]. Glucagon for 
the treatment of hypoglycemia, for example, has a half-life of less than 10 min [14]. For 
antibodies longer residence times in the body were observed [14]; cetuximab has a half-
life of 2.9 d, bevacizumab of 9.7 d (in cynomolgus monkeys) [14]. However, despite the 
longer half-life of antibodies periodic application is required to ensure the therapeutic 
benefit. Ranibizumab (anti-VEGF Fab) for the treatment of age-related macular 
degeneration, for example, needs to be injected intravitreous monthly [9]. However, 
intravitreous injections are associated with the risk of hemorrhages, retinal detachment, 
cataract or endophthalmy [9]. Furthermore, they can be painful and traumatic at the 
injection site [9]. 
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As described above, the challenge is to make a protein available at the desired target site 
and to retain its structure during formulation and subsequent delivery in order to obtain 
the best therapeutic benefit.  
One possibility to improve availability is the application of depot formulations directly 
to the site of action. Implants or in-situ gelling systems are very promising tools to 
increase the efficiency of protein drugs. The controlled release directly at the target 
tissue ensures the availability over a longer period of time, while the depot matrix 
protects the sensitive protein against degradation and denaturation.  
Furthermore, the controlled delivery prevents dose-dependent side reactions. Protein 
therapeutics are generally considered as highly specific and well tolerable [15]. 
However, like for other drugs the side effects of proteins are dose-dependent [9]. For a 
safe application of proteins, formulations for controlled delivery are a good strategy to 
prevent dose-dependent side effects [9]. In addition, the sustained release improves 
patient compliance and reduces the risk of traumas and infections during application due 
to reduced application frequency. The delivery system should ideally be injectable and 
biodegradable [9]. 
However, especially for depot formulations, the compatibility of drug and the used 
matrices and solvents is important due to the long contact time of the components. Of 
course internal factors such as primary and secondary structure of the protein influence 
the tendency towards instabilities such as aggregation [10]. These factors depend on the 
protein drug itself and could not be tailored by the formulation. However, some of the 
described issues of protein therapeutics such as aggregation, instability and inactivity 
are associated with the formulation and formulation conditions. Incompatibility between 
protein and polymer, for example may result in stability problems during storage and 
release [1]. Especially in depot formulations, protein stability may be affected by the 
long time exposure to physiological temperature, the used polymer matrix and its 
degradation products [16]. Additionally, mechanical forces even via simple shaking can 
induce aggregation [7]. Due to increased air/water interfaces caused by shaking, the 
exposure of hydrophobic residues to the air is increased leading to higher risk towards 
aggregation [10]. Further important factors influencing the tendency towards 
aggregation are the temperature, the pH of the formulation, protein concentration, 
solvents and additives [7, 10]. The temperature during formulation preparation is an 
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important factor to maintain protein integrity. Higher temperatures increase the risk of 
aggregation [7, 10]. Above 40 °C the tendency towards the formation of so called fibrils 
is increased. Therefore, low temperatures are more appropriate also during storage [7]. 
In contrast to high-temperature, denaturation at low temperature is reversible in most of 
the cases [7].  
Also the pH of a formulation is of great importance to retain protein stability and 
activity. Deamidation (hydrolysis of aspargine or glutamine), for example, is catalyzed 
by acidic as well as basic pH values [17]. Outside the optimal pH range proteins tend to 
aggregation and denaturation [18]. High charge density within the protein, caused by 
pH values different from the isoelectric point (pI) of the protein, lead to unfolding due 
to charge repulsion [18]. Furthermore, electrostatic interactions within the tertiary 
protein structure can be affected by changing charges [18]. On the other hand, the 
availability of both charges at pH values near to the pI may lead to protein assembling 
in form of aggregates [18]. Low pH values may lead to hydrolytic protein degradation 
and formation of aggregates [1]. Especially pH values below 3 or above 10 induce the 
formation of so called fibrils [7]. Degradation of PLGA for example lowers the pH of 
the microenvironment which may result in protein denaturation [1]. Zhu et al. described 
peptide hydrolysis and non-covalent aggregation of BSA encapsulated in PLGA 
implants [19]. Here, a pH < 3 during degradation of PLGA triggered the unfolding of 
BSA resulting in site effects [19]. In contrast, the addition of a strong base (Ca(OH)2) 
resulted in covalent aggregation of BSA via disulfide bonds [19]. Due to the basic pH, 
the cysteine residues formed free thiolates which is a precondition for the formation of 
disulfides [19]. However, not only the pH itself, also the type and concentration of the 
used buffer influence the tendency towards aggregation [10]. On the other hand, the 
protein itself and its buffer capacity may influence the pH of the formulation. Van de 
Weert et al., for example, observed some buffering effect of BSA and lactalbumin in 
contrast to lysozyme [20]. The slightly lower pH of lysozyme and the catalyzing effect 
of the amine residues triggered faster degradation of the used polymer, resulting in 
accelerated protein release [20]. Furthermore, hydrophobic, organic solvents (e.g. 
methylene chloride, dimethyl sulfoxide etc.) induce the exposure of hydrophobic amino 
groups, normally buried inside the protein, leading to destroyed protein structure and 
increased tendency towards aggregation. For this reason, solvent-free formulation 
preparation in water should be preferred. The approved product Eligard™ is a depot 
formulation of the LHRH agonist leuprolide acetate in PLGA and N-methyl-2-
1.1 Challenges in Protein Formulations 
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pyrrolidone [21]. After injection a gel-like precipitation of the polymer is formed by 
phase separation due to penetration of water in the organic N-methyl-2-pyrrolidone 
phase [21]. Eligard™ needs to be injected within 30 min after mixing to prevent protein 
denaturation caused by the organic solvent [21].  
Similar stability problems may also be triggered by hydrophobic polymers such as 
PLGA itself [12]. Electrostatic and hydrophobic interactions of PLGA and incorporated 
proteins result in incomplete protein release [22]. Furthermore, reactions between the 
protein and the used polymer can result in loss of activity and undesired immune 
response. For example incorporation of proteins in PLGA microparticles can lead to 
amide bonds between primary protein amines and carboxyl groups of the degrading 
polymer [22]. Lucke et al. described the acylation of atrial natriuretic peptide and 
salmon calcitonin by lactic and glycolic acid units during the degradation of PLA and 
PLGA microspheres. The described protein acylation may result in loss of activity or 
changed receptor specificity [23]. With regard to the matrix, side reactions of the 
protein with functional groups of the used polymer should be kept in mind. The 
formation of disulfide bonds between thiol groups of the protein and thiol groups of the 
used polymer are one example for unwanted side reactions during cross-linking of 
hydrogels. The formation of disulfides can result in aggregates and should be prevented 
for thiol-functionalized polymers [24]. The tendency towards these reactions depends 
on the polymer and the protein. Qiu et al. for example did not observe any side reactions 
with BSA and EPO during cross-linking of the poly(ethylene glycol)(PEG)-based thiol-
containing copolymer and a divinylsulfone-derivative [24]. In contrast, Hiemstra et al. 
reported side reactions of the amino or thiol groups of IgG, BSA, and lysozyme with the 
functional groups of tetrafunctional mercapto-PEG or dextran vinyl sulfone during 
cross-linking [25]. These side reactions resulted in denaturation, aggregation and 
subsequent precipitation of the proteins incorporated in the analyzed hydrogels [25]. 
In addition, protein modifications can impact the biological efficacy [7]. Protein 
modification with PEG (PEGylation) is a popular method to enhance the stability and 
half live of proteins [26]. However, PEGylation may also result in loss of activity 
depending on the number of attached polymer chains and the binding sites [26]. In the 
study of Maiser et al., lysozyme PEGylated at lysine 33 showed 35 % activity, while 
PEGylation at lysine residue 1 resulted in 24 % activity [26]. The number of attached 
PEG chains and the binding sites highly depends on the PEGylation conditions (e.g. pH, 
PEG excess, etc.) [26]. For that reason, batch-to-batch variations regarding the degree 
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and site of PEGyaltion and subsequently the activity of PEG-asparaginase (Oncospar® 
from Enzon) led to recalls in the past [26]. 
 
Compared to other drugs proteins have a complex and sensitive structure as described 
above. This requires a special careful handling to prevent degradation, to retain protein 
activity and to ensure drug availability at the target site. Consequently, the development 
of protein formulations is very challenging. Many factors such as instabilities, side 
effects, availability and loss of activity may hamper the successful realization. The most 
serious issue is the formation of aggregates, which finally stops market release of the 
formulation.  
Depot formulations applied at the site of action are a promising strategy to overcome 
these issues. In-situ gelling hydrogels, for example, may improve bioavailability by 
application at the target site und protect the sensitive structure against degradation and 
denaturation. However, also the formulation itself and the formulation conditions may 
affect protein stability. Solvent free manufacturing, the use of compatible polymers, 
moderate temperatures and optimized pH values are important to maintain protein 
integrity and activity. 
In the following chapters, suitable hydrogels as depot formulations for controlled 
protein delivery were developed and investigated. A special focus was set on the 
conservation of protein integrity and activity during hydrogel formulation and 
subsequent protein delivery. Additionally, the formation of side products between cross-
linking agents and proteins was examined in order to prevent side effects and loss of 
efficacy. 
 
The goal of the thesis was to develop hydrogels as depot formulations for the controlled 
delivery of protein drugs at the target site. 
To investigate release profiles, protein compatibility and side reactions a commercial 
available model protein was used. Due to its well characterized structure and properties, 
lysozyme is ideally suited as model drug. A further advantage of lysozyme is the 
established and well known activity assay to verify integrity and lytic activity after 
protein release.  
1.2 Goals of the Thesis 
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Due to its advantages in handling and application, poly(ethylene) glycol (PEG) was 
chosen as polymeric backbone of the developed formulations. PEG is an approved 
polymer for parenteral applications. Hydrogel preparation occurs without organic 
solvents in water preventing incompatibilities at the application site and with 
incorporated proteins. End-group functionalization can be performed with simple 
procedures under moderate conditions. PEGs of different chain length and branching are 
commercially available enabling the variation of mesh size and further hydrogel 
properties.  
 To match the goal of controlled delivery, two different strategies to tailor release 
kinetics were investigated. Firstly, release kinetics was regulated by reversible covalent 
attachment of the protein to the hydrogel backbone via hydrolytically cleavable linkers. 
Secondly, release was controlled by the interplay of protein size and hydrogel mesh 
size. For both cases, a special focus was set on protein integrity and activity after 
release.  
To realize controlled release via cleavable linkers, the protein was tethered to the 
hydrogel backbone via carbamate linkers with different cleaving kinetics. For this 
purpose, lysozyme was first PEGylated with the linker. Statistically one arm of the four-
armed PEG was modified with the linker group, while the remaining arms were 
functionalized with an alkyne group. Via copper-catalyzed click reactions of the alkyne 
group with azide functionalized four-armed PEG the protein was reversibly 
incorporated into the hydrogel during cross-linking.  
 In Chapter 2, the synthesis of the gel precursors and the used linkers is described in 
detail. Furthermore, Chapter 2 reports on the influence of the protein and linker 
incorporation on the gel characteristics (gel stiffness, swelling and gelation time). In 
addition, the suitability of these click hydrogels as model systems to investigate protein 
release is discussed. 
Carbamate linkers are hydrolytically cleavable making cleavage and subsequent protein 
release independent of special conditions of the surrounding tissues such as the presence 
of enzymes for example. Furthermore, cleavage occurs without the formation of toxic 
leaving groups or remaining ‘tags’ at the released protein indicating good tolerability of 
these formulations. The kinetics of linker hydrolysis and subsequent protein release can 
be controlled by the substitution pattern of the aromatic linker group. The influence of 
three different substitution patterns on cleaving kinetics was investigated in Chapter 3. 
For this purpose, firstly, PEGylation and De-PEGylation of protein amino groups was 
Chapter 1 
10 
analyzed by Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) 
using linear methoxy-PEG. A special focus was set on protein integrity and activity 
after PEGylation and PEG chain elimination. To this end, effects on protein secondary 
structure were determined by CD spectroscopy (circular dichroism spectroscopy) and an 
activity assay was performed. The influence of the different linkers on subsequent 
protein release was investigated using the non-degradable click-hydrogels described 
above. 
SDS-PAGE is an excellent method to investigate PEGylation and follow PEG chain 
elimination. However, the experimental procedure is time consuming and requires toxic 
acrylamide for gel preparation. Furthermore, sample preparation including freezing in 
order to stop elimination and thawing before starting the experiments might negatively 
affect the protein samples. To overcome these drawbacks a non-toxic, automated real-
time measurement was realized using a SEC (size exclusion chromatography) method to 
investigate PEGylation and PEG chain elimination (Chapter 4).   
Another possibility to control protein release is by adjusting the hydrogel mesh size and 
its degradation. After cross-linking the protein is trapped in the hydrogel network due to 
its large hydrodynamic diameter. During hydrogel swelling and degradation the mesh 
size increases resulting in increasing protein mobility and subsequent controlled protein 
release. Using this strategy the incorporated drug should remain unaffected during 
cross-linking increasing the chance of protein integrity during formulation and 
subsequent release. Different delivery systems based on this mechanism have already 
been developed. Michael addition, Diels-Alder reactions or radical polymerization are 
common cross-linking reactions to prepare those hydrogels. A critical factor for 
successful application of such delivery systems is once more the compatibility with the 
incorporated protein. For that purpose, side reactions between frequently used cross-
linking agents and lysozyme were analyzed using SDS-PAGE (Chapter 5). 
A specially promising strategy is cross-linking via Dials-Alder reactions. Hydrogel 
preparation occurs without catalyst or initiator making the reaction excellently suitable 
for in-situ gelation at the target site. Furthermore, due to the retro-Diels-Alder reaction 
the hydrogels are biodegradable enabling degradation controlled release. The suitability 
of Diels-Alder hydrogels for controlled release was investigated in Chapter 6. Two 
further model proteins, α-CT (α-Chymotrypsin) and γ-globulin were used besides 
lysozyme to determine protein mobility inside the prepared hydrogels by FRAP 
1.2 Goals of the Thesis 
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(fluorescence recovery after photobleaching) and to study release profiles. A special 
focus was again set on possible side reactions and protein activity. 
 
 
  
 
 
 
  
 
   
  13 
 
 
 
 
  
Chapter 2 
14 
Hydrolytically cleavable carbamte linkers were integrated in the hydrogel network using 
DCC/NHS chemistry of branched poly(ethylene glycol) (PEG) amine. Statistically one 
arm was modified with the linker group (5a, 5b, 5c) by choosing the adequate molar 
ratio. The other arms were functionalized with an alkyne group in a similar way for 
cross-linking with 4armPEG-azide. The incorporation of linker groups resulted in 
defects in the hydrogel network. The influence of the linker group and the resulting 
network defects on gel stiffness, hydrogel swelling, and gelation time was investigated 
in this chapter to evaluate the suitability of the used hydrogels as model systems to 
analyze protein release. The complex shear modulus was significantly lower compared 
to the reference gels (without linker groups, without lysozyme (Ctrl): 7908 ± 634 Pa / 
without linker, with lysozyme (w/o): 7923 ± 506 Pa) due to defects in the network 
structure caused by the linker groups (5a: 3564 ± 57 Pa / 5b: 2897 ± 174 Pa / 
5c: 4325 ± 114 Pa). The extent of swelling increased to 152 ± 3.0 % (Mt/M0) (5b) with 
decreasing cross-linking density due to the network defects. Gelation of all tested gels 
occurred after a few minutes (Ctrl.: 19.4 ± 0.5 min / w/o: 19.1 ± 0.1 min / 5a: 15.9 ± 
0.4 min / 5b: 15.5 ± 0.4 min / 5c: 15.1 ± 0.1 min). 
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Different ways to control the release of incorporated proteins have been reported since 
hydrogels were investigated as suitable carriers for protein delivery. The reversible 
covalent attachment of proteins to the hydrogel backbone is a promising strategy to 
control protein release. For this purpose, the protein is PEGylated by the linker in the 
first step (Figure 2.1 Illus. 1). Afterwards, the linker with the attached protein is 
incorporated in the hydrogel network during cross-linking (Figure 2.1 Illus. 2). This 
allows controlling protein release by the cleavage kinetics of the used linker (Figure 2.1 
Illus. 3). In order to achieve this goal, three poly(ethylene glycol) (PEG) based carbamte 
linkers with different rates of hydrolysis were developed.  
 
Figure 2.1: Reversible covalent protein attachment to the hydrogel network. Published 
as graphical abstract in Hammer, Nadine; Brandl, Ferdinand P.; Kirchhof, Susanne; 
Goepferich, Achim M, Cleavable carbamate linkers for controlled protein delivery 
from hydrogels, Journal of Controlled Release (2014) 183, S. 67–76. 
To investigate the incorporation of linker groups and proteins in the hydrogel matrix, a 
model hydrogel was developed. For this model hydrogel, cross-linking via a copper-
catalyzed click reaction was chosen. Copper-catalyzed click chemistry is highly 
specific, which is essential to prevent side reactions with incorporated proteins [27, 28]. 
Cross-linking occurs fast without the formation of side products, which is important for 
sample preparation of model hydrogels. The gelation time should be fast enough to 
allow timesaving sample preparation and slow enough for accurate handling. 
Furthermore, using PEG as backbone, these hydrogels are non-biodegradable, which 
allows studying protein release without the influence of hydrogel degradation.  
Further hydrogel properties, such as swelling and hydrogel stiffness, play an important 
role for the suitability of a hydrogel as model system to study protein release. The 
hydrogel stiffness is closely associated with the cross-linking density [29], which has a 
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great impact on protein mobility within the hydrogel and consequently protein release 
[12]. Furthermore, the cross-linking density affects the swelling capacity, which 
influences the release kinetics due to the increased water content and enlarged pore size 
[30]. An ideal model system should show a similar degree of swelling for all samples, 
because increasing the degree of swelling, increases the diffusion coefficient resulting in 
enhanced protein mobility [31]. In addition, swelling lowers the mechanical strength of 
a hydrogel [32]. The mechanical stiffness is important for handling the gels during the 
experiments.  
In this chapter, the synthesis of linkers and hydrogel precursors is described. 
Furthermore, this chapter focuses on the characterization of click hydrogel preparations 
containing cleavable carbamate linkers and its suitability as model systems. For this 
purpose, the influence of linkers on gelation time and gel stiffness of the hydrogels was 
determined by rheological measurements and the swelling behavior in the presence of 
linkers and attached protein was investigated. Protein PEGylation, cleaving kinetics of 
the linkers and the resulting protein release from hydrogels is discussed in detail in the 
next chapter (Chap. 3). 
 
 
3-Hydroxybenzoic acid, 3-(4-hydroxyphenyl)propionic acid, phthalimide and toluene 
were purchased from Acros Organics (Geel, Belgium). Deuterated Chloroform (CDCl3)  
was obtained from Deutero GmbH (Kastellaun, Germany). Dulbecco’s phosphate-
buffered saline (DPBS) was purchased from Invitrogen GmbH (Karlsruhe, Germany). 
Four-armed poly(ethylene glycol) (molecular weight 10 kDa, 4armPEG10k-OH) was 
purchased from JenKem Technology (Allen, TX, USA). Acetonitril, N,N’-
dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS), diisopropyl 
azodicarboxylate (DIAD), N,N’-discuccinimidyl carbonate (DSC), fluorescamine, 4-
hydroxybenzoic acid, lysozyme (from chicken egg white), magnesium sulfate, sodium 
tetraborate decahydrate, 4-pentynoic acid, and tetrahydrofuran were obtained from 
Sigma-Aldrich (Taufkirchen, Germany). Acetone, methylene chloride (DCM), diethyl 
ether and ethanol were purchased from CSC Jäcklechemie (Nürnberg, Germany). All 
other chemicals were from Merck KGaA (Darmstadt, Germany). Deionized water was 
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prepared freshly every day using a Milli-Q water purification system from Millipore 
(Schwalbach, Germany). 
 
1H-NMR measurements were performed on a Bruker Avance 300 spectrometer (Bruker 
BioSpin GmbH, Rheinstetten, Germany). All spectra were recorded in CDCl3 at room 
temperature. The polymer concentration was about 30 mg/mL.  
 
For the determination of free amino groups, a fluorescamine stock solution (0.3 mg/mL) 
was prepared in acetone [33]. The sample (0.2 µmol/mL) was dissolved in 50 mM 
borate buffer pH 8.5 and mixed with 1300 µL of borate buffer and 100 µL of the 
fluorescamine stock solution. The fluorescence intensity (λex = 390 nm, λem =  480 nm) 
was measured on a PerkinElmer LS 55 Fluorescence spectrometer (Perkin-Elmer, 
Wiesbaden, Germany). The number of free amino groups was calculated using a 
calibration curve prepared with 4armPEG10k-amine (compound 3). 
 
4armPEG10k-NH2 was synthesized according to a protocol published by Brandl et al. 
[34]. In brief, 12.5 g of 4armPEG10k-OH, 0.88 g of phthalimide (0.006 mmol) and 
1.57 g of triphenylphosphine (PPh3) (0.006 mmol) were dissolved in tetrahydrofuran. 
Then, 0.006 mmol of DIAD in 15 mL of Tetrahydrofuran were added dropwise. The 
mixture was stirred for 72 h at room temperature. Afterwards, the solvent was 
evaporated under reduced pressure. The residue was dissolved in 100 mL of water, 
filtered, and washed twice with 100 mL of diethylether. After evaporation of water, the 
raw product was dissolved in 25 mL of DCM and crystallized at 0 °C under addition of 
250 mL of diethylether. 4armPEG10k-phthalimide was collected by filtration and dried 
under vaccum to yield 10.7 g (81.8 %).  
1H-NMR (CDCl3, 300 MHz): δ 3.66 ppm (s, -OCH2CH2-), 7.74 ppm (d, 8H, Ar-H), 
7.84 ppm (d, 8H, Ar-H).  
Then, 10.7 g of 4armPEG10k-phthalimide were dissolved in 100 mL of ethanol. After 
addition of 1061 µL of hydrazine hydrate, the mixture was refluxed for 5 h at 85 °C. 
The reaction mixture was cooled to room temperature and the formed precipitate was 
filtered off. After adjusting the pH to 2 - 3, the solvent was evaporated. The residue was 
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dissolved in 50 mL of water and the pH was adjusted to 9 - 10. The raw product was 
extracted four times with DCM and the combined organic phases were dried over 
anhydrous MgSO4. The solvent was evaporated and the residue was taken up in 20 mL 
of DCM. The product was crystallized at 0 °C by addition of diethylether. The 
precipitate was dried under vacuum to yield 9.7 g (95.6 %).  
1H-NMR (CDCl3, 300 MHz): δ 2.93 ppm (t, 8H, –CH2NH2), 3.66 ppm (s, –OCH2- 
CH2–). 
 
4armPEG10k-pent-4-yne-amide was synthesized as already published [35]. In brief, 
0.24 g of 4-pentynoic acid (2.4 mmol), 0.28 g of NHS (2.4 mmol) and 0.50 g of DCC 
(2.4 mmol) were dissolved in 10 mL of 1,4-dioxane und stirred at room temperature for 
6 h. Afterwards, the precipitated dicyclohexylurea was filtered off and the filtrate was 
combined with a mixture of 4armPEG10k-NH2 (0.3 mmol) and NaHCO3 (2.4 mmol) in 
water. After stirring overnight at 50 °C, the solvent was evaporated under reduced 
pressure. The residue was taken up in water and the raw product was extracted four 
times with DCM. The organic phases were combined and dried over anhydrous MgSO4. 
The solution was concentrated and the product was crystallized by dropwise addition of 
diethylether at 0 °C. 4armPEG10k-pentyne was dried under vacuum to yield 2.8 g 
(90 %).  
1H-NMR (CDCl3, 300 MHz): δ 2.05 ppm (t, 4 H, HC≡C–), 2.44 ppm (t, 8 H, –C(O)- 
CH2CH2–), 2.55 ppm (t, 8 H, –C(O)CH2CH2–), 3.66 ppm (s, –OCH2CH2–). 
 
5a was synthesized as previously published [35]. In brief, 0.03 g of 4-hydroxybenzoic 
acid (0.2 mmol), 0.02 g of NHS (0.2 mmol), and 0.04 g of DCC (0.2 mmol) were 
dissolved in 7 mL of 1,4-dioxane. After stirring at room temperature for 6 h, the 
precipitated dicyclohexylurea was filtered off. The filtrate was combined with 2.0 g of 
4armPEG10k-NH2 (0.2 mmol) and 0.02 g of NaHCO3 (0.22 mmol) in 7 mL of water. 
The mixture was stirred overnight at 50 °C. The solvent was evaporated and the residue 
was taken up in 20 mL of water the next day. The raw product was extracted four times 
with DCM. The organic phases were combined and dried over anhydrous MgSO4. The 
solvent was evaporated to a volume of 5 mL and the product was crystallized at 0 °C by 
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dropwise addition of diethylether. The reaction intermediate of 5a was dried under 
vacuum to yield 1.81 g (90 %).  
1H-NMR (CDCl3, 300 MHz): δ 2.97 ppm (t, 6 H, –CH2-NH2), 3.66 ppm (s, –OCH2-
CH2–), 6.91 ppm (d, 2 H, –C6H4OH), 7.73 ppm (d, 2 H, –C6H4OH).  
The degree of end-group conversion was 30 % as calculated from the number of free 
amino groups. In a second step, the remaining amino groups were functionalized with 4 
pentynoic acid as described above to yield 1.62 g (77 %).  
1H-NMR (CDCl3, 300 MHz): δ 2.04 ppm (t, 3 H, HC≡C–), 2.44 ppm (t, 6 H, –C(O)-
CH2CH2–), 2.55 ppm (t, 6 H, –C(O)CH2CH2–), 3.66 ppm (s, –OCH2CH2–), 6.93 ppm 
(d, 2 H, –C6H4OH), 7.75 ppm (d, 2 H, –C6H4OH).  
The degree of end-group conversion was almost 100 %. In the last step, the phenolic 
hydroxyl group was activated. To this end, 1.6 g of the intermediate (0.15 mmol) and 
0.2 g of DSC (0.75 mmol) were dissolved in anhydrous acetonitrile. Then, 96 µL of 
pyridine (1.2 mmol) were added and the mixture was stirred at room temperature 
overnight. The next day, the solvent was evaporated and the residue was taken up in 
DCM. The raw product was filtrated and concentrated to 5 mL. Compound 5a was 
crystallized at 0 °C by addition of diethylether and dried under vacuum to yield 1.38 g 
(92 %).  
1H-NMR (CDCl3, 300 MHz): δ 2.05 ppm (t, 3 H, HC≡C–), 2.44 ppm (t, 6 H, –C(O)-
CH2CH2–), 2.55 ppm (t, 6 H, –C(O)CH2CH2–), 2.91 ppm (s, 4 H, –C(O)CH2CH2C(O)-), 
3.66 ppm (s, –OCH2CH2–), 6.92 ppm (d, 2 H, –C6H4OSu), 7.75 ppm (d, 2 H, –C6H4-
OSu). 
 
5b was synthesized in the same way as described for 5a using 3-hydroxybenzoic acid as 
phenolic compound. The first intermediate was synthesized in 90 % yield (1.81 g).  
1H-NMR (CDCl3, 300 MHz): δ 2.97 ppm (t, 6 H, –CH2-NH2), 3.66 ppm (s, –OCH2-
CH2–), 7.00 ppm (d, 1 H, –C6H4OH), 7.27 ppm (d, 1 H, –C6H4OH), 7.37 ppm (d, 1 H,  
–C6H4OH).  
The degree of end-group conversion was 32 %, as calculated from the number of free 
amino groups. In a second step, the remaining amino groups were modified as described 
for 5a. The yield was 1.52 g (72 %).  
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1H-NMR (CDCl3, 300MHz): δ 2.05 ppm (t, 3 H, HC≡C–), 2.44 ppm (t, 6 H, –C(O)CH2-
CH2–), 2.55 ppm (t, 6 H, –C(O)CH2CH2–), 3.66 ppm (s, –OCH2CH2–), 7.00 ppm (d, 
1 H, –C6H4OH), 7.31 ppm (d, 1 H, –C6H4OH), 7.39 ppm (d, 1 H, –C6H4OH).  
The end-group conversion was almost quantitative as determined by a fluram assay. The 
intermediate was activated by DSC in 86 % yield (1,29 g) as described above.  
1H-NMR (CDCl3, 300 MHz): δ 2.05 ppm (t, 3 H, HC≡C–), 2.44 ppm (t, 6 H, –C(O)-
CH2CH2–), 2.55 ppm (t, 6 H, –C(O)CH2CH2–), 2.91 ppm (s, 4 H, –C(O)CH2CH2- 
C(O)–), 3.66 ppm (m, –OCH2CH2–), 7.38 ppm (d, 1 H, –C6H4OSu), 7.52 ppm (d, 1 H, 
 –C6H4OSu), 7.79 ppm (d, 1 H, –C6H4OSu). 
 
5c was synthesized according to previously published protocols [35]. In brief, 0.12 g of 
4-pentynoic acid (1.2 mmol), 0.06 g of 3-(4-hydroxyphenyl)propionic acid (0.4 mmol), 
0.15 g of NHS (1.6 mmol) and 0.33 g of DCC (1.6 mmol) were dissolved in 7 mL of 
1,4-dioxane. After stirring for 6 h at room temperature, the precipitated 
dicyclohexylurea was filtered off. The filtrate was combined with 2 g of 4armPEG10-
NH2 (0.2 mmol) and 0.13 g of NaHCO3 dissolved in 7 mL water. The mixture was 
stirred overnight at 50 °C. Then, the solvent was evaporated and the residue was 
dissolved in water. After extraction with DCM (4x), the combined organic phases were 
dried over anhydrous MgSO4. The raw product was concentrated to 5 mL and 
crystallized at 0 °C by dropwise addition of diethylether. The intermediate was dried 
under vaccum to yield 1.52 g (73 %).  
1H-NMR (CDCl3, 300 MHz): δ 2.05 ppm (t, 3 H, HC≡C–), 2.43 ppm (t, 2 H, 
C(O)CH2CH2–),  2.46 ppm (t, 6 H, –C(O)CH2CH2–), 2.55 ppm (t, 6 H, –C(O)CH2- 
CH2–), 2.89 ppm (t, 2 H, –C(O)CH2CH2–), 3.66 ppm (s, –OCH2CH2–), 6.79  ppm (d, 
2 H, –C6H4OH), 7.06 ppm (d, 2 H, –C6H4OH).  
The degree of end-group conversion was 98 %, as determined by a fluram assay. The 
intermediate was activated using DSC to yield 1.13 g (77 %) as described above.  
1H-NMR (CDCl3, 300 MHz): δ 2.05 ppm (t, 3 H, HC≡C–), 2.44 ppm (t, 6 H, –C(O)-
CH2CH2–), 2.55 ppm (t, 6 H, –C(O)CH2CH2–), 2.86 ppm (s, 4 H, –C(O)CH2CH2- 
C(O)–), 2.89 ppm (t, 2 H, –C(O)CH2CH2–),  3.66 ppm (s, –OCH2CH2–), 6.79 ppm (d, 
2 H, –C6H4-OH), 7.06 ppm (d, 2 H, –C6H4OH). 
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Imidazole-1-sulfonyl azide hydrochloride was synthesized according to a method 
described by Goddard-Borger et al. [36]. As already published, 3.0 g of 4armPEG10k-
NH2 (0.3 mmol), 292 µL of triethylamine and 3.0 mg of copper(II) sulfate were 
dissolved in 10 mL of methanol [35]. 0.3 g of imidazole-1-sulfonyl azide (1.44 mmol) 
was added and the mixture was stirred overnight at room temperature. Then, the mixture 
was concentrated under reduced pressure and diluted with water. Afterwards the 
mixture was acidified with HCl. The raw product was extracted four times with DCM 
and the combined organic phases were dried over anhydrous MgSO4. The raw product 
was concentrated to 10 mL and crystallized at 0 °C by addition of diethylether. The 
product was dried under vacuum to yield 2.85 g (95 %).  
1H-NMR (CDCl3, 300 MHz): δ 3.66 ppm (s, –OCH2CH2–). 
 
Hydrogels with a total polymer content of 5 % were prepared as previously described 
[35]. For the control group (Ctrl) equal amounts of four-armed PEG functionalized with 
alkyne (compound 4 / 4armPEG10k-pentyne) and azido (compound 6 / 4armPEG10k-
azide) groups were dissolved in 25 mM phosphate buffer pH 7.4. In all other cases, a 
lysozyme stock solution (1.33 mg/mL) was prepared in 25 mM phosphate buffer pH 
7.4. For the group without linker (w/o) equal amounts of 4armPEG10k-pentyne (4) and 
4armPEG10k-azide (6) were dissolved in the lysozyme stock solution. For the samples 
containing linkers, lysozyme was first PEGylated. For this purpose, the linkers 5a, 5b or 
5c were incubated with the lysozyme stock solution for 1 h (5a and 5b) or 2 h (5c), 
respectively; the ratio of activated linker groups (SC) to protein amino groups (NH2) 
was 14 : 7. After PEGylation, the required amounts of 4armPEG10k-pentyne (4) and 
4armPEG10k-azide (6) were added to achieve a nearly balanced ratio of alkyne to azido 
groups. Cross-linking was induced by the addition of 0.5 μmol/mL of CuSO4 and 
2.5 μmol/mL of ascorbic acid in all cases. 
 
The rheological characterization was performed on a TA Instruments AR 2000 
rheometer (TA Instruments, Eschborn, Germany). A parallel plate geometry with 
40 mm diameter was used for all experiments. 
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Hydrogel precursors were prepared as described above (see Chap. 2.2.10). Directly after 
the addition of CuSO4 and ascorbic acid, 750 µL of the hydrogel precursor were poured 
on the bottom plate of the rheometer. The upper plate was lowered to a gap size of 
500 µm and the measurement was started. Storage modulus (Gʹ) and loss modulus (Gʹʹ) 
were recorded as a function of time at 25 °C for 2 h. An oscillatory shear stress with a 
constant frequency of 1 Hz was applied. A solvent trap was used to minimize water 
evaporation during the measurement. The cross-over point of loss and storage modulus 
was regarded as the gel point. The absolute value of the complex shear modulus (|G*|) 
served as a measure for the gel stiffness. All experiments were done in triplicate. The 
results are presented as mean ± standard deviation.  
 
For swelling studies, 750 µL of each hydrogel precursor (see Chap. 2.2.10) were cast 
into glass cylinders (10 mm diameter) and allowed to gel for 2 h at room temperature. 
Afterwards, each gel cylinder was incubated in 10 mL PBS at 37 °C. The gels were 
weighed before incubation (M0) and every 24 h (Mt) during swelling. The swelling ratio 
was calculated using the following equation:  
 Swelling ratio (%)=
Mt
M଴
 x 100 % (1) 
The swelling studies were done in triplicate and results are shown as mean ± standard 
deviations.  
 
The results of the rheological characterization were analyzed (p < 0.05) using one-way 
ANOVA followed by Tukey´s post-hoc test. The testing was performed using GraphPad 
Prism (Version 5.01, GraphPad Software Inc., La Jolla, CA).  
 
 
The idea behind this project was the reversible covalent attachment of proteins to the 
hydrogel backbone in order to control protein release. The reversibility was ensured by 
using aromatic succinimidyl carbonates (Table 2.1) forming hydrolytically cleavable 
carbamates with protein amino groups.  
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Table 2.1: Chemical structures of 4armPEG10k-pentyne (compound 4), 4-armPEG10k-
linkers (compound 5a, 5b, 5c), and 4armPEG10k-azide (compound 6). The 
hydrolytically cleavage of the linkers is discussed in the next chapter (Chapter 3). 
Compound Structure 
4 / 5 
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First of all, it was important to integrate the linker into the hydrogel network. This was 
achieved by using branched PEG with different end-group functionalization. For cross-
linking via copper-catalyzed click reaction, four-armed PEG was modified with alkyne 
or azide groups, respectively (Table 2.1).  
The incorporation of the linker into the hydrogel network was realized using four-armed 
PEG with two different types of functionalization. One arm of these molecules was 
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modified with the cleavable linker group (5a – 5c); the remaining arms were alkyne-
functionalized to allow cross-linking with the azide groups. 
In the first step, the hydroxyl end groups of four-armed PEG were converted into amine 
groups in order to prepare the polymer for end-group functionalization. This was 
achieved using a Mitsunobu reaction and subsequent hydrazinolysis (Figure 2.2).  
 
 
 
Figure 2.2: Synthesis of compound 3 (4armPEG10k-amine). 
The hydrogel precursors and linkers were synthesized starting from the amine. The 
functionalization with the alkyne group (Figure 2.3) and the linker groups (Figure 2.4) 
were obtained in a similar way using DCC/NHS chemistry.  
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Figure 2.3: Synthesis of compound 4 (4armPEG10k-pentyne). 
 
 
 
 
Figure 2.4: Synthesis and activation of the linkers. The synthesis 
 of 5a is shown exemplarily for all linkers. 
Using the same reaction mechanism for both modifications allowed for the synthesis of 
5c in one step. Due to the different reactivity of the carboxylic acids, the synthesis of 5a 
and 5b occurred in two steps. First, statistically one arm was modified with the linker 
group. Using the molar ratios described above, it was possible to modify statically one 
arm of each linker molecule as verified by 1H-NMR spectroscopy and fluram assay. 
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This allowed a simple synthesis without additional protection or de-protection reactions. 
Afterwards, the remaining arms were modified with alkyne groups according to Figure 
2.3. The last step in the synthesis of all linkers was the activation using DSC. The 
resulting succinimidyl functionalization served for protein PEGylation via carbamte 
formation with protein amine groups. Protein PEGylation and de-PEGylation is 
discussed in detail in the next chapter (Chapter 3). 
For the synthesis of 4armPEG-azide (6), the four arms were functionalized using a 
diazotransfer reaction (Figure 2.5).  
 
Figure 2.5: Synthesis of compound 6 (4armPEG10k-azide).  
The synthesized azide was used to form 1,2,3-triazoles with the alkyne group in a 
copper-catalyzed click reaction during cross-linking.  
 
To determine the influence of linker incorporation on gel stiffness and gelation time, the 
different hydrogels with and without linker were analyzed by rheological 
measurements. In Figure 2.6, the rheogram of a reference gel without linker is shown 
exemplarily. At the beginning of the measurement, cross-linking had not yet occurred 
and the mixture behaved like a viscous liquid (Gʹʹ > Gʹ) [37]. With proceeding cross-
linking, the stiffness of the mixture increased and the mixture behaved more like an 
elastic solid (Gʹ > Gʹʹ) [37]. The cross-over point of loss (Gʹʹ) and storage modulus (Gʹ) 
was defined as gelation time. The absolute value of the complex shear modulus |G*| 
(G* = Gʹ + i·Gʹʹ) is a measure of the stiffness of the hydrogel and was used to compare 
the stiffness of the different formulations [38].  
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Figure 2.6: Rheogram of a reference gel without linker. The storage modulus Gʹ is 
represented by closed circles, the loss modulus Gʹʹ is represented by open circles. 
The measurement was carried out at 25 °C and 1.0 Hz oscillatory frequency with a 
40 mm steel plate with 500 µm gap size. 
In Table 2.2 the gelation times and maximal complex shear moduli of all analyzed 
hydrogel formulations are presented. Gelation occurred between 15.1 ± 0.1 min and 
19.4 ± 0.5 min. The Cu(I)-catalyzed cycloaddition of the azide and alkyne 
functionalities, which was used for cross-linking, is known for its rapid reaction kinetics 
[39]. In Figure 2.7 the results are visualized and statistical significant differences are 
shown. The gelation times of the reference gels without lysozyme (Ctrl) and with 
lysozyme but without linker (w/o) were nearly the same. This indicates that 
incorporation of the model protein did not affect the gelation time. The gelation times of 
the samples with incorporated linker groups were significantly lower. The reason for 
that behavior is not clear. It can be speculated that cross-linking is completed faster, due 
to the excess of azide groups. In the hydrogels containing linker groups, about one 
quarter of the alkyne groups are replaced by a linker group, which is not involved in 
cross-linking. This results in a lower amount of reactive alkyne groups and 
consequently an excess of azide groups.  
However, no differences in gelation time were detected between the different linker 
groups. So, the chemical structure of the linker seemed not to affect the gelation time. 
The gelation times of all analyzed samples matched the requirements of a model 
hydrogel. The gelation occurred fast enough for timesaving preparation, but still 
provided enough time for accurate handling. A possible way to tailor the gelation time 
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would be the variation of the amount of copper-catalyst, which also influences the 
gelation time of click hydrogels [40].  
The maximal detected absolute value of the complex shear modulus ranged between 
2897 ± 174 Pa and 7923 ± 506 Pa indicating high stiffness of all samples (Table 2.2). 
Click reactions are highly efficient and lead to almost quantitative conversion [27, 41]. 
This results in high homogeneity and low amount of network defects, which is reflected 
in the strong mechanical properties [42]. These are ideal properties for a model system 
with regard to sample handling and minimizing interfering effects on drug release 
studies.  
Table 2.2: Characterization of the prepared hydrogels with 5 % total polymer 
concentration. 
Group Gelation time (min) |G*| (Pa) 
Ctrl. 19.4 ± 0.5 7908 ± 634 
w/o  19.1 ± 0.1 7923 ± 506 
Linker 5a 15.9 ± 0.4 3564 ± 57 
Linker 5b 15.5 ± 0.4 2897 ± 174 
Linker 5c 15.1 ± 0.1 4325 ± 114 
 
For the different complex shear moduli, similar results were observed as for the detected 
gelation times (Figure 2.7). No significant differences existed between the reference 
gels with or without lysozyme. However, the incorporation of linker groups resulted in 
significant lower stiffness. The gel stiffness of hydrogels after incorporation of 5c was 
significantly higher than after incorporation of 5b. Between 5a and 5b, no significant 
differences were detected. The stiffness of a hydrogel depends on the cross-linking 
density [43]. Decreasing the cross-linking density results in decreased mechanical 
strength [43]. By incorporating the linker into the hydrogel, additional network defects 
are introduced at each polymer-arm functionalized with the linker group instead of an 
alkyne group. These defects decrease the cross-linking density of the hydrogel, which is 
reflected by the lower complex shear modulus. Due to less functional groups and steric 
hindrance of the incorporated bulky protein, network defects will appear in every model 
system when working with linker groups and covalent protein attachment. So, this small 
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drawback of little differences in cross-linking density between the samples was 
accepted for the investigation of protein release kinetics. 
 
Figure 2.7: Rheological characterization of click hydrogels with regard to gelation time 
(A) and absolute value of the complex shear modulus |G*| (B). Samples with 
lysozyme incorporated via linker 5a, 5b, or 5c are shown in comparison to reference 
hydrogels without lysozyme (Ctrl) and hydrogels with lysozyme but without linker 
(w/o). The measurements were performed in triplicate and the results are shown as 
means ± standard deviations. * indicates statistical significance (p < 0.05) versus the 
reference groups. # indicates statistical significant differences between two groups.   
The reported changes regarding gelation time and gel stiffness after incorporation of 
linker molecules should also be kept in mind, when developing hydrogels for clinical 
applications. Especially for in-situ gelling systems, the gelation time is of great 
importance. During injection, the gel precursor should preferably show low viscosity to 
ensure simple application. After injection a fast gelation is required to prevent diffusion 
of the drug and the gel precursors into the surrounding tissue [44]. The gel strength 
should be similar to the strength of the tissue at the application site [12]. 
 
The swelling behavior of the reference hydrogels and the hydrogels with incorporated 
linkers was determined (Figure 2.8). The swelling of the reference hydrogels without 
linker and with (w/o) or without (Crtl.) model protein was completed after 24 h. The 
reference hydrogels showed only little mass increase not exceeding 108 % during 
swelling experiments. This low extent of mass increase can be explained by the high 
cross-linking density due to almost complete conversion of the used click chemistry [27, 
31, 45].  
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Figure 2.8: Swelling of the prepared hydrogels. Comparison of control group without 
protein (open circle), hydrogels without linker (open square) and hydrogels 
containing lysozyme PEGylated by 5a (closed square), 5b (closed triangle) or 5c 
(closed circle). The experiment was carried out in PBS at 37 °C.  
The mass of hydrogels with incorporated linker molecules increased rapidly over 24 h.  
After about 4 d the mass increase was completed. Swelling behavior of these hydrogels 
was in line with the complex shear modulus; with decreasing cross-linking density due 
to the incorporated linker groups, the extent of swelling increased to 135 ± 1 % (5c), 
145 ± 2 % (5a), and 152 ± 3.0 % (5b) [43].  
However, the degree of swelling of the analyzed hydrogels containing linker groups was 
still low compared to other hydrogel systems such as Diels-Alder hydrogels for example 
[46]. This makes these hydrogels excellently suitable to determine protein release. 
Excluding the influence of swelling, the influence of the cleavage kinetics of the linker 
on protein release can be analyzed.  
The optimal swelling behavior with regard to medical applications depends on the type 
of application. For hydrogels used as wound dressings, high water absorption may be 
desired in order to take up the exudate [47]. On the other hand, strong swelling at 
application sites with sensitive tissue and limited expansibility, such as cartilage trauma 
sites for example, may damage the surrounding tissue or aggravate the situation [48]. 
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A simple synthesis allowed the functionalization of one of the cross-linking agents with 
linker groups for reversible protein attachment. By choosing the adequate molar ratio of 
the raw materials, the modification of one arm could be realized. This enabled the 
integration of the linker groups into the hydrogel backbone during cross-linking. The 
integration of the linker group affected the gelation time, gel stiffness und hydrogel 
swelling. About the reasons for the lower gelation times after incorporation of linker 
groups could just be speculated. The significant lower gel stiffness compared to the 
reference gels resulted from the induced defects in the hydrogel network after 
incorporation of the linker group. The results of the swelling studies were in good 
agreement with the rheological characterization. Due to the network defects caused by 
the incorporation of linker groups, the extent of hydrogel swelling increased. However, 
using click chemistry, the resulting hydrogels still showed fast gelation, high gel 
stiffness and low swelling even after incorporation of linker groups. In conclusion, these 
hydrogels are ideally suitable as model hydrogels to study protein release based on 
linker cleavage without the influence of swelling or degradation.  
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The reversible attachment of proteins to polymers is one potential strategy to control 
protein release from hydrogels. This chapter reports on the reversible attachment of 
lysozyme to poly(ethylene glycol) (PEG) by degradable carbamate linkers. Phenyl 
groups with different substituents were used to control the rate of carbamate hydrolysis 
and the resulting protein release. Sodium dodecyl sulfate (SDS) polyacrylamide gel 
electrophoresis (PAGE) showed modification with 1 – 3 PEG chains per lysozyme 
molecule. Protein PEGylation and PEG chain elimination occurred without changes in 
secondary protein structure, as demonstrated by circular dichroism (CD) spectroscopy. 
The lytic activity of lysozyme was restored to 73.4 ± 1.7 % – 92.5 ± 1.2 % during PEG 
chain elimination. Attached PEG chains were eliminated within 24 h to 28 d, depending 
on the used linker molecule. When formulated into hydrogels, a maximum of about 
60 % of the initial dose was released within 7 d to 21 d. Linker elimination occurs 
‘traceless’, so that the protein is released in its native, unmodified form. Altogether, 
tethering proteins by degradable carbamate linkers is a promising strategy to control 
their release from hydrogels. 
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Even though the significance of therapeutic proteins has increased enormously since the 
development of recombinant insulin in 1979, several shortcomings still outweigh 
potential therapeutic benefits in many cases [12, 49]. First and foremost it is often 
difficult to reach effective protein concentrations at the target tissue due to degradation 
in the blood stream, unspecific binding to off-target sites or difficulties in crossing 
endothelial barriers [50]. The necessary injections and the short application intervals 
often compromise the patient compliance and increase the health care costs. 
Furthermore, many proteins do not target specific cell types, which limits their use as 
therapeutics. For example, growth factors may be highly selective in vitro, but show a 
significant number of systemic side effects in vivo [50]. One promising approach to 
solve these problems would be the local release of proteins from injectable hydrogels 
that serve as a drug carrier and control the release kinetics of their payload. Among the 
different strategies to control protein release, the reversible binding of proteins to the 
hydrogel carrier seems most promising; the release rate would then be controlled by the 
degradation kinetics of the used linker molecules and not only by the fast diffusion of 
the incorporated protein [12, 50, 51]. 
This approach has already been successfully applied to control the release of small 
molecules from hydrogels using hydrolytically [52, 53] or enzymatically cleavable 
linkers [54]. Similar techniques have been proposed for sustained protein release. 
Bovine serum albumin was covalently bound to poly(ethylene glycol) (PEG) hydrogels 
containing labile ester bonds and slowly released while the hydrogels degraded [55]. In 
another approach, vascular endothelial growth factor was immobilized in enzymatically 
degradable PEG hydrogels, which would allow cell-demanded protein release [56, 57]. 
Biotinylated insulin-like growth factor 1 was tethered to biotinylated peptide nanofibers 
using streptavidin as a cross-linker and proved to be successful in the treatment of 
myocardial infarction [58]. Reduction-sensitive linkers were investigated as an 
alternative way for temporary protein immobilization. Upon incubation with 
glutathione, the immobilized lysozyme was released from dextran hydrogels to the same 
extent as native lysozyme [59]. And recently, a very interesting concept has been 
proposed that relies on the formation of thermally reversible covalent bonds. Cell 
adhesion peptides with furan functionalities were covalently bound to maleimide 
moieties of the hydrogel and released by retro-Diels-Alder reactions [60]. A common 
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disadvantage of these approaches is the use of linker molecules that remain bound to the 
proteins even after their release from the hydrogel. These remaining ‘tags’ may 
compromise protein bioactivity or induce immune responses [23, 61, 62]. 
Our concept, in contrast, relies on the use of aromatic succinimidyl carbonates that react 
with protein amino groups under formation of degradable carbamates. These linker 
molecules have been originally developed for the reversible PEGylation of proteins and 
decompose without leaving any ‘tags’ on the protein [61, 63]. In an earlier publication, 
Brandl et al. reported on the synthesis of branched PEG-succinimidyl carbonates that 
react with branched PEG-amines to form hydrolytically degradable hydrogels. Proteins 
present in the reaction mixture were reversibly tethered to the hydrogel network and 
released during gel degradation [64]. A possible drawback of this approach is that 
protein release is controlled by both the decomposition of the linker molecules and the 
degradation of the hydrogel carrier. In this chapter, the entire focus was set on the 
carbamate linkers and the investigation of the influence of their chemical structure on 
the release kinetics of tethered proteins. Three different linker molecules were studied; 
lysozyme was used as a model protein. Linear methoxy poly(ethylene glycol) (mPEG) 
was used to study lysozyme PEGylation and PEG chain elimination kinetics. Non-
degradable hydrogels were prepared by cross-linking branched PEG molecules using 
the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC). For lysozyme 
immobilization, branched carbamate linkers with two different types of reactive groups 
were synthesized and subsequently used for hydrogel preparation. Release studies were 
performed to demonstrate the feasibility of our approach. 
 
 
3-Hydroxybenzoic acid, 3-(4-hydroxyphenyl)propionic acid, phthalimide and toluene 
were purchased from Acros Organics (Geel, Belgium). Tetramethylethylenediamine 
(TEMED) was purchased from Carl Roth GmbH & Co. KG (Karlsruhe, Germany). 2-
Amino-2-hydroxymethyl-propane-1,3-diol (TRIS) was obtained from GE Healthcare 
Europe GmbH (Freiburg, Germany). Deuterated Chloroform (CDCl3) was purchased 
from Deutero GmbH (Kastellaun, Germany). Phosphate-buffered saline (PBS) was 
purchased from Invitrogen GmbH (Karlsruhe, Germany). Four-armed poly(ethylene 
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glycol) with a molecular weight of 10 kDa was purchased from JenKem Technology 
(Allen, TX, USA). Iodine was purchased from Riedel-de Haën AG (Seelze, Germany). 
Acrylamide/bisacrylamide solution (37.5 : 1) and sodium dodecylsulfate were obtained 
from Serva Electrophoresis GmbH (Heidelberg, Germany). Acetonitril, Coomassie 
brilliant blue G-250, N,N’-dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide 
(HOSu), diisopropyl azodicarboxylate, N,N’-discuccinimidyl carbonate (DSC),  
fluorescamine, 4-hydroxybenzoic acid, lysozyme (from chicken egg white), magnesium 
sulfate, micrococcus lysodeikticus, sodium tetraborate decahydrate, 4-pentynoic acid, 
methoxy poly(ethylene glycol) with a molecular weight of 5 kDa and tetrahydrofuran 
were purchased from Sigma-Aldrich (Taufkirchen, Germany). Acetone, methylene 
chloride (DCM), diethyl ether and ethanol were from CSC Jäcklechemie (Nürnberg, 
Germany). All other chemicals were purchased from Merck KGaA (Darmstadt, 
Germany). Deionized water was obtained using a Milli-Q water purification system 
from Millipore (Schwalbach, Germany). 
 
1H-NMR spectra were recorded in CDCl3 at room temperature on a Bruker Avance 300 
spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany). 
The number of free amino groups was determined as described by Udenfriend et 
al. [33]. The sample was dissolved in 50 mM borate buffer, pH 8.5 and diluted to a 
concentration of 0.2 µmol/mL. Then, 100 µL of the sample were mixed with 1300 µL 
of borate buffer and 600 µL of a fluorescamine solution in acetone (0.3 mg/mL). The 
fluorescence intensity (ʎex = 390 nm, ʎem = 480 nm) was measured on a PerkinElmer LS 
55 Fluorescence spectrometer (Perkin-Elmer, Wiesbaden, Germany). Compound 1 
(Table 3.1) was used to prepare a calibration curve and the number of free amino 
groups was calculated.  
Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) was 
conducted using polyacrylamide gels of 14 % cross-linking. The gels were loaded with 
26.25 µg of protein per lane; native lysozyme was used as a reference. The running 
buffer consisted of 25 mM TRIS, 192 mM glycine and 0.1 % SDS. The system was 
programmed to apply a constant voltage of 120 V and decreasing current starting at 
68 mA over 1.5 h. Afterwards the gels were stained with Coomassie brilliant blue G-
250 and scanned. The conjugated PEG was detected by placing the gels into barium 
chloride and iodine solutions as described by Natarajan et al. [65]. For quantification, 
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the band areas and densities of the Coomassie brilliant blue-stained gels were measured 
using the NIH software ImageJ [66]. 
For circular dichroism (CD) spectroscopy, protein samples were diluted to a 
concentration of approx. 0.25 mg/mL; the exact concentration was determined 
spectrophotometrically at 280 nm. CD spectra were recorded on a Jasco J-815 CD 
spectrometer (Jasco Germany GmbH, Groß-Umstadt, Germany) from 260 to 190 nm at 
room temperature using cuvettes with a path length of 0.5 mm. Secondary structure 
fractions were quantified as described by Böhm et al. [67]. 
 
Compounds 1 (Table 3.1) and 3 (Table 3.2) were synthesized in 95 % and 93 % yield as 
described by Brandl et al. [34]. 
 
For the synthesis of compound 2a (Table 3.1), a previously published procedure was 
modified as follows [64]. First, 0.11 g of 4-hydroxybenzoic acid (0.8 mmol), 0.09 g of 
HOSu (0.8 mmol) and 0.17 g of DCC (0.8 mmol) were dissolved in 10 mL of 1,4-
dioxane and stirred for 4 – 6 h at room temperature. The N,N’-dicyclohexylurea (DCU) 
byproduct was filtered off; 2.0 g of compound 1 (0.40 mmol) and 0.04 g (0.48 mmol) of 
NaHCO3 were then dissolved in 10 mL of water and mixed with the filtrate. The 
reaction mixture was stirred overnight at 50 °C. The next day, the solvent was 
evaporated and the residue was taken up in water. The raw product was extracted with 
DCM and the combined organic phases were dried over anhydrous MgSO4. The 
solution was concentrated under reduced pressure and the product was crystallized at 
0 °C by dropwise addition of diethyl ether. The precipitate was washed with cold 
diethyl ether and dried under vacuum to yield 1.9 g (93 %).  
1H-NMR (CDCl3, 300 MHz): δ 3.40 ppm (s, 3 H, H3CO–), 3.66 ppm (s, –OCH2CH2–), 
6.90 ppm (d, 2 H, –C6H4OH), 7.33 ppm (d, 2 H, –C6H4OH). The degree of end-group 
conversion was 98 %, as calculated from the number of free amino groups.  
The product from above (0.37 mmol) and 0.380 g of DSC (1.48 mmol) were dissolved 
in 7 mL of dried acetonitrile; 238 µL of pyridine were then added. The mixture was 
stirred overnight at room temperature. The next day, the solvent was evaporated under 
reduced pressure and the residue was taken up in DCM. The insoluble residue was 
filtered off. The solution was concentrated under reduced pressure and the product was 
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crystallized at 0 °C by dropwise addition of diethyl ether. The precipitate was washed 
with cold diethyl ether and dried under vacuum to yield 1.8 g (97 %) of compound 2a.  
1H-NMR (CDCl3, 300 MHz): δ 2.92 ppm (s, 4 H, –C(O)CH2CH2C(O)–),  3.40 ppm (s, 
3 H, H3CO–), 3.66 ppm (s, –OCH2CH2–), 7.38 ppm (d, 2 H, –C6H4OSu), 7.93 ppm (d, 
2 H, –C6H4OSu). 
 
The precursor of compound 2b was synthesized from compound 1 and 3-
hydroxybenzoic acid in 90 % yield (1.83 g) as described above.  
1H-NMR (CDCl3, 300 MHz): δ 3.40 ppm (s, 3 H, H3CO–), 3.66 ppm (m, –OCH2CH2–), 
7.00 ppm (d, 1 H, –C6H4OH), 7.26 ppm (d, 1 H, –C6H4OH), 7.39 ppm (d, 1 H, –C6H4-
OH), 7.68 ppm (d, 1 H, –C6H4OH). The degree of end-group conversion was almost 
quantitative, as calculated from the number of free amino groups.  
Compound 2b (Table 3.1) was synthesized in 82 % yield (0.56 g) as described above.  
1H-NMR (CDCl3, 300 MHz): δ 2.91 ppm (s, 4 H, –C(O)CH2CH2C(O)–), 3.40 ppm (s, 
3 H, H3CO–), 3.66 ppm (s, –OCH2CH2–), 7.26 ppm (d, 1 H, –C6H4OSu), 7.38 ppm (d, 
1 H, –C6H4OSu), 7.52 ppm (d, 1 H, –C6H4OSu), 7.80 ppm (d, 1 H, –C6H4OSu). 
 
The precursor of compound 2c was synthesized from compound 1 and 3-(4-hydroxy-
phenyl)propionic acid in 92 % yield (1.9 g) as described above.  
1H-NMR (CDCl3, 300 MHz): δ 2.45 ppm (t, 2 H, –C(O)CH2CH2–), 3.89 ppm (t, 2 H,  
–C(O)CH2CH2–), 3.40 ppm (s, 3 H, H3CO–), 3.66 ppm (s, –OCH2CH2–), 6.80 ppm (d, 
2 H, –C6H4OH), 7.03 ppm (d, 2 H, –C6H4OH). The degree of end-group conversion was 
almost quantitative, as calculated from the number of free amino groups.  
Compound 2c (Table 3.1) was synthesized in 93 % yield (1.42 g) as described above.  
1H-NMR (CDCl3, 300 MHz): δ 2.53 ppm (t, 2 H, –C(O)CH2CH2–), 2.90 ppm (s, 4 H,  
–C(O)CH2CH2C(O)–), 3.01 ppm (t, 2 H, –C(O)CH2CH2–), 3.40 ppm (s, 3 H, H3CO–), 
3.66 ppm (s, –OCH2CH2–), 7.21 ppm (d, 2 H, –C6H4OSu), 7.27 ppm (d, 2 H, –C6H4-
OSu). 
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Table 3.1:  Linear poly(ethylene glycol) derivatives (molecular weight 5 kDa)  
 
Compound R 
1 NH2 
2a 
 
2b 
 
2c 
 
 
0.24 g of 4-pentynoic acid (2.4 mmol), 0.28 g of HOSu (2.4 mmol) and 0.50 g of DCC 
(2.4 mmol) were dissolved in 10 mL of 1,4-dioxane. The reaction mixture was stirred 
for 6 h at room temperature and the precipitated DCU was filtered off. Then, 3.0 g 
(0.3 mmol) of compound 3 and 0.20 g (2.4 mmol) of NaHCO3 were dissolved in 10 mL 
of water and combined with the filtrate. The mixture was stirred overnight at 50 °C. The 
next day, the solvent was evaporated and the residue was taken up in 20 mL of water. 
The raw product was extracted with DCM and the combined organic phases were dried 
over anhydrous MgSO4. The solution was concentrated under reduced pressure and the 
product was crystallized at 0 °C by dropwise addition of diethyl ether. The precipitate 
O
O O
O
N
H
N
O
O
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was washed with cold diethyl ether and dried under vacuum to yield 2.9 g (95 %) of 
compound 4 (Table 3.2).  
1H-NMR (CDCl3, 300 MHz): δ 2.05 ppm (t, 4 H, HC≡C–), 2.44 ppm (t, 8 H, –C(O)-
CH2CH2–), 2.55 ppm (t, 8 H, –C(O)CH2CH2–), 3.66 ppm (s, –OCH2CH2–). 
 
The precursor of compound 5a was synthesized in a similar manner to that of 
compound 2a. In brief, 0.03 g of 4-hydroxybenzoic acid (0.2 mmol), 0.02 g of HOSu 
(0.2 mmol), 0.04 g of DCC (0.2 mmol), 2.0 g of compound 3 (0.2 mmol) and 0.02 g of 
NaHCO3 (0.22 mmol) were allowed to react as described above to yield 1.82 g (90 %).  
1H-NMR (CDCl3, 300 MHz): δ 2.94 ppm (t, 6 H, –CH2-NH2), 3.66 ppm (s, –OCH2-
CH2–), 6.93 ppm (d, 2 H, –C6H4OH), 7.74 ppm (d, 2 H, –C6H4OH). The degree of end-
group conversion was 27 % as calculated from the number of free amino groups.  
In the next step, the remaining amino groups were modified with 4-pentynoic acid as 
described for compound 4 to yield 1.6 g (88 %).  
1H-NMR (CDCl3, 300 MHz): δ 2.04 ppm (t, 3 H, HC≡C–), 2.44 ppm (t, 6 H, –C(O)-
CH2CH2–), 2.55 ppm (t, 6 H, –C(O)CH2CH2–), 3.66 ppm (s, –OCH2CH2–), 6.93 ppm 
(d, 2 H, –C6H4OH), 7.76 ppm (d, 2 H, –C6H4OH). The degree of end-group conversion 
was almost quantitative. In the last step, the phenolic hydroxyl groups were activated 
using DSC to yield 1.39 g (86 %) of compound 5a (Table 3.2).  
1H-NMR (CDCl3, 300 MHz): δ 2.05 ppm (t, 3 H, HC≡C–), 2.44 ppm (t, 6 H, –C(O)-
CH2CH2–), 2.55 ppm (t, 6 H, –C(O)CH2CH2–), 2.92 ppm (s, 4 H, –C(O)CH2CH2- 
C(O)–), 3.66 ppm (s, –OCH2CH2–), 7.38 ppm (d, 2 H, –C6H4OH), 7.94 ppm (d, 2 H,  
–C6H4OH). 
 
The precursor of compound 5b was synthesized in 93 % yield (2.8 g) as described for 
compound 5a.  
1H-NMR (CDCl3, 300 MHz): δ 2.97 ppm (t, 6 H, –CH2-NH2), 3.66 ppm (s, –OCH2-
CH2–), 6.98 ppm (d, 1 H, –C6H4OH), 7.28 ppm (d, 1 H, –C6H4OH), 7.39 ppm (d, 1 H,  
–C6H4OH). The degree of end-group conversion after the first coupling step was 33 %, 
as calculated from the number of free amino groups.  
The second intermediate was synthesized in 82 % yield (2.53 g) as described above.  
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1H-NMR (CDCl3, 300MHz): δ 2.04 ppm (t, 3 H, HC≡C–), 2.44 ppm (t, 6 H, –C(O)CH2-
CH2–), 2.55 ppm (t, 6 H, –C(O)CH2CH2–), 3.66 ppm (s, –OCH2CH2–), 7.00 ppm (d, 
1 H, C6H4OH), 7.28 ppm (d, 1 H, –C6H4OH), 7.39 ppm (d, 1 H, –C6H4OH).  
Compound 5b (Table 3.2) was synthesized in 72 % yield (2.28 g) as described above.  
1H-NMR (CDCl3, 300 MHz): δ 2.05 ppm (t, 3 H, HC≡C–), 2.44 ppm (t, 6 H, –C(O)-
CH2-CH2–), 2.55 ppm (t, 6 H, –C(O)CH2CH2–), 2.91 ppm (s, 4 H, –C(O)CH2CH2-
C(O)–), 3.66 ppm (m, –OCH2CH2–), 7.44 ppm (d, 1 H, –C6H4OH), 7.52 ppm (d, 1 H,  
–C6H4OH), 7.81 ppm (d, 1 H, –C6H4OH). 
 
Compound 5c was synthesized in a slightly different manner. First, 0.12 g of 4-
pentynoic acid (1.2 mmol), 0.06 g of 3-(4-hydroxyphenyl)propionic acid (0.4 mmol), 
0.15 g of HOSu (1.6 mmol) and 0.33 g of DCC (1.6 mmol) were dissolved in 7 mL of 
1,4-dioxane. The mixture was stirred for 6 h at room temperature and the precipitated 
DCU was filtered off. Then, 2 g of compound 3 (0.2 mmol) and 0.13 g of NaHCO3 were 
dissolved in water and combined with the filtrate. The mixture was stirred overnight at 
50 °C. The next day, the solvent was evaporated; the residue was taken up in water and 
extracted with DCM. The combined organic phases were dried over anhydrous MgSO4. 
The solution was concentrated under reduced pressure and the product was crystallized 
at 0 °C by dropwise addition of diethyl ether. The precipitate was washed with cold 
diethyl ether and dried under vacuum to yield 1.65 g (79 %).  
1H-NMR (CDCl3, 300 MHz): δ 2.05 ppm (t, 3 H, HC≡C–), 2.42 ppm (t, 2 H, 
C(O)CH2CH2–),  2.44 ppm (t, 6 H, –C(O)CH2CH2–), 2.55 ppm (t, 6 H, –C(O)CH2- 
CH2–), 2.90 ppm (t, 2 H, –C(O)CH2CH2–), 3.66 ppm (s, –OCH2CH2–), 6.80  ppm (d, 
2 H, –C6H4OH), 7.04 ppm (d, 2 H, –C6H4OH). The degree of end-group conversion was 
97 %, as determined by 1H-NMR.  
The product from above was activated using DSC to yield 1.06 g (56 %) of compound 
5c (Table 3.2).  
1H-NMR (CDCl3, 300 MHz): δ 2.05 ppm (t, 3 H, HC≡C–), 2.44 ppm (t, 6 H, –C(O)-
CH2CH2–), 2.55 ppm (t, 6 H, –C(O)CH2CH2–), 2.86 ppm (s, 4 H, –C(O)CH2CH2- 
C(O)–), 2.91 ppm (t, 2 H, –C(O)CH2CH2–),  3.66 ppm (s, –OCH2CH2–), 6.95 ppm (d, 
2 H, –C6H4OH), 7.21 ppm (d, 2 H, –C6H4OH). 
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Imidazole-1-sulfonyl azide hydrochloride was synthesized as described by Goddard-
Borger et al. [36]. In the next step, 3.0 g of compound 3 (0.3 mmol), 292 µL of 
triethylamine and 3.0 mg of copper(II) sulfate were dissolved in 10 mL of methanol. 
Imidazole-1-sulfonyl azide hydrochloride was added subsequently. The mixture was 
allowed to react overnight at room temperature. The next day, the mixture was 
concentrated under reduced pressure, diluted with 40 mL of water and acidified with 
HCl. The raw product was extracted with DCM and the combined organic phases were 
dried over anhydrous MgSO4. The solution was concentrated under reduced pressure 
and the product was crystallized at 0 °C by dropwise addition of diethyl ether. The 
precipitate was washed with cold diethyl ether and dried under vacuum to yield 2.85 g 
(95 %) of compound 6 (Table 3.2).  
1H-NMR (CDCl3, 300 MHz): δ 3.66 ppm (s, –OCH2CH2–). 
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Table 3.2: Branched poly(ethylene glycol) derivatives (molecular weight 10 kDa) 
 
Compound R1 R2 
3 NH2 NH2 
4 
  
5a 
 
 
5b 
 
 
5c 
 
 
6 N3 N3 
  
 
O
O O
O
N
H
N
O
O
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A lysozyme stock solution (concentration of amino groups 6.10 µmol/mL) was prepared 
in 25 mM phosphate buffer pH 7.4 For PEGylation, specified amounts of compound 2a, 
2b and 2c were dissolved in the lysozyme stock solution and allowed to react for 1 h at 
room temperature. Different PEG concentrations were used (0.087 µmol/mL, 0.3 
µmol/mL, 0.61 µmol/mL, 1.22 µmol/mL, 2.44 µmol/mL and 3.66 µmol/mL); the ratio 
of reactive succinimidyl (SC) : protein amino groups (NH2) varied between 1 : 7 and 
42 : 7. The protein conjugates were analyzed by SDS-PAGE to determine the degree of 
PEGylation. CD spectroscopy was used to estimate the secondary structure fractions of 
native and PEGylated lysozyme. The PEGylation studies were done in triplicate and the 
results are presented as means ± standard deviations. 
 
Lysozyme (protein concentration 1mg/mL) was PEGylated with compound 2a, 2b and 
2c as described above; the ratio of SC : NH2 groups was 7 : 7. A lysozyme solution 
containing an equivalent amount of compound 1 served as reference. All samples were 
diluted to a protein concentration of 0.01 mg/mL. The enzymatic activity of lysozyme 
was determined directly after PEGylation, and after incubation at 37 °C using a method 
described by Shugar with the following modifications [68]. In a cuvette, 2.5 mL of a 
0.015 % Micrococcus lysodeikticus cell suspension in 66 mM phosphate buffer pH 6.2 
were added to 100 µL protein sample. The decrease in the absorption at 450 nm was 
measured over 4.8 min in 0.8 min intervals. The enzymatic activity was calculated from 
the slope of the linear part of the curve. All measurements were done in triplicate and 
the results are presented as means ± standard deviations. 
 
Lysozyme (concentration of amine groups 6.10 µmol/mL) was PEGylated with 
compound 2a, 2b and 2c as described above. The molar ratio of SC : NH2 groups was 
7 : 7. To follow the elimination of PEG chains, 250 µl aliquots of the samples were 
incubated in a shaking water bath at 37 °C. The samples were removed at defined time 
points and stored at –20 °C for further analysis by SDS-PAGE. The experiment was 
done in triplicate and the results are presented as means ± standard deviations. 
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Hydrogels were prepared from PEG macromonomers substituted with alkyne 
(compound 4) and azido groups (compound 6). A lysozyme stock solution (protein 
concentration 1.33 mg/mL) was prepared in 25 mM phosphate buffer pH 7.4. 
PEGylation with compound 5a, 5b and 5c was carried out as described above with the 
exception that 5c was allowed to react for 2 h. The ratio of SC : NH2 groups was 14 : 7 
in all cases. The successful PEGylation of lysozyme was verified by SDS-PAGE. After 
PEGylation, the required amounts of compound 4 and 6 were dissolved in the protein 
solution. The stoichiometric ratio between alkyne and azido groups was nearly balanced 
and the total polymer content was 5 % (w/v). Cross-linking was started by the addition 
of 0.5 µmol/mL CuSO4 and 2.5 µmol/mL ascorbic acid. Samples of 750 µL were cast 
into glass cylinders with a diameter of 10 mm and allowed to gel for 2 h at room 
temperature. As control, hydrogels containing physically entrapped, non-PEGylated 
lysozyme were prepared in a similar manner. For the release studies, the hydrogel 
cylinders were immersed in 10 mL of PBS containing 0.1 % NaN3 and incubated in 
shaking water bath at 37 °C. Samples were withdrawn at regular time intervals and 
replaced by fresh buffer. The samples were stored at 4 °C until the completion of the 
release experiment. Protein quantification was carried out as described by Bradford 
[69]. The released protein amount was normalized to the initial dose (1 mg per gel 
cylinder). For better comparability, all release profiles were additionally scaled to their 
maximum values, which were taken as 100 %. At least three repetitions were done and 
the results are presented as means ± standard deviations. 
 
 
Different types of linkers, such as aromatic linkers employing the 1,4- or 1,6-benzyl 
elimination [63, 70, 71], linkers based on the trimethyl lock lactonization [72], or 
aliphatic bicin linkers [73], have been developed for the reversible PEGylation of 
proteins. Although these linkers have been successfully used for the generation of 
PEGylated protein prodrugs [74, 75], this approach of using phenyl carbamates for 
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protein conjugation offers several advantages. First of all, the here described PEG 
linkers can be readily synthesized from commercially available reagents. The synthesis 
involves a condensation reaction between an amine and a carboxylic acid function 
followed by an activation step, and does not require any chromatographic purification 
steps. The desired polymers were obtained in satisfactory yields and acceptable purity, 
as calculated from the number of free amino groups and 1H-NMR spectra. Second, 
different to the above-mentioned elimination reactions, the hydrolysis of phenyl 
carbamates does not involve the departure of potentially toxic leaving groups [76–80]. 
For example, the generation of reactive quinone methides during the 1,6-benzyl 
elimination reaction may result in the alkylation of proteins with important biochemical 
and toxicological consequences [81]. Apart from that, most of the existing linkers were 
designed to release the attached PEG chains within a few hours after protein 
administration [74, 75], whereas the aim of this investigation was the development of 
hydrogels that release their tethered proteins over days to weeks. To achieve this goal, 
linkers employing the 1,4- or 1,6-benzyl elimination reaction would have required the 
introduction of enzymatically cleavable groups [74, 75], which could have made the 
resulting release rates less predictable and controllable. In contrast to that, the 
decomposition rate of phenyl carbamates can be modulated over a wide range by 
changing the substitution pattern of the phenolic leaving group [76–79]. 
 
The first experiment was aimed at investigating the reactivity of the synthesized PEG 
linkers and establishing optimal conditions for lysozyme PEGylation. Lysozyme has 
seven amino groups, namely six lysine residues and one amino terminus. Three lysine 
amino groups are located on the protein surface and can be easily PEGylated by amine-
reactive reagents. PEGylation of the three other lysine residues that are hidden within 
the protein is associated with structural breakdown and irreversible denaturation [82]. 
To find optimal reaction conditions, lysozyme was PEGylated at different SC : NH2 
ratios and the degree of PEGylation was determined by SDS-PAGE. After Coomassie 
brilliant blue staining, SDS-PAGE showed PEGylation with 1 – 3 PEG chains per 
lysozyme molecule (Figure 3.1). This is in good agreement with previously published 
studies, which also showed PEGylation with 1 – 3 PEG chains under similar reaction 
conditions [63, 71, 73, 83]. The low degree of PEGylation and the mild reaction 
conditions (25 mM phosphate buffer pH 7.4, room temperature) suggest that 
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PEGylation with linker 2a, 2b and 2c most likely does not affect the protein structure. 
For all tested PEG linkers, the number of attached PEG chains per lysozyme molecule 
increased with increasing SC : NH2 ratio. At the same time, the fraction of free 
lysozyme decreased to a minimum of 4 – 10 %, depending on the used linker molecule 
and SC : NH2 ratio. Linker 2b and 2c both gave a similar PEGylation pattern; at higher 
SC : NH2 ratios, however, linker 2b favored the formation of highly PEGylated 
lysozyme derivatives (Figure 3.1 B and C). Linker 2a, in contrast, generally yielded less 
PEGylated derivatives. In particular at low SC : NH2 ratios, the amount of free 
lysozyme was considerably higher when linker 2a was used for PEGylation (Figure 
3.1 A). This can be explained by different reactivity of the synthesized succcinimidyl 
carbonates. Faster hydrolysis of linker 2a, which decreases the amount of amine-
reactive succinimidyl carbonates, would be another explanation for the observed 
differences. Last, once attached PEG chains could be cleaved off faster compared to the 
other linkers, which would also increase the amount of free lysozyme.  
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Figure 3.1: PEGylation of lysozyme with 2a (A), 2b (B) and 2c (C). The ratio of 
SC : NH2 groups varied between 1 : 7 and 42 : 7. The relative abundance of the 
different protein species was determined by SDS-PAGE and the results are presented 
as means ± standard deviations (n = 3). 
Chapter 3 
50 
CD spectroscopy was used to check if PEGylation affects the secondary structure of 
lysozyme. This method has previously been used to investigate the effects of acylation 
with succinimidyl-S-acetylthioacetate on the secondary structure of lysozyme [83]. The 
recorded CD spectra did not show any changes due to PEGylation compared to native 
lysozyme (Figure 3.2 A).  
 
Figure 3.2: CD spectra of native and PEGylated lysozyme. Lysozyme was PEGylated 
with linker 2a; the ratio of SC : NH2 groups was 7 : 7. CD spectra were recorded 
directly after PEGylation (A) and after 48 h of incubation at 37 °C (B). The 
measurements were done in triplicate and representative curves are shown. 
The secondary structure fractions of native and PEGylated lysozyme are listed in Table 
3.3. In both samples, the secondary structure consisted of 34.0 – 34.8 % α-helix, 7.6 – 
7.8 % antiparallel β-sheet, 8.6 – 8.8 % parallel β-sheet, 16.5 – 16.7 % β-turn and 32.1 – 
32.7 % random coil. The differences between the two samples were all within the 
experimental error. Therefore, it can be concluded that PEGylation with up to three 
PEG chains does not affect the secondary structure of lysozyme. This is consistent with 
previously published results, which showed that up to three amino groups of lysozyme 
could be acylated while maintaining the secondary protein structure [83]. 
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Table 3.3: Secondary structure fractions of native and PEGylated lysozyme. Lysozyme 
was PEGylated with compound 2a at a SC : NH2 ratio of 7 : 7. The CD 
measurements were done in triplicate and the results are presented as means ± 
standard deviations. 
 
Secondary structure Native lysozyme PEGylated lysozyme 
α-Helix 34.0 % ± 0.6 % 34.8 % ± 1.3 % 
Antiparallel β-sheet 7.8 % ± 0.2 % 7.6 % ± 0.3 % 
Parallel β-sheet 8.8 % ± 0.2 % 8.6 % ± 0.4 % 
β-Turn 16.7 % ± 0.0 % 16.5 % ± 0.2 % 
Random coil 32.7 % ± 0.4 % 32.1 % ± 1.0 % 
 
 
The enzymatic activity of PEGylated lysozyme was measured before and after PEG 
chain elimination. Although none of the possible PEGylation sites are within its active 
center, lysozyme shows decreased activity due to PEGylation, partly from the exclusion 
of the substrate from the binding site [82, 84]. Therefore, lysozyme is an excellent 
model protein to study reversible PEGylation. After PEGylation, the enzymatic activity 
of lysozyme decreased to 50.3 ± 0.4 % (linker 2a), 29.4 ± 1.1 % (linker 2b) and 
28.3 ± 1.4 % (linker 2c) of the activity of the non-PEGylated reference (Figure 3.3). 
This confirms the results of the SDS-PAGE, which also showed incomplete PEGylation 
at SC : NH2 ratios of 7 : 7 (Figure 3.1). To test if the conjugated PEG chains can be 
cleaved off and the enzymatic activity of lysozyme is restored, the samples were 
incubated at 37 °C and reanalyzed at predetermined time points. After 24 h of 
incubation, the enzymatic activity of lysozyme PEGylated with linker 2a had increased 
to 90.7 ± 1.0 % of the activity of the unmodified protein. Lysozyme PEGylated with 
linker 2b completely regained its activity after 7 d of incubation. The activity of 
lysozyme PEGylated with linker 2c increased to 73.9 ± 1.7 % within 28 d of incubation 
(Figure 3.3).  
Chapter 3 
52 
 
Figure 3.3: Effect of PEG attachment and elimination on the enzymatic activity of 
lysozyme. The experiment was done in triplicate and the results are expressed as 
percent of the activity of native lysozyme (means ± standard deviations). 
These findings are consistent with previously published results, which showed recovery 
of the lysozyme activity after release from PEG conjugates [63, 71, 73, 84]. Therefore, 
it can be concluded that the synthesized linkers are hydrolyzed in aqueous media at 
37 °C and conjugated PEG chains are cleaved off. The obtained results also demonstrate 
that the kinetics of PEG chain elimination depends on the nature of the linker molecules 
used for PEGylation. However, it has been shown in previous studies on releasable 
PEGylation reagents that the activity increase is not strictly dependent on the amount of 
free lysozyme but also includes conjugates where PEG chains have been released near 
the active center [84]. Consequently, measuring the enzymatic activity overestimates the 
amount of free lysozyme, due to that reason it was decided to follow the kinetics of 
PEG chain elimination by SDS-PAGE. To complement the activity measurements, the 
secondary structure of the recovered lysozyme was additionally analyzed by CD 
spectroscopy. As shown in Figure 3.2 B, the recorded CD spectra did not show any 
significant differences to native lysozyme. Therefore, it can be concluded that neither 
PEGylation nor the elimination of the conjugated PEG chains affects the secondary 
structure of lysozyme. 
 
Lysozyme was PEGylated and the subsequent PEG chain elimination was followed by 
SDS-PAGE. The different protein species were identified by a combination of 
Coomassie brilliant blue and barium iodide staining in which PEGylated proteins appear 
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as brown spots and non-PEGylated proteins give a dark-blue staining. In the experiment 
shown in Figure 3.4, lysozyme was PEGylated using linker 2a and the elimination of 
PEG chains was followed over time.  
 
Figure 3.4: Elimination of conjugated PEG chains over time followed by SDS-PAGE. 
Lysozyme was PEGylated with linker 2a; the molar ratio of SC : NH2 groups was 
7 : 7. A combination of Coomassie brilliant blue (A) and barium iodide staining (B) 
was used to identify the different protein species. Free lysozyme (“Lys”) served as a 
reference. 
SDS-PAGE showed an increase for unmodified lysozyme over time while the amount 
of PEGylated lysozyme decreased at the same time. The relative amounts of PEGylated 
and free lysozyme were measured using ImageJ and the results are presented in Figure 
3.5.  
Linker 2a was hydrolyzed very rapidly; after 24 h, a maximum amount of 63 % of free 
lysozyme could be detected. No further increase was observed between 24 h and 7 d 
(Figure 3.5 A). The hydrolysis of linker 2b was slower compared to 2a and continued 
over at least 7 d; the amount of free lysozyme was determined to be 56 % after 7 d of 
incubation (Figure 3.5 B). The elimination of PEG chains was slowest when linker 2c 
was used for PEGylation. The hydrolysis of the carbamate group proceeded very slowly 
and only 44 % of the introduced lysozyme was in its free form after 28 d (Figure 3.5 C). 
This is different from previously reported studies. Lysozyme was almost completely 
released from conjugates with PEGylation reagents employing the 1,6-benzyl 
elimination reaction [63, 71] or bicin linkers [73] after 24 h of incubation at 37 °C. 
However, these experiments were carried out at pH 8.0 – pH 9.2, whereas our 
elimination studies were done at pH 7.4. 
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Figure 3.5: Elimination of PEG chains over time. Lysozyme was PEGylated with 2a 
(A), 2b (B) or 2c (C); the molar ratio of SC : NH2 groups was 7 : 7. The relative 
abundance of the different protein species was determined by SDS-PAGE and the 
results are presented as means ± standard deviations (n = 3). 
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The hydrolysis of phenyl carbamtes in neutral and basic solutions proceeds by an E1cB 
elimination reaction involving the intermediate formation of an unstable isocyante, 
which then disintegrates into a primary amine and carbon dioxide [76–80]. Substituents 
in the phenolic leaving group have a great effect on the rate of carbamate hydrolysis 
(Table 3.4). Electron withdrawing groups in the ortho or para-position stabilize the 
phenolate ion by resonance and accelerate hydrolysis compared to the unsubstituted 
compound [76–79]. In compound 2a, the electron withdrawing carbamoyl group is in 
the para-position to the carbamate group and able to stabilize the phenolate ion by 
resonance. In compound 2b, on the other hand, the carbamoyl group is located in the 
meta-position and, therefore, unable to stabilize the phenolate ion. The substitution 
pattern of compound 2c is different; unlike the other linker molecules, 2c is substituted 
with an electron releasing alkyl group in the para-position to the carbamate group, 
which destabilizes the phenolate ion. Based on these theoretical considerations, linker 
2a should hydrolyze more rapidly than 2b and 2c. This was fully reflected by the 
experimental data. The electron releasing alkyl group in para-position to the carbamate 
group (linker 2c) dramatically slows down hydrolysis, whereas shifting the electron 
withdrawing carbamoyl group from the para (linker 2a) into the meta-position (linker 
2b) only has a minor influence on the hydrolysis rate. 
Table 3.4: Chemical structures of the formed carbamates 
     
Linker R1 R2 
2a C(O)NH[CH2CH2O]nCH3 H 
2b H C(O)NH[CH2CH2O]nCH3 
2c CH2CH2C(O)NH[CH2CH2O]nCH3 H 
Although PEGylation with aromatic succinimidyl carbonates should be completely 
reversible [61, 63], a maximum of 63 % of the PEGylated lysozyme could be recovered 
in its free form. There are two possible explanations for this incomplete elimination of 
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PEG chains. First, 1 may contain residual hydroxyl groups that will react with DSC to 
aliphatic succinimidyl carbonates, which in turn form stable carbamates with protein 
amino groups. Additionally, incomplete substitution of 1 with 4-hydroxybenzoic acid, 
3-hydroxybenzoic acid or 3-(4-hydroxyphenyl)propionic acid and subsequent reaction 
with DSC will yield aliphatic succinimidyl carbamates that can react with protein amino 
groups to stable ureas [85]. And second, nucleophilic groups (e.g. amino or hydroxyl 
groups) might attack the isocyanate formed during the hydrolysis of phenyl carbamates 
and produce stable protein conjugates [86, 87]. 
The intermediate isocyanate could also be attacked by nucleophilic groups of other 
proteins (e.g. hydroxyl, sulfhydryl, imidazole or amino groups) [88], which would result 
in the formation of protein aggregates. In fact, lysozyme dimers were identified after 
Coomassie brilliant blue and barium iodide staining by their dark-blue color. When 
using linker 2a or 2b for PEGylation, first lysozyme dimers were detected after 1 h of 
incubation. The tendency to form oligomers further increased during the experiment; 
after 7 d of incubation, lysozyme dimers accounted for approx. 10 % of the total protein 
amount (Figure 3.4). After PEGylation with linker 2c, only few aggregates were 
observed after 15 d of incubation (data not shown). Self-association of lysozyme in 
aqueous solution would be another explanation for the observed aggregation [89]. 
PEGylation can prevent the aggregation of proteins by steric shielding [90], which 
might explain why less lysozyme dimers were observed when linker 2c was used for 
PEGylation. 
 
In the final experiment, the release of lysozyme from PEG based hydrogels was 
investigated. For this purpose, four-armed PEG was functionalized with alkyne 
(compound 4, Table 3.2) and azide groups (compound 6, Table 3.2), respectively. To 
enable lysozyme immobilization, branched PEG linkers with two different types of 
reactive groups were synthesized. In the first synthetic step, compound 3 (Table 3.2) 
was partially functionalized with 4-hydroxybenzoic acid (linker 5a, Table 3.2), 3-
hydroxybenzoic acid (linker 5b, Table 3.2) or 3-(4-hydroxyphenyl)propionic acid 
(linker 5c, Table 3.2). The remaining amino groups were then acylated with 4-pentynoic 
acid to allow cross-linking with 6. In the last step, the phenolic hydroxyl groups were 
activated with DSC to yield amine-reactive succinimidyl carbonates. (For more details 
see Chapter 2.) For hydrogel preparation, lysozyme was first PEGylated with 5a, 5b or 
3.3 Results and Discussion 
57 
5c and subsequently mixed with the required amounts of 4 and 6. Gel formation and 
protein immobilization occurred within a few minutes by azide-alkyne cyclodaddition 
in the presence of CuSO4 and ascorbic acid (CuAAC). As a control, non-PEGylated 
lysozyme was physically entrapped in PEG hydrogels. 
The successful PEGylation with linker 5a, 5b and 5c was verified by SDS-PAGE 
(Figure 3.6). The results are in good agreement with the data obtained from PEGylation 
with linker 2a, 2b and 2c (Figure 3.1). The amount of free, non-PEGylated lysozyme 
was comparable for the three different linkers and varied between 16 % and 27 %. 
 
 
Figure 3.6: PEGylation of lysozyme with linker 5a, 5b and 5c. The ratio of SC : NH2 
groups was 14 : 7. The relative abundance of the different protein species was 
determined by SDS-PAGE and the results are presented as means ± standard 
deviations (n = 3). 
The results of the release experiments are presented in Figure 3.7. As expected, 
physically entrapped lysozyme was released very fast; 83 % of the initial dose was 
released within the first 24 h. The protein release reached a plateau after 3 d; by that 
time, 92 % of the initial dose had been released into solution (Figure 3.7 A). This is 
explained by the high water content (> 95 %) and low cross-linking density of the 
hydrogels, which both lead to a high diffusivity of the incorporated lysozyme. When the 
incorporated lysozyme was tethered to the hydrogel network, a maximum of about 60 % 
of the initial dose was released (Figure 3.7 B). The release rate was dependent on the 
used linker; the maximum values were reached after 7 d (linker 5a), 10 d (linker 5b) and 
21 d (linker 5c). These results are in good agreement with those obtained by SDS-
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PAGE (Figure 3.5). The incomplete protein release is most likely due to irreversible 
binding to the hydrogel network, as outlined in the previous section.  
 
Figure 3.7: Release of lysozyme from PEG hydrogels. The released protein amounts 
were calculated in percent of the initial dose (A and B). For better comparability, the 
release profiles were additionally scaled to their maximum values (C and D). All 
experiments were done in triplicate and the results are presented as means ± standard 
deviations. 
For better comparability, all release profiles were scaled to their maximum values, 
which were taken as 100 % (Figure 3.7 C and D). As already discussed above, the 
release from hydrogels loaded with physically entrapped lysozyme was very fast. After 
5 h, already 50 % of the total amount had been released into solution; 75 % of the total 
amount was released after 16 h. Tethering lysozyme to the hydrogel network 
considerably slowed down the release kinetics. The release rates were found to depend 
on the used linker molecules; 50 % of the total amount was released after 17 h (linker 
5a), 34 h (linker 5b) and 105 h (linker 5c). The effect of the different linker molecules 
becomes even more distinct when looking at later time points of the release profiles; 
75 % of the total amount was released after 1.5 d (linker 5a), 2.7 d (linker 5b) and 
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13.6 d (linker 5c). In addition, the initial release rate could have been dominated by the 
presence of free, non-tethered lysozyme in the hydrogels. As shown in Figure 3.6, 
however, the amount of non-PEGylated lysozyme was similarly low for all three 
linkers. Therefore, the observed differences in the release kinetics are most likely not 
due to different sized fractions of free lysozyme. The measured release profiles match 
the kinetics of PEG chain elimination very well (Figure 3.5). As already discussed in 
the previous section, linker 5a and 5b both hydrolyze much faster than linker 5c 
because of their different aromatic substitution patterns [76–79]. Therefore, linker 5a 
and 5b both retard protein release to a much lesser extent than linker 5c. It can be 
concluded from the SDS-PAGE that tethered lysozyme will be released in its free, 
unmodified form. This is an advantage over previous approaches since the absence of 
any remaining ‘tags’ helps to preserve protein bioactivity and reduces the risk of 
generating immune reactions [23, 61, 62]. 
Although it was shown that the synthesized linker molecules, in particular linker 5c, can 
control the release of tethered proteins, the used hydrogels will require further 
modification before they can be applied as a protein delivery system. First of all, using 
the CuAAC as cross-linking reaction could be problematic because of the toxicity of the 
copper(I) catalyst [91]. Second, the hydrogels used in this study are non-degradable, 
which would require their surgical removal after complete protein release. From a 
research perspective, however, the prepared hydrogels offer several advantages. The 
CuAAC is an orthogonal reaction, which avoids unwanted side reactions with proteins 
during the cross-linking process. Furthermore, the use of stable hydrogels allows 
studying the effects of the different linker molecules on protein release without having 
to consider hydrogel swelling and degradation. For in vivo application, the hydrogels 
could be cross-linked, for example, by strain-promoted azide-alkyne cycloadditions, 
thiolene reactions or Michael additions [92]. Gel degradation could be achieved by 
introducing hydrolytically or enzymatically cleavable groups. Alternatively, PEG 
macromonomers could be cross-linked by Diels-Alder reactions. The resulting 
hydrogels were recently shown to dissolve after several weeks of incubation at body 
temperature [46]. 
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The use of aromatic succinimidyl carbonate linkers is a promising strategy for the 
reversible PEGylation of proteins. Succinimidyl carbonates react with lysine residues of 
proteins to generate degradable carbamate groups. The kinetics of PEG chain 
elimination can be controlled by the substitution pattern of the generated carbamates. 
These linker groups were integrated into star-shaped, cross-linkable PEG 
macromonomers. When formulated into hydrogels, present proteins are reversibly 
tethered to the polymer network and immobilized. Such systems could serve the 
localized delivery of therapeutic proteins in certain applications, where controlled 
protein release over days to weeks is required. The release of the tethered proteins is 
then controlled by the decomposition of the linker molecules rather than protein 
diffusion. Most importantly, linker decomposition is ‘traceless’, which helps to preserve 
protein bioactivity and reduces the risk of immunological reactions. One remaining 
problem is the incomplete and comparatively fast protein release over a maximum of 
three weeks. This could be addressed by further modifying the chemical structure of the 
linker molecules, for example by introducing additional electron donating groups or 
shielding the carbamates with bulky side groups. Altogether, tethering proteins by 
degradable carbamate groups is a promising strategy to control their release from 
hydrogels independent from diffusion, swelling or degradation. 
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A method to separate free lysozyme and PEGylated derivatives by size exclusion 
chromatography (SEC) was established. The measurements were performed on a 
TSKgel G3000SWXL column using 0.3 M NaCl in 0.05 M phosphate buffer pH 6.9 
containing 20 % ethanol as mobile phase. A special device allowed for holding the 
samples at 37 °C during the experiment. The method enabled to follow PEG chain 
elimination over time. Quantification of the recorded chromatograms showed complete 
elimination after about 26 h with a maximum amount of 73.6 % (sample 1) and 75.9 % 
(sample 2) of free lysozyme, respectively.  
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Different methods, like high-performance liquid chromatography (HPLC), Sodium 
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE), matrix-assisted laser 
desorption ionization mass spectrometry (MALDI MS) or capillary electrophoresis 
(CE), are commonly used to analyze PEGylated proteins with regard to the number of 
attached PEG chains, the extent of PEGylation, and the kinetics of PEGylation and De-
PEGylation [84, 93–96]. In Chap. 3, the investigation of PEGylation and PEG chain 
elimination by SDS-PAGE was introduced. Although the method worked reliably, SDS-
PAGE has some drawbacks such as a protein stressing sample preparation and a time 
consuming experimental procedure. Samples for SDS-PAGE had to be frozen at defined 
time points to stop the elimination process, stored at –20 °C until measurement, and 
thawed just before gel electrophoresis. During this process of freezing and thawing the 
risk of protein aggregation is increased due to the intermediate presence of an ice-water 
interface stimulating nucleation of aggregates [7]. To avoid this, real-time 
measurements at each defined time point would be the optimal way of sample handling. 
Furthermore, gel preparation, running and staining is time consuming and must be 
carried out manually. Moreover, the gel precursor, acrylamide, is toxic in its un-
polymerized form. It may cause cancer and genetic defects, and it is suspected to be 
harmful to human fertility. Using HPLC, the whole measurement process can be 
automated avoiding time consuming and toxic gel preparation and allowing real-time 
measurements.  
Generally, HPLC is a frequently used method in the entire field of protein analysis and 
purification [97]. Different HPLC techniques are available to analyze proteins in general 
and PEGylated proteins in particular. One common technique is reversed phase HPLC 
(RP-HPLC). Here, separation is based on hydrophobic interactions between the protein, 
the stationary phase, and the mobile phase [97]. Zalipsky et al. used RP-HPLC to follow 
elimination of thiolytically cleavable PEG linkers [93]. However, gradients containing 
organic solvents as mobile phase limit its use for preparative applications due to protein 
denaturation [98]. Separation by charge, ion-exchange chromatography, is another 
frequently used chromatographic technique to separate PEGylated proteins [97]. The 
separation is based on analyte binding to the charged stationary phase by exchange 
reactions with the counterions of the functional group of the column. Afterwards, an 
excess of counterions in the eluent or a pH gradient initiate displacement of the analyte 
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[26, 98]. In the case of PEGylated proteins, ion-exchange chromatography can be used 
to separate PEGylated proteins depending on the site of PEGylation [99]. Isoforms 
differ in protein areas shielded by the attached PEG groups and therefore, in surface 
charge distribution [99]. This makes ion-exchange chromatography suitable for 
determining the sites of PEGylation of different isoforms [100]. Furthermore, ion-
exchange chromatography is often used to separate PEGylated and unreacted 
components for purification purposes [93, 94, 101].  
Furthermore, separation by size is used in protein analytics. In size exclusion 
chromatography (SEC) separation is based on interaction with a porous stationary phase 
consisting of porous dextran, agarose, polyacrylamide or silica particles [97, 98]. 
During elution, the solutes diffuse into and out of the pores and are, thereby, sorted by 
size; the solutes too big to enter the pores are eluted first, followed by smaller 
components with longer pore residence time [98]. In case of PEGylated proteins, the 
hydrodynamic radius is markedly increased compared to native proteins [8]. Due to the 
absence of intramolecular interactions (e.g., disulfide bonds, hydrogen bonds, van der 
Waals interactions) and the ability to bind approximately 16 water molecules per ethoxy 
group, PEG is shaped as a coil with large hydrodynamic radius in aqueous media [8]. 
This makes SEC ideally suited to follow the PEGylation process and quantify the 
degree of PEGylation [26, 95, 102]. The eluent does not directly influence the 
separation process. For natural polymers, such as proteins, aqueous buffers are useful to 
control the pH during the experiment and to prevent denaturation in preparative 
separation (gel filtration chromatography (GFC)) [97, 103]. Further techniques like 
normal-phase chromatography, hydrophobic interaction chromatography, or 
immunoaffinity chromatography are less common for separating PEGylated proteins 
[104, 105].  
In the following experiments, SEC was used to analyze PEGylated lysozyme. SEC 
operates with non-toxic aqueous buffer systems [106]. Furthermore, the method is 
simple and reproducible, and all required components are commercially available [106, 
107]. A method was established to separate free lysozyme from PEGylated derivatives. 
For method development, lysozyme was irreversibly PEGylated by linker 2d (Table 
4.1). For elimination experiments, lysozyme was PEGylated using the rapidly 
hydrolyzing linker 2a (Table 4.1). The recorded SEC chromatograms were used to 
quantify the increasing amounts of free lysozyme during PEG chain elimination. 
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Narrow opening screw caps (black) with septa and 2 mL screw vial (amber) were 
purchased from BGB Analytik Vertrieb (Schlossboekelheim, Germany). Deuterated 
chloroform (CDCl3) was purchased from Deutero GmbH (Kastellaun, Germany). 
Acetonitril, N,N’-discuccinimidyl carbonate (DSC), lysozyme (from chicken egg white) 
and methoxy poly(ethylene glycol) with a molecular weight of 5 kDa were purchased 
from Sigma-Aldrich (Taufkirchen, Germany). GHP Acrodisc® 13 mm syringe filters 
(0.2 µm pore size) were purchased from Pall GmbH (Dreieich, Germany). Sodium 
chloride was purchased from VWR International GmbH (Darmstadt, Germany). Spartan 
30 / 0.2 RC syringe filters were purchased from Whatman GmbH (Dassel, Germany). 
Methylene chloride (DCM), diethyl ether and ethanol were from CSC Jäcklechemie 
(Nürnberg, Germany). All other chemicals were purchased from Merck KGaA 
(Darmstadt, Germany). Purified water was freshly prepared each day using a Milli-Q 
water purification system from Millipore (Schwalbach, Germany).  
 
1H-NMR spectra were recorded in CDCl3 at room temperature using a Bruker Avance 
300 spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany).  
 
Linker 2a (Table 4.1) was synthesized as described in Chap. 3 [35].  
 
Linker 2d (Table 4.1) was synthesized according to a procedure described by Brandl et 
al. [64]. In brief, 5.0 g (1 mmol) of dried mPEG5k-OH and 1.3 g (5 mmol) of DSC were 
dissolved in 50 mL of acetonitrile; 645 µL of pyridine were added and the reaction 
mixture was stirred over night at room temperature. The next day, the acetonitrile was 
evaporated under reduced pressure. Afterwards, the residue was dissolved in 
dichloromethane and the insoluble residue was filtered off. The solution was 
concentrated under reduced pressure and precipitated at 0 °C by dropwise addition of 
diethyl ether. The precipitate was dried under vacuum to yield 4.55 g (88.5 %) of linker 
2d. 
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1H-NMR (CDCl3, 300 MHz): δ 2.86 ppm (s, 4 H, –C(O)CH2CH2C(O)–),  3.40 ppm (s, 
3 H, H3CO–), 3.66 ppm (s, –OCH2CH2–), 4.46 ppm (t, 2 H, –OCH2CH2OC(O)O–). 
Table 4.1:  Linear poly(ethylene glycol) linkers (molecular weight 5 kDa) 
Linker Chemical structure  
 
2a 
 
 
 
 
2d 
 
 
 
SEC experiments were performed using a Shimadzu HPLC system (Shimadzu Europa 
GmbH, Duisburg, Germany). The HPLC installation consisted of a SCL–10A VP 
controller, an auto injector SIL–10AD VP, a pump LC–10AT and a column oven CTO–
6A. The fluorescence detector RF-551 was used for protein detection (λex 295 nm, λem 
360 nm). Furthermore, the degasser WellChrom K-5004 was used to prevent air bubbles 
in the system (Wissenschaftliche Gerätebau Dr. Ing. Herbert Knauer GmbH, Berlin, 
Germany). 
For separation of free and PEGylated lysozyme, a TSKgel G3000SWXL column 
(7.8 mm x 30 cm; 5 µm particle size; 250 Å pore size) (Tosoh Bioscience GmbH, 
Stuttgart, Germany) was used at a flow rate of 1 mL/min and 25 °C. The mobile phase 
consisted of 0.3 M NaCl in 0.05 M phosphate buffer pH 6.9 containing 20 % ethanol. 
The mobile phase was filtered through a cellulose membrane syringe filter (Spartan 
30 / 0.2 RC syringe filter) before use.  
 
A lysozyme stock solution (conc. 1 mg/mL) was prepared in 25 mM phosphate buffer 
pH 7.4. For PEGylation, 50.0 mg (9.8 µmol) or 12.5 mg (2.4 µmol) of linker 2d were 
dissolved in 5 mL of the lysozyme stock solution (2.4 µmol amino groups) and 
incubated for 1 h at room temperature. The ratio of reactive succinimidyl groups 
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(SC) : amino groups of lysozyme (NH2) was 28:7 and 7:7, respectively. The lysozyme 
stock solution and PEGylated lysozyme were diluted to a protein concentration of 
0.1 mg/mL. All samples were filtered through a hydrophilic propylene membrane 
syringe filter (GHP Acrodisc® 13 mm syringe filter). For SEC, 10 µL of each sample 
were injected automatically. Chromatograms of all samples were recorded using the 
method described above.  
 
A lysozyme stock solution (conc. 1 mg/mL) was prepared in 25 mM phosphate buffer 
pH 7.4. For PEGylation, 12.5 mg of linker 2a (2.4 µmol) were incubated in 5 mL of the 
lysozyme stock solution (2.4 µmol amino groups) for 1 h at room temperature. The ratio 
of SC: NH2 groups was 7 : 7. The experiment was done in duplicate; PEGylation of the 
second sample was started with a time delay of 1 h.  
Directly after PEGylation, the determination of the elimination kinetics of the first 
sample via SEC was started; the second sample was started one hour later. To this end, 
the samples were diluted to a protein concentration of 0.1 mg/mL and filtered through a 
hydrophilic propylene membrane syringe filter (GHP Acrodisc® 13 mm syringe filter). 
The sample vials were put in the auto injector rack and heated to 37 °C using a special 
device (Figure 4.1). 
To determine the elimination kinetics, 10 µL of the sample were injected at defined time 
points. Every 58 min, a new measurement run was started. Sample 1 and sample 2 were 
injected alternating; this resulted in a measurement interval of 2 h for each sample. The 
elution of protein derivatives from the column was recorded by a fluorescence detector 
over 20 min (λex 295 nm, λem 360 nm) for each sample. The chromatograms were 
analyzed by the Class VP software (Shimadzu Europa GmbH, Duisburg). For 
quantification, the amount of free lysozyme was calculated from the area under the 
curve using a calibration curve (see below) and normalized to the total initial amount of 
lysozyme (1 mg/mL). Furthermore, the peak areas of free and PEGylated lysozyme 
were normalized to the total peak area.  
 
Using the temperature regulator of the auto injector, room temperature could be reached 
at the most because the auto injector is not designed for heating. Therefore, a way had to 
be found to hold the samples at body temperature (37 °C) during the experiment. To this 
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end, a special device (Figure 4.1) was manufactured to heat samples to 37 °C during the 
experiment.  
The heating device consisted of a metal block equipped with round boreholes on the top 
to provide the vials for sample injection. Connections to a water bath at both ends 
ensured water circulation inside the metal block and sample heating during the 
experiment.  
 
Figure 4.1: Device for sample heating during determination of PEG chain elimination. 
(Schematic drawings and manufacturing of the device were kindly realized by Stefan 
Kolb and Herbert Tischhoefer.) 
 
For calibration, the lysozyme stock solution was diluted to concentrations between 
0.02 mg/mL and 0.1 mg/mL. The samples were filtered through a hydrophilic propylene 
membrane syringe filter (GHP Acrodisc® 13 mm syringe filter). For quantification, 
10 µL of each concentration were injected. The chromatograms were recorded using the 
fluorescence detector RF-551 (λex 295 nm, λem 360 nm) and the areas under the curve 
were determined using the Class VP software (Shimadzu Europa GmbH, Duisburg).   
 
 
SEC experiments were performed using a column containing a silica-based, hydrophilic 
bonded phase packing and a mobile phase composed of ethanol and 0.3 M NaCl in 
0.05 M phosphate buffer pH 6.9. Silica-based packings are less compressible compared 
to other packings, like agarose or dextran based packings, and suitable for higher 
pressure due to their mechanical robustness [98]. The non-derivatized surface silanol 
groups of the packing show a pKa of 3.5 to 4.0 and are, therefore, deprotonated at 
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neutral conditions [98, 109]. Lysozyme (pI 11) is positively charged under these 
conditions and would be adsorbed on the stationary phase [109, 110]. To prevent the 
overlaying of size exclusion effects by ionic interactions between lysozyme and the 
column packing, the mobile phase was adjusted to intermediate ionic strength with 
NaCl [97, 98, 107, 109, 111]. A drawback of SEC is the short life time of the column, 
especially in the presence of PEG.  Ethanol was added to the mobile phase to prevent 
PEG induced degradation of the column [112]. Hydrogen bonding or dipolar 
interactions between the ether functions of PEG and the diol functionalized silica 
surface are assumed to be the reason for column degradation [112]. The addition of 
ethanol prevents those interactions between PEG and the stationary phase [112].  
For the same column, Conze et al. and Christel et al. suggested another mobile phase 
composed of 0.1 M Na2SO4 in 0.1 M phosphate buffer pH 6.7 for the separation of free 
lysozyme, mono-PEGylated and di-PEGylated species [99, 113]. However, this method 
could not be successfully applied. Peak separation of free and PEGylated lysozyme was 
insufficient using the respective mobile phase. Furthermore, the eliminated PEG chain 
of linker 2a was eluted at the same time as free lysozyme interfering with qualitative 
and quantitative analysis.  
For method establishment, the individual components were characterized first. An 
overlay of the detected chromatograms is shown in Figure 4.2.  
Free lysozyme was eluted from the column after about 11.4 min. PEGylated lysozyme 
was eluted faster compared to unmodified lysozyme. The increased size due to the 
attached PEG chains led to less interaction with the stationary phase and faster elution 
from the column. To prevent PEG chain elimination during development of the method, 
lysozyme was irreversible PEGylated with linker 2d. Linker 2d forms aliphatic 
carbamates with primary amines [64]. Due to the absence of an aromatic spacer, the 
carbamate bond is not degradable under the used conditions [64]. Two different ratios of 
reactive succinimidyl (SC) to protein amino groups (7 : 7 and 28 : 7) were used for 
PEGylation to create different degrees of protein modification as determined by SDS-
PAGE [35]. Lysozyme PEGylated with an excess of linker 2d (28 : 7) was eluted after 
about 7.9 min. No free lysozyme was detected in this case. After incubation with less  
linker 2d (SC : NH2 7 : 7) a small amount of free lysozyme was detected at about 
11.4 min. Different derivatives of PEGylated lysozyme were eluted after about 
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10.8 min, 9.5 min, and 8.5 min. However, a clear separation of mono-, di-, and tri-
PEGylated lysozyme derivatives was not possible. Maybe PEGylation with a higher 
molecular weight PEG would improve resolution. Nevertheless, the overlay of the 
individual chromatograms clearly demonstrated that the method is suitable to separate 
free and PEGylated lysozyme and to follow PEG chain elimination.  
 
Figure 4.2: Chromatograms of lysozyme and irreversible PEGylated lysozyme. The 
ratio of SC : NH2 groups during irreversible PEGylation was 7 : 7 and 28 : 7. 
Samples were detected by a fluorescence detector (λex 295nm, λem 360nm). 
 
For SDS-PAGE experiments (see Chap. 3), samples taken during elimination process 
were stored at -20 °C until measurement to stop hydrolysis. To circumvent protein 
denaturation and changes within the sample by freezing and thawing, the elimination 
samples for SEC were incubated in HPLC vials and directly injected at defined time 
points.  
Figure 4.3 exemplarily shows an overlay of two chromatograms detected during PEG 
chain elimination. At the beginning of the experiment (0 h), lysozyme was freshly 
PEGylated with linker 2a. PEGylated lysozyme was eluted first (11.3 min) because of 
its increased size compared to free lysozyme. A small amount of lysozyme remained 
unmodified and was eluted after about 12.6 min. During incubation, linker 2a was 
hydrolyzed and, thereby, the amount of free lysozyme increased. After 24 h of 
incubation, the peak of free lysozyme was clearly enlarged. At this time, free lysozyme 
was eluted after about 12.5 min, while the PEGylated lysozyme was already eluted after 
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about 10.7 min. The peak shift of PEGylated lysozyme might be a first indicator for 
column degradation during the sequence.  
 
Figure 4.3: Elimination of linker 2a from lysozyme. Chromatograms after 0 h and 24 h 
detected by a fluorescence detector (λex 295nm, λem 360nm). 
Problems, which could be traced back to column degradation, manifested after about 
160 injections. The peak for PEGylated lysozyme disappeared from the chromatograms, 
probably meaning that PEGylated lysozyme was no longer eluted from the column. 
Furthermore, the maximum pressure was exceeded a couple of times, indicating 
clogging of the column. After another 75 injections, the broadness of the lysozyme peak 
increased to a time span of about 20 min. Several cleaning steps could not improve the 
resolution, indicating final column degradation. In the future, column life time could be 
possibly extended by purifying the samples from unreacted PEG by ion-exchange 
chromatography, for example [94].  
Besides monitoring PEG chain elimination, SEC can be used as an indicator for the 
stability of protein formulations [98]. Dimerization and aggregation, as a consequence 
of instability, are detectable due to the increased protein size [98]. The appearance of 
lysozyme in only one peak without shifts in the retention time indicates protein stability 
during PEGylation and PEG chain elimination. This is in good agreement with the data 
already obtained by CD spectroscopy and Micrococcus assay (see Chap. 3). The 
different retention times determined during method establishment and elimination 
experiments can be explained by the use of two different columns of the same type with 
different age and small variations in column packing. 
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For quantification, lysozyme calibration solutions of different concentrations were 
injected at the end of the sequence (Figure 4.4). As expected, the peak area increased 
with increasing lysozyme concentration. The retention time (12.5 min) corresponded to 
the retention time of the unmodified lysozyme fraction during PEG chain elimination.  
 
Figure 4.4: Chromatograms of different lysozyme concentrations from 0.02 mg/mL to 
0.1 mg/mL were detected using a fluorescence detector (λex 295nm, λem 360nm) for 
lysozyme calibration. 
The resulting calibration curve was used to quantify the increasing amount of free 
lysozyme during PEG chain elimination (Figure 4.5 A). Directly after PEGylation, only 
24.5 % (sample 1) and 28.1 % (sample 2) of the protein, respectively, remained 
unmodified. Over time, the amount of free lysozyme increased due to linker hydrolysis. 
After about 26 h, with a maximum amount of 73.6 % (sample 1) and 75.9 % (sample 2) 
of free lysozyme, respectively, PEG chain elimination was completed. Quantification of 
the PEGylated lysozyme using the calibration shown in Figure 4.4 was not possible, 
because the fluorescence of the aromatic linker groups might interfere with the 
fluorescence of the protein. For further information about the kinetics of PEG chain 
elimination, the peak areas of free and PEGylated lysozyme were normalized to the total 
peak area as shown in Figure 4.5 B. Due to the possibly interfered fluorescence  
described above the obtained data must be understood as an indication of the order of  
magnitude not as absolute values. The fraction of free lysozyme increased from 44.8 % 
(sample 2: 39.3 %) to 82.4 % (sample 2: 82.9 %) within 24 h, while the fraction of 
PEGylated lysozyme decreased from 55.2 % (sample 2: 60.7 %) to 17.6 % (sample 2: 
17.1 %). This is in good agreement with the data obtained by SDS-PAGE (see Chap. 3). 
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When normalizing the lysozyme band to the sum of all bands per lane, an increase of 
free lysozyme from 43.0 % ± 2.5 % to 63.4 % ± 3.7 % after 24 h was detected [35].  
 
Figure 4.5: Elimination of linker 2a from lysozyme. The amount of free lysozyme as 
determined by SEC. Concentration of free lysozyme calculated using calibration 
curve (A). Peak area percentage of free and PEGylated lysozyme (B).  
 
These results prove that SEC is an adequate alternative to SDS-PAGE for the purpose 
of following PEG chain elimination and quantification of released lysozyme. 
Investigation of PEG chain elimination using linker 2b or 2c (see Chap. 3) should also 
be possible with the introduced method. However, a new column has to be used in each 
experiment.  
 
A SEC method to separate PEGylated and non-PEGylated lysozyme was established. A 
TSKgel G3000SWXL column and a mobile phase containing 0.3 M NaCl in 0.05 M 
phosphate buffer pH 6.9 and 20 % ethanol proved to be appropriate to follow PEG 
chain elimination over time. After about 26 h, no further increase of lysozyme was 
detected indicating that PEG chain elimination was completed. No shift or double peak 
of lysozyme was observed during the experiments. This indicates structural integrity 
and the absence of aggregates during PEGylation and PEG chain elimination. Data 
regarding elimination kinetics as well as structural integrity was in good agreement with 
the results described in Chap. 3. SEC proved as an adequate alternative to SDS-PAGE 
for the determination of elimination kinetics. 
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The protein compatibility of selected cross-linking reactions was investigated. 
Lysozyme was incubated with methoxy poly(ethylene glycol) (mPEG5k) derivatives. 
Formed protein-polymer conjugates were analyzed by gel electrophoresis. Michael-type 
addition reactions of nucleophilic amino acids, especially lysine residues, to maleimide, 
vinyl sulfone and acrylamide groups were detected. The degree of modification 
depended on the polymer species and the pH. Complete modification with more than 
five PEG chains was observed after incubation with mPEG5k-vinyl sulfone at pH 9, 
whereas 96 % of the introduced protein remained unmodified after incubation with 
mPEG5k-acrylamide at pH 4. Incubation with mPEG5k-thiol resulted in thiol-disulfide 
exchange reactions; 83 % to 93 % of the introduced lysozyme remained unaffected. 
Hydrogel preparation was simulated by using mixtures of mPEG5k-maleimide and 
mPEG5k-furan, mPEG5k-vinyl sulfone and mPEG6k-thiol, mPEG5k-acrylamide and 
mPEG6k-thiol, or mPEG5k-acrylamide and a radical initiator. Protein modifications 
were detected, which may affect the protein structure, decrease activity and 
bioavailability, and increase the risk for immune responses. 
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Hydrogels are attractive for biomedical applications because of their chemical 
versatility and favorable properties. For example, hydrogels are considered 
biocompatible, they exhibit mechanical properties similar to those of the natural 
extracellular matrix, they can be made biodegradable, and they can be injected by 
minimally invasive techniques [12, 114, 115]. Among the many possible applications, 
the use of hydrogels as delivery system for therapeutic peptides and proteins seems 
especially promising [12, 115]. As a consequence of this, different strategies of 
hydrogel preparation have been proposed and investigated over the past decades. 
Compared to physical cross-linking (e.g., by hydrophobic or ionic interactions), 
chemical or covalent cross-linking has the benefit of forming more stable hydrogels and 
allows fine-tuning of the resulting release rates [12, 51, 115]. Several cross-linking 
reactions are frequently used for hydrogel preparation. One prominent example is 
radical polymerization of acrylate, methacrylate or acrylamide groups, which can be 
triggered by various initiators (e.g., peroxides or persulfates) or irradiation with light 
[116–120]. Michael-type addition reactions between thiol groups and acrylate groups 
[121, 122], vinyl sulfone groups [56, 115, 123, 124], or maleimide groups [125–127] 
are another possibility to prepare hydrogels at physiological conditions. Besides acting 
as electrophiles in Michael-type addition reactions, maleimides can react with 
conjugated dienes by means of Diels-Alder reactions. Thanks to its high efficiency and 
selectivity, the Diels-Alder reaction has been investigated as a cross-linking mechanism 
for hydrogels [128, 129]. For example, Kirchhof et al. functionalized star-shaped 
poly(ethylene glycol) (PEG) with furyl and maleimide groups. Step-growth 
polymerization of the two macromonomers yielded covalently cross-linked hydrogels 
that might be suitable for the controlled release of therapeutic proteins [46]. 
If hydrogels are used for controlled protein delivery, the stability and availability of the 
incorporated proteins must be ensured. Proteins can be loaded into hydrogels by 
incubating cross-linked gels in concentrated protein solutions (post-fabrication 
partitioning) or by in situ encapsulation during cross-linking. The former technique has 
the advantage of preserving protein stability; however, it offers less control over the 
amount of protein loading [51]. Furthermore, injection of pre-formed hydrogels might 
not always be possible [130]. On the other hand, in situ encapsulation permits the 
preparation of hydrogels loaded with large quantities of proteins in a fast and 
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reproducible manner. However, side reactions during cross-linking can affect the 
bioactivity of proteins, decrease their availability, and trigger undesired immune 
responses [12, 51]. This chapter reports on the protein compatibility of cross-linking 
reactions that are frequently used for the preparation of hydrogel-based protein delivery 
systems. As a model polymer, methoxy poly(ethylene glycol) functionalized with 
maleimide, vinyl sulfone, acrylamide, furyl, and thiol groups was investigated; 
lysozyme served as a model protein to determine occurring side reactions. Protein 
modifications, like Michael-type addition reactions of nucleophilic amino acids or thiol-
disulfide exchange reactions were detected by sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE). Although possible side reactions between 
proteins and cross-linking agents are discussed in the literature, no in-depth analysis of 
the protein compatibility of common cross-linking mechanisms has been done so far. To 
the best of our knowledge, this is the first study comparing the protein compatibility of 
cross-linking reactions under standardized conditions.  
 
 
Tetramethylethylenediamine (TEMED) was obtained from Carl Roth GmbH & Co. 
KG (Karlsruhe, Germany). 2-Amino-2-hydroxymethyl-propane-1,3-diol (TRIS) was 
purchased from GE Healthcare Europe GmbH (Freiburg, Germany). Dulbecco’s 
phosphate-buffered saline (PBS) was obtained from Invitrogen GmbH (Karlsruhe, 
Germany). Methoxy poly(ethylene glycol) vinyl sulfone with a molecular weight of 
5 kDa (mPEG5k-vinyl sulfone, Table 5.1) was puchased from JenKem 
Technology (Allen, TX, USA). Iodine was obtained from Riedel-de Haën AG (Seelze, 
Germany). Acrylamide/bisacrylamide solution (37.5 : 1), bromphenol blue sodium salt 
and sodium dodecylsulfate were purchased from Serva Electrophoresis 
GmbH (Heidelberg, Germany). Coomassie brilliant blue G-250, lysozyme (from 
chicken egg white), methoxy poly(ethylene glycol) with a molecular weight of 5 kDa, 
poly(ethylene glycol) methyl ether thiol with a molecular weight of 6 kDa (mPEG6k-
thiol, Table 5.1) and sodium tetraborate decahydrate were obtained from Sigma-
Aldrich (Taufkirchen, Germany). All other chemicals were purchased from Merck 
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KGaA (Darmstadt, Germany). Deionized water was obtained by using a Milli-Q water 
purification system from Millipore (Schwalbach, Germany). 
 
Methoxy poly(ethylene glycol) maleimide, molecular weight 5 kDa (mPEG5k-
maleimide, Table 5.1) and methoxy poly(ethylene glycol) 3-(furan-2-yl)propanamide, 
molecular weight 5 kDa (mPEG5k-furan, Table 5.1) were synthesized according to 
previously published protocols [46]. Methoxy poly(ethylene glycol) acrylamide, 
molecular weight 5 kDa (mPEG5k-acrylamide, Table 5.1) was synthesized from 
methoxy poly(ethylene glycol) amine as described by Browning et al. [34, 120]. 
Table 5.1: Linear poly(ethylene glycol) derivatives 
Name Chemical structure 
mPEG5k-maleimide 
 
mPEG5k-furan 
 
mPEG5k-vinyl sulfone 
 
mPEG5k-acrylamide 
 
mPEG6k-thiol 
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Lysozyme stock solutions (c = 1.33 mg/mL) were prepared in water, 25 mM acetate 
buffer pH 4.0, 25 mM acetate buffer pH 5.0, 25 mM phosphate buffer pH 6.0, PBS 
(pH 7.0 – 7.2) and 50 mM borate buffer pH 9.0. To determine the protein reactivity, 
1.83 µmol of each polymer (Table 5.1) were dissolved in 400 µL of the prepared 
lysozyme stock solutions and incubated for 24 h at 37 °C. Additionally, stoichiometric 
mixtures of mPEG5k-maleimide and mPEG5k-furan, mPEG5k-vinyl sulfone and 
mPEG6k-thiol, and mPEG5k-acrylamide and mPEG6k-thiol in 400 µL of lysozyme 
stock solution were investigated; 1.83 µmol of each polymer were used. In a further 
experiment, 1.83 µmol of mPEG5k-acrylamide in 400 µl of lysozyme stock solution 
were combined with a radical initiator consisting of 4 % (m/m) ammonium persulfate 
and 2 % (m/m) TEMED based on the polymer mass. SDS-PAGE was used to analyze 
the resulting protein-polymer conjugates [35]. In brief, polyacrylamide gels of 14 % 
cross-linking were run for about 1.5 h at a constant voltage of 120 V and a decreasing 
current starting at 68 mA. The protein amount was 27.93 µg per lane. The gels were 
stained with Coomassie brilliant blue G-250 and imaged with a ChemiDoc™ MP gel 
imaging system (Bio-Rad Laboratories GmbH, München, Germany). The relative 
abundance of the different protein species was determined by using the software Image 
Lab™ (Bio-Rad Laboratories GmbH, München, Germany). Afterwards, the conjugated 
PEG chains were visualized by iodine staining as described by Natarajan [65]. All 
conjugation studies were done in triplicate and the results are presented as 
means ± standard deviations. 
 
 
The protein-polymer conjugates that formed during incubation with hydrogel cross-
linking agents were analyzed by SDS-PAGE. Figure 5.1 exemplarily shows the 
modification of lysozyme with mPEG5k-maleimide at different pH-values.  
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Figure 5.1: Modification of lysozyme with mPEG5k-maleimide analyzed by SDS-
PAGE. Gels were stained with Coomassie brilliant blue (A) and barium iodide (B). 
Lysozyme was incubated with the polymer at different pH values at 37 °C for 24 h. 
After protein staining with Coomassie brilliant blue, the conjugated PEG chains were 
visualized by an iodine staining. In this way, protein species with attached PEG chains 
appeared as brown spots, while free lysozyme was detected by its dark blue staining. 
The relative abundance of free and modified lysozyme was determined and the results 
are presented in Figure 5.2.  
Lysozyme incubated with mPEG5k-maleimide was modified with one to three PEG 
chains. Depending on the pH of the incubation medium, the amount of unmodified 
lysozyme decreased from 79 ± 1.1 % (pH 4) to 36 ± 1.8 % (pH 9); 76 ± 4.3 % of the 
total protein amount were unmodified after incubation with mPEG5k-maleimide in 
water (Figure 5.2 A). When lysozyme was incubated with mPEG5k-vinyl sulfone, the 
degree of modification increased with increasing pH (Figure 5.2 B). In water and at 
pH 4, lysozyme was modified with one PEG chain, at pH 5 with two PEG chains, at 
pH 6 with three PEG chains and in PBS with four PEG chains. At pH 9, lysozyme was 
completely modified with more than five PEG chains; the highest amount of free 
lysozyme (87 ± 3.2 %) was detected at pH 4. Incubation with mPEG5k-acrylamide 
caused conjugation of one or two PEG chains per protein molecule at pH 9 (Figure 5.2 
C). With increasing pH, the relative abundance of free lysozyme decreased from 
96 ± 1.2 % (pH 4) to 64 ± 1.2 % (pH 9). 
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Figure 5.2: Modification of lysozyme with mPEG5k-maleimide (A), mPEG5k-vinyl 
sulfone (B), and mPEG5k-acrylamide (C) at different pH-values. The relative 
abundance of the different lysozyme species was determined by SDS-PAGE. The 
gray scale indicates the number of attached PEG chains. The experiments were done 
in triplicate and the results are shown as means ± standard deviations. 
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After incubation with mPEG6k-thiol, lysozyme was modified with one to two PEG 
chains (Figure 5.3). The degree of modification did not depend on the pH; 
83 ± 0.9 % (water) to 93 ± 0.8 % (pH 6) of the total lysozyme amount remained 
unmodified. 
 
Figure 5.3: Incubation of lysozyme with mPEG6k-thiol for 24 h at 37 °C. The relative 
abundance of lysozyme species was analyzed by SDS-PAGE. The gray scale 
indicates the number of attached PEG chains. Results are shown as means ± standard 
deviations (n = 3). 
After incubation with the stoichiometric mixture of mPEG5k-maleimide and mPEG5k-
furan, pH-dependent modification of lysozyme was observed (Figure 5.4 A); the 
amount of free lysozyme decreased with increasing pH form 75 ± 0.4 % (pH 4) to 
33 ± 1.9 % (pH 9). Incubation with mPEG5k-furan alone also resulted in modification 
of 2 ± 0.7 % to 7 ± 1.7 % of the total lysozyme amount (data not shown). Upon 
incubation with mPEG5k-vinyl sulfone and mPEG6k-thiol, the degree of modification 
slightly increased at low pH-values and decreased at high pH-values (Figure 5.4 B). At 
pH 4, 73 ± 4.8 % of the total lysozyme amount remained unmodified; however, 
lysozyme was completely modified with two to seven PEG chains at pH 9. The 
incubation of lysozyme with mPEG5k-acrylamide and mPEG6k-thiol resulted in the 
conjugation of two PEG chains (Figure 5.4 C). The degree of modification increased at 
basic pH. At pH 4, 88 ± 1.9 % of the introduced lysozyme were unmodified, whereas 
only 72 ± 1.7 % remained unmodified at pH 9. The addition of a radical initiator to 
mPEG5k-acrylamide resulted in heavily modified protein species, with up to five PEG 
chains being attached in water (Figure 5.4 D). The amount of unmodified lysozyme 
varied between 82 ± 2.5 % (pH 4) and 72 ± 1.8 % (pH 9).  
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Figure 5.4: Modification of lysozyme after incubation with mixtures of mPEG5k-
maleimide and mPEG5k-furan (A), mPEG5k-vinyl sulfone and mPEG6k-thiol (B), 
mPEG5k-acrylamide and mPEG6k-thiol (C), and mPEG5k-acrylamide with a radical 
initiator (D) at different pH-values. The gray scale indicates the number of attached 
PEG chains. Results are shown as means ± standard deviations (n = 3). 
 
Several amino acids of proteins are prone to side reactions during cross-linking of 
hydrogels. Nucleophilic amino acids (e.g., arginine, cysteine, histidine, lysine and 
tryptophan) can react with α,β-unsaturated carbonyl compounds in Michael-type 
addition reactions. Sulfhydryl groups of cysteine residues are strong nucleophiles, 
especially in the ionized form. These are followed by primary and secondary amino 
groups; the α-amino group of the N-terminus, ε-amino groups of lysine residues, 
secondary amines of histidine and tryptophan, and the guanidino group of arginine 
exhibit moderate nucleophilicity. The α-carboxyl group of the C-terminus, ß-carboxyl 
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groups of aspartic acid, γ-carboxyl groups of glutamic acid, and hydroxyl groups of 
tyrosine residues are weak nucleophiles [131]. As nucleophilicity depends on the 
ionization of the involved functional groups, nucleophilic addition reactions of proteins 
are pH-dependent. Generally speaking, nucleophilicity is increased near or above the 
pKa of the functional group. However, the actual pKa-values within the three-
dimensional protein structure differ from the theoretical values due to strong effects of 
the existing microenvironment [131]. The reactivity of amino acid residues further 
depends on their position in the protein structure. Nucleophiles on the protein surface 
can react more easily than those located in the core of the protein. For example, 
hydrophilic amino acids, in particular lysine residues, are mostly located on the protein 
surface, while hydrophobic amino acids are usually buried inside the protein structure 
[131]. Most cysteine residues are located in the protein core and covalently bound to 
other cysteine residues to form disulfide bonds [132]. Therefore, their reactivity in 
Michael-type addition reactions is low despite the high nucleophilicity of the free thiol 
group. Possible side reactions occurring at cysteine residues of proteins also include 
thiol-disulfide exchange reactions between thiol groups of polymers and disulfide 
bonds. 
In our experiments, lysozyme served as a model protein to determine possible side 
reactions with polymers commonly used for hydrogel preparation (Figure 5.5). The 
amino acid sequence of lysozyme contains eight cysteine residues (Cys 6, 30, 64, 76, 
80, 94, 115, and 127) bound in four disulfide bonds, which can be attacked during 
cross-linking [133]. Besides, lysozyme has six lysine residues and one N-terminus. 
Three of the lysine residues are located on the protein surface (Lys 1, 33, and 97), while 
the others are buried inside the three-dimensional protein structure [82, 133–136]. 
Furthermore, four out of eleven arginine residues are located on the protein surface (Arg 
14, 21, 73, 128) [134, 135, 137]. However, the guanidino of arginine is less nucleophilic 
than the ε-amino group of lysine and, therefore, less susceptible to side reactions [137]. 
Lysozyme additionally contains one histidine residue (His 15), which is located on the 
protein surface [133, 138]; but secondary amines are generally less reactive in Michael-
type addition reactions than primary amines [139]. The same applies to the five 
tryptophan residues on the protein surface (Trp 62, 63, 108, 111, and 123) [140]. 
Consequently, lysine residues mainly react in Michael-type addition reactions, while 
cysteine residues are sensitive to thiol-disulfide exchange reactions.  
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Figure 5.5: Three-dimensional structure of lysozyme with highlighted nucleophilic 
amino acids (red: lysine; cyan: cysteine; coral: arginine, histidine, and tryptophan). 
The structure model was created using the CCP4 Moleclar Graphics software [5]. 
Structural information is based on results from Diamond (PDB ID: 2 LYZ) [6]. 
To study potential side reactions with lysozyme, mono-functional PEG derivatives were 
used to prevent gelation of the protein solutions during incubation and electrophoresis. 
The used polymer amounts corresponded to the typical concentrations of cross-linking 
agents in common hydrogel formulations [46, 120, 127]. It should be pointed out that 
low molecular weight cross-linkers, such as N,N’-methylenebisacrylamide, are also 
commonly used in hydrogel formations. In comparison to polymers, these cross-linkers 
may lead to even higher degrees of protein modification due to less steric hindrance and 
easier approach to reactive amino acids. Michael-type additions of nucleophilic side 
chains to vinyl groups were observed after incubation of lysozyme with mPEG5k-
maleimide, mPEG5k-vinyl sulfone, and mPEG5k-acrylamide (Figure 5.2). This type of 
reaction has already been exploited for site-specific protein PEGylation [61, 141]. As 
already discussed above, Michael-type addition reactions are pH-dependent due to 
ionization of the involved functional groups [131, 142]. As a result of this, the extent of 
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protein modification and the number of attached PEG chains increased with increasing 
pH of the incubation medium. Interestingly, incubation of lysozyme with mPEG5k-
maleimide, mPEG5k-vinyl sulfone, or mPEG5k-acrylamide in ultrapure water resulted 
in low degrees of modification comparable to those at pH 4 or pH 5. This is explained 
by protonation of amino groups in ultrapure water, which has a slightly acidic pH due to 
dissolved carbon dioxide. The degree of modification was similar after incubation of 
lysozyme with mPEG5k-maleimide and mPEG5k-vinyl sulfone (Figure 5.2 A and B). 
Incubation with mPEG5k-maleimide resulted in a slightly increased degree of 
modification at acidic pH, while incubation with mPEG5k-vinyl sulfone caused heavy 
protein modification at neutral and basic pH. In comparison to mPEG5k-maleimide and 
mPEG5k-vinyl sulfone, only moderate protein modification was detected after 
incubation with mPEG5k-acrylamide (Figure 5.2 C). Especially at neutral and basic pH, 
the degree of modification was much lower compared to the two other Michael 
acceptors. The reactivity of Michael acceptors mostly depends on the electron 
deficiency of the vinyl group. Therefore, maleimide and vinyl sulfone groups are more 
reactive in Michael-type addition reactions than acrylamides [139, 143]. Furthermore, 
maleimide is obviously a stronger electrophile than vinyl sulfone; Michael-type 
additions to vinyl sulfone groups are slower, with the reaction rate increasing with the 
pH of the incubation medium [61, 141]. Besides Michael-type addition reactions, thiol-
disulfide exchange reactions were observed after incubation of lysozyme with mPEG6k-
thiol (Figure 5.3). Thiol groups of the polymer can reduce disulfide bonds of the protein 
independent from the pH of the incubation medium [51]. 
To mimic the conditions during hydrogel formation, mPEG5k-maleimide, mPEG5k-
vinyl sulfone, and mPEG5k-acrylamide were incubated together with suitable reaction 
partners and lysozyme. For example, branched PEG-maleimides can be polymerized 
with furan substituted PEG derivatives by means of Diels-Alder reactions to form 
covalently cross-linked hydrogels [46]. The addition of stoichiometric amounts of 
mPEG5k-furan should, therefore, suppress side reactions between mPEG5k-maleimide 
and lysozyme. However, Tang et al. found that the Michael addition of methanethiol to 
N-methylmaleimide has a much lower energy barrier than the Diels-Alder reaction 
[144]. This is in good agreement with our experimental data showing only slightly 
decreased levels of protein modification in the presence of both mPEG5k-maleimide 
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and mPEG5k-furan (Figure 5.4 A). Obviously, Michael-type additions of primary 
amino groups to maleimides are generally favored over Diels-Alder reactions.  
Besides Diels-Alder reactions, Michael-type additions of nucleophiles to α,β-
unsaturated carbonyl compounds have been frequently exploited for hydrogel 
preparation. For example, thiol-maleimide coupling [51, 92, 127] and Michael-type 
additions of thiol groups to vinyl sulfone or acrylate groups [56, 121–124] were used as 
cross-linking reactions for hydrogels. Lutolf et al. used PEG-acrylates and cysteine-
containing oligopeptides for the preparation of covalently cross-linked hydrogels [123]. 
They postulated selectivity of PEG-acrylates for thiols over biological amines at 
physiological conditions [131, 142]. Elbert et al. reported that the reaction rates of 
amino groups in Michael-type addition reactions were lower than those of thiol groups 
[121]. The half-lives of N-actyl-L-cysteine and α-N-acetyl-L-lysine in Michael-type 
additions to PEG-monoacrylates at physiological conditions were approx. 7 min and 
21 h, respectively. Albumin remained almost unmodified after 1 h of incubation with 
PEG-diacrylate. However, the expected selectivity of mPEG5k-vinyl sulfone and 
mPEG5k-acrylamide for thiol groups was not fully confirmed in our experiments. 
Incubation of lysozyme with both mPEG5k-vinyl sulfone and stoichiometric amounts of 
mPEG6k-thiol resulted in slightly increased levels of protein modification in water and 
at pH 4, most likely due to thiol-disulfide exchange reactions (Figure 5.4 B). Above 
pH 5, however, the extent of protein modification and the number of attached PEG 
chains clearly decreased. The addition of stoichiometric amounts of mPEG6k-thiol to 
mPEG5k-acrylamide slightly increased the degree of polymer conjugation under all 
tested conditions except for pH 9 (Figure 5.4 C). Side reactions between proteins and 
polymers during hydrogel formation have also been reported in the literature. For 
example, van de Wetering et al. described modification of human growth 
hormone (hGH) during cross-linking of PEG-acrylates with dithiothreitol [122]. 
Hiemstra et al. observed incomplete protein release and precipitation due to reactions of 
amino groups and disulfide bonds with vinyl sulfone and thiol groups of the gel-forming 
polymers [124]. 
Radical polymerization of acrylate or acrylamide derivatives is another frequently 
applied cross-linking chemistry. The addition of a radical initiator increased the degree 
of protein modification compared to mPEG5k-acrylamide alone (Figure 5.4 D). Side 
reactions between proteins and acrylate-containing polymers during radical 
polymerization of hydrogels have been described by several groups [59, 119, 145]. For 
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example, incomplete protein release and loss of activity were observed, most likely due 
to covalent binding of proteins through radical chain transfer to thiols or other 
susceptible groups. Modification of proteins by Michael-type addition reactions may be 
less pronounced in radical polymerizations. Furthermore, protein denaturation and 
aggregation can be triggered by the presence of free radicals [146]. 
When cross-linking of hydrogels is performed in the presence of proteins, side reactions 
between the incorporated proteins and the gel-forming polymers are likely to occur. 
This may affect the three-dimensional protein structure, which is often associated with 
loss of activity, decreased availability and increased risk for immune responses. The 
number of the attached polymer chains and the site of modification play an important 
role for the extent of structural damage and the observed loss of activity. In our 
experiments, the number of conjugated PEG chains was dependent on the cross-linking 
reagent and the reaction conditions. In several instances, more than three PEG chains 
were attached to the protein. Lysozyme can be modified with one to three polymer 
chains at the three lysine residues on the protein surface without causing structural 
damage [35, 83]; however, a higher degree of modification may lead to structural 
breakdown [82, 83]. Incubation of lysozyme with mPEG5k-vinyl sulfone in PBS 
resulted in modification with more than three PEG chains; at pH 9, more than five PEG 
chains had been attached to the protein (Figure 5.2 B). The addition of mPEG6k-thiol 
increased the amount of unmodified lysozyme and decreased the number of attached 
PEG chains (Figure 5.4 B). Nevertheless, protein species with more than three 
conjugated PEG chains were still detectable at pH 9. Likewise, incubation with 
mPEG5k-acrylamide and a radical initiator resulted in protein species with more than 
three conjugated PEG chains (Figure 5.4 D). Although it is not possible to determine the 
exact site of protein modification by SDS-PAGE, structural damage of lysozyme is very 
likely.  
Several strategies can be applied to protect proteins against side reactions during cross-
linking of hydrogels. For example, cross-linking can be performed in slightly acidic 
solutions below pH 5. This decreases the nucleophilicity of amino groups by 
protonation and reduces their reactivity in Michael-type addition reactions. Cross-
linking by Diels-Alder reactions is, on the other hand, unaffected by acidic pH-values as 
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this reaction is basically pH-independent. It should be pointed out that lowering the pH 
may induce protein degradation and aggregation [18, 147]. The majority of antibodies, 
however, seem to be stabilized in slightly acidic solution [147]. Nevertheless, the 
stability of each individual protein must be carefully evaluated for all cross-linking 
conditions in question. In hydrogels formed by Michael-type addition reactions, protein 
modification can be prevented by precipitation with PEG or Zn2+ [122]. The 
incorporation of solid protein particles effectively protected hGH during hydrogel 
formation, and complete protein release was observed. To protect proteins during 
radical polymerizations, Lin et al. proposed the addition of transition metal chelators 
during hydrogel formation. Iminodiacetic acid and Cu2+ were used as protein binding 
ligands to minimize the exposure of reactive amino acid residues to free radicals [146]. 
In a different approach, Censi et al. succeeded in retaining protein activity during 
photopolymerization of methacrylate groups by separating hydrophobic polymerization 
sites from more hydrophilic protein-containing areas [118].  
 
In this chapter, potential side reactions of selected cross-linking agents with proteins 
were investigated. The conjugation of polymer chains by Michael-type addition 
reactions, thiol-disulfide exchange reactions or radical reactions was determined by 
SDS-PAGE. Incubation of lysozyme with mPEG5k-maleimide, mPEG5k-vinyl sulfone 
or mPEG5k-acrylamide resulted in pH-dependent Michael-type additions of 
nucleophilic amino acid residues to the vinyl group. The addition of suitable reaction 
partners (e.g., mPEG5k-furan or mPEG6k-thiol) did not noticeably reduce the degree of 
protein modification. Protein-polymer conjugates detected after incubation with 
mPEG6k-thiol were attributed to thiol-disulfide exchange reactions. Incubation of 
lysozyme with mPEG5k-acrylamide and a radical initiator caused radical-induced 
protein modifications, with a large number of PEG chains being attached. Although 
many cross-linking reactions (e.g., Diels-Alder reactions and Michael-type addition 
reactions) are considered selective, caution should be used when hydrogels are cross-
linked in the presence of proteins. Proteins contain a large number of nucleophilic 
amino acid residues and are, therefore, prone to side reactions with cross-linking agents. 
The occurring protein modifications are often accompanied by incomplete release, 
structural damage, loss of bioactivity, or increased risk for immune responses [12, 51]. 
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Therefore, side reactions between proteins and polymers, and possible strategies to 
prevent these should always be considered when developing new hydrogels for protein 
delivery.  
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In this chapter, the suitability of Diels-Alder hydrogels for controlled protein release 
was investigated. For this purpose, three model proteins (lysozyme, α-chymotrypsin (α-
CT), γ-globulin) were used. α-CT and γ-globulin were incubated with linear derivatives 
of the gel precursor in order to detect side reactions. The extent of modification detected 
by SDS-PAGE varied between 0 % (incubation of γ-globulin with mPEG5k-maleimide 
at pH 4 and incubation of α-CT with mPEG5k-furan at pH 9) and 89 ± 5.5 % 
(incubation of γ-globulin with a mixture of mPEG5k-maleimide and mPEG5k-furan at 
pH 9) depending on the protein, the pH during incubation and the functionalization of 
the polymer. The mobile fraction of the three proteins incorporated in Diels-Alder 
hydrogels decreased with increasing pH due to covalent protein binding to the hydrogel 
network at pH 7.4 as detected by fluorescence recovery after photobleaching (FRAP). 
The diffusion coefficients depended on the hydrodynamic diameter of the protein and 
mesh size of the hydrogel. Likewise protein release depended on both parameters and 
the pH during cross-linking. After cross-linking in water 94.2 ± 3.4 % of lysozyme and 
54.2 ± 6.2 % of α-CT was released over 24 h. After cross-linking in PBS (pH 7.0 - 7.2), 
protein release occurred along with hydrogel degradation. γ-Globulin was released 
along with hydrogel degradation in all cases due to its large hydrodynamic diameter. 
Protein activity could be almost retained (lysozyme) or even improved (α-CT) 
compared to reference solution by incorporating the protein in Diels-Alder hydrogels 
and cross-linking at pH 4.  
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For many diseases controlled delivery of therapeutic proteins directly to the site of 
action over a longer period of time is the best way of application for an efficient 
treatment [50]. In the field of bone regeneration, for example, Jeon et al. reported on an 
enhanced therapeutic benefit of prolonged delivery of bone morphogenetic protein 
compared to rapid release of the same protein [148]. Especially tissues, which are hard 
to target systemically, can be treated more effectively by an application directly to the 
site of action. The retina, for example, is hard to reach via systemic applications due to 
the blood retina barrier [9, 149]. To overcome this problem, intravitreous injections 
proved to be an effective treatment of retinal diseases and offer the advantage of 
minimal systemic side effects [9, 149]. Hydrogels are suitable protein carrier to meet 
both requirements: local application and long-time release. In form of in-situ gelling 
systems, hydrogels can be minimally invasively injected directly to the diseased site 
[124, 150, 151]. Furthermore, hydrogels offer a broad range of technological 
opportunities to tailor the release profiles [12]. These methods include polymer-protein 
interactions, such as reversible covalent protein attachment to the hydrogel backbone, or 
non-covalent interactions, such as electrostatic interactions [12, 35]. Furthermore, 
encapsulation in secondary carriers, such as micro- or nanoparticles, has been reported 
[12]. A simple and mild strategy to control the release is to tailor drug diffusion inside 
the hydrogel and to optimize swelling and degradation behavior of the hydrogel via 
structural properties, such as the cross-linking density [12]. Diffusion controlled release 
is associated with protein mobility inside the hydrogel, which depends on the hydrogel 
mesh size and the hydrodynamic radius of the protein [118]. For proteins with a 
hydrodynamic diameter larger than the mesh size, diffusion out of the hydrogel is 
limited; protein release is only possible with increasing mesh size during degradation or 
at least swelling of the hydrogel [12, 124].  
Besides others, Diels-Alder hydrogels developed by Kirchhof et al. are promising 
formulations to control protein release via hydrogel mesh size, swelling and degradation 
[46]. These hydrogels consist of star-shaped 8armed poly(ethylene glycol) (PEG) 
resulting in well-defined networks [46]. The network mesh-size can be tailored by 
varying the molecular weight of the PEG derivatives [46]. The PEG functionalization 
with furyl and maleimide groups allows cross-linking by Diels-Alder reaction. Diels-
Alder reactions are part of the “click” chemistry and occur without catalyst or initiator 
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[128, 129]. Due to the reported biodegradability by retro-Diels-Alder reaction, the 
formulations are promising for degradation controlled release [46]. However, besides 
these advantages, side reactions of the gel precursor with proteins have been observed 
(see Chap. 5) [152]. Especially at basic pH, Michael-type addition reactions of 
nucleophilic amino acids with the maleimide group occur (see Chap. 5) [152].  
In this chapter, the suitability of Diels-Alder hydrogels as protein depot formulations for 
controlled delivery was investigated. A special focus was on optimizing hydrogel 
preparations in order to prevent side reactions of the gel precursors with the 
incorporated proteins and to retain protein activity. For this purpose, alpha 
chymotrypsin (α-CT) and γ-globulin were incubated with linear, mono-functionalized 
PEG derivatives (mPEG5k-maleimide, mPEG5k-furan) at different pH values and 
analyzed by SDS-PAGE in order to detect side reactions as already described for 
lysozyme (see Chap. 5). Additionally, the three model proteins (lysozyme, α-CT, γ-
globulin) were incorporated in Diels-Alder hydrogels in order to determine their 
mobility inside the hydrogel using fluorescence recovery after photobleaching (FRAP) 
and classical release studies. Finally, the enzymatic activity of lysozyme and α-CT after 
incubation with mPEG5k-maleimide, and after release from Diels-Alder hydrogels was 
analyzed.  
 
 
Mini-Protean TGX Precast Gels Any kD were purchased from Bio-Rad Laboratories 
GmbH (München, Germany). Tetramethylethylenediamine (TEMED) was purchased 
from Carl Roth GmbH & Co. KG (Karlsruhe, Germany). 2-Amino-2-hydroxymethyl-
propane-1,3-diol (TRIS) was obtained from GE Healthcare Europe GmbH (Freiburg, 
Germany). Dulbecco’s phosphate-buffered saline (PBS) (pH 7.0 – 7.2) was purchased 
from Invitrogen GmbH (Karlsruhe, Germany). Ethanol was from CSC Jäcklechemie 
(Nürnberg, Germany). Eight-armed poly(ethylene glycol) with a molecular weight of 
10 kDa and 20 kDa was purchased from JenKem Technology (Allen, TX, USA). 
Acrylamide/bisacrylamide solution (37.5 : 1), bromphenol blue sodium salt, and sodium 
dodecylsulfate were obtained from Serva Electrophoresis GmbH (Heidelberg, 
Germany). α-Chymotrypsin (α-CT) (from bovine pancreas), γ-globulins (from bovine 
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blood), Coomassie brilliant blue G-250, lysozyme (from chicken egg white), 
micrococcus lysodeikticus, sodium tetraborate decahydrate, N-succinyl-Ala-Ala-Pro-
Phe p-nitroanilide, and methoxy poly(ethylene glycol) with a molecular weight of 5 kDa 
were purchased from Sigma Aldrich (Taufkirchen, Germany). Lab-TekTM II chambered 
cover glass slides were purchased form Thermo Fisher Scientific (Langenselbold, 
Germany). GHP Acrodisc®13 mm syringe filters (0.2 µm pore size) were purchased 
from Pall GmbH (Dreieich, Germany). All other chemicals were purchased from Merck 
KGaA (Darmstadt, Germany). Deionized water was freshly prepared using a Milli-Q 
water purification system from Millipore (Schwalbach, Germany). Py1-labeled proteins 
(Py1-lysozyme, Py1-α-Ct, Py1-γ-globulin) were kindly provided by Dr. Robert Meier, 
Institute of Analytical Chemistry, Chemo- and Biosensors, University of Regensburg.  
 
Methoxy poly(ethylene glycol) amine (mPEG5k-NH2), methoxy poly(ethylene glycol) 
maleimide (mPEG5k-maleimide), and methoxy poly(ethylene glycol) 3-(furan-2-
yl)propanamide (mPEG5k-furan) with a molecular weight of 5 kDa  were synthesized 
according previously published procedures [34, 46].  
 
Eight-armed poly(ethylene glycol) maleimide (8armPEG10k-maleimide, 8armPEG20k-
maleimide) and eight-armed poly(ethylene glycol) 3-(furan-2-yl)propanamide 
(8armPEG10k-furan, 8armPEG20k-furan) with molecular weights of 10 kDa or 20 kDa 
were synthesized as described by Kirchhof et al. [46]. 
 
Side reactions of the hydrogel precursors with α-CT were detected by SDS-PAGE. α-CT 
stock solutions with concentrations of 2.66 mg/mL were prepared in water and different 
buffers (25 mM acetate buffer pH 4.0, 25 mM acetate buffer pH 5.0, 25 mM phosphate 
buffer pH 6.0, PBS (pH 7.0 – 7.2) and 50 mM borate buffer pH 9.0). To determine 
protein modifications, 400 µL of each stock solution were incubated with 3.66 µmol of 
mPEG5k-furan, mPEG5k-maleimide, or stoichiometric mixtures of both polymers at 
37 °C for 24 h. Afterwards all samples were analyzed by SDS-PAGE. For comparison, 
stock solutions were handled the same way and loaded next to the corresponding 
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protein-polymer mixtures on the stacking gel. SDS-PAGE was conducted on Mini-
Protean TGX Precast Gel Any kD at a constant voltage of 120 V and a decreasing 
current starting at 68 mA. For all samples, 55.86 µg of α-CT were loaded per lane. 
Afterwards, the gels were stained with Coomassie brilliant blue G-250. For 
documentation and quantification, the gels were imaged with a ChemiDoc™ MP gel 
imaging system (Bio-Rad Laboratories GmbH, München, Germany). The software 
Image Lab™ (Bio-Rad Laboratories GmbH, München, Germany) was used to 
determine the relative abundance of protein-polymer conjugates. The experiments were 
performed in triplicate and the results are presented as means ± standard deviations. 
 
γ
Side reactions of the gel precursors with γ-globulin were detected by SDS-PAGE. γ-
Globulin stock solutions (c = 1.33 mg/mL) were prepared in water and different buffers 
(25 mM acetate buffer pH 4.0, 25 mM acetate buffer pH 5.0, 25 mM phosphate buffer 
pH 6.0, PBS (pH 7.0 – 7.2) and 50 mM borate buffer pH 9.0). To detect possible side 
reactions, 1.83 µmol of mPEG5k-furan, mPEG5k-maleimide or stoichiometric mixtures 
of both polymers were incubated with 400 µL of each stock solution at 37 °C for 24 h. 
Protein-polymer conjugates were analyzed by SDS-PAGE using polyacrylamide gels of 
5 % cross-linking. Stock solutions treated the same way were loaded next to the 
corresponding protein-polymer mixtures for comparison. The amount of γ-globulin per 
lane was 27.93µg. Electrophoresis and quantification were carried out as described for 
α-CT in 6.2.4.  
 
FRAP experiments were performed following a method described by Brandl et al. 
[153]. 3.0 mg/mL stock solutions of Py1-labeled proteins (Py1-lysozyme, Py1-α-CT, 
Py1-γ-globulin) were prepared in 50 mM acetate buffer pH 4 or 50 mM phosphate 
buffer pH 7.4, respectively. 8armPEG-furan with molecular weights of 10 kDa or 
20 kDa were dissolved in 50 mM acetate buffer pH 4 or 50 mM phosphate buffer 
pH 7.4, respectively, to a final concentration of 156.3 mg/mL. Afterwards, the solution 
was filtered through a hydrophilic propylene membrane syringe filter (GHP 
Acrodisc®13 mm syringe filter).  
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8armPEG-maleimide (10 kDa / 20kDa) (c = 143.7mg/mL) was dissolved in 50 mM 
acetate buffer pH 4 or 50 mM phosphate buffer pH 7.4, respectively. For hydrogel 
preparation, equal amounts of protein stock solution, filtered 8armPEG-furan solution, 
and 8armPEG-maleimide solution were combined. 250 µL of the mixture were cast into 
a Lab-TekTM II Chambered Cover glass and allowed to gel for 24 h at 37 °C. The final 
composition for all hydrogels (8armPEG10k-hydrogels / 8armPEG20k-hydrogels) was 
10 % total polymer content and 1 mg/mL Py1-labeld protein.  
FRAP experiments were conducted using a LSM 510 META scanning device installed 
on a Zeiss Axiovert 200 M microscope (Carl Zeiss MicroImaging GmbH, Jena, 
Germany) equipped with a Plan-Neofluar 10x objective lens (numerical aperture 0.30). 
Imaging and bleaching was performed with an argon laser (488 nm, 30 mW) at 25 % 
output power with completely opened confocal pinhole. For the measurement, a 
homogenous area inside the gel was brought into focus. Digital images were recorded 
every 8 s using 0.5 % transmission. After the first five intervals, a defined area with a 
diameter of 36 µm was bleached at 100 % transmission with 30 iterations. Afterwards, 
75 further images of fluorescence recovery were recorded.  
To analyze the obtained data, fluorescence intensities in the bleached area (Iroi) and in 
the reference region (Iref) were calculated for each time point t using the NIH software 
ImageJ. The intensity of the bleached area Iroi(t) was normalized to the mean intensity 
detected before bleaching Iroi(pre). A correction factor for any bleaching effect 
occurring during image recording was included.  
 ݂(ݐ) =  ூೝ೐೑(௣௥௘)
ூೝ೐೑(௧)
∙ ூೝ೚೔(௧)
ூೝ೚೔(௣௥௘)
     (7.1) 
f(t) is the corrected and normalized intensity of the bleached region of interest. 
Iref(pre) is the fluorescence intensity of the reference region before bleaching. 
Iref(t) is the fluorescence intensity of the reference region at each time point t. 
Iroi(pre) is the fluorescence intensity of the region of interest before bleaching. 
Iroi(t) is the fluorescence intensity of the region of interest at each time point t. 
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In the next step, f(t) was normalized to full scale using the following equation (7.2).  
ܨ(ݐ) =  ௙(௧)ି௙(଴)
௙(௣௥௘)ି௙(଴)
     (7.2) 
F(t) is the fluorescence intensity of the region of interest normalized to full 
scale. 
f(t) is the normalized intensity of the bleached region of interest. 
f(0) is the normalized intensity of the region of interest directly after bleaching. 
f(pre) is the normalized intensity of the region of interest before bleaching. 
The last step was a least-squares fit of the following equation to the experimental 
recovery data to determine the diffusion time TD and mobile fraction k. 
ܨ(ݐ) = ݇ ∙  ݁ି
೅ವ
మ೟  ቂܫ଴ ቀ ವ்ଶ௧ቁ  +  ܫଵ ቀ
ವ்
ଶ௧
ቁቃ  (7.3) 
k is the mobile fraction. 
TD is the diffusion time.  
I0 is the modified Bessel function of the first kind zero order. 
I1 is the modified Bessel function of the first kind first order. 
 
The diffusion time was used to calculate the diffusion coefficient D: 
ܦ =  
ݓଶ
஽ܶ
 
w is the radius of the bleached region of interest (18 µm in all experiments).  
 
Protein stock solutions of lysozyme, α-CT, or γ-globulin with a concentration of 
1.33 mg/mL were prepared in water and PBS. Stoichiometric amounts of 8armPEG-
furan and 8armPEG-maleimide were dissolved in the protein stock solution. The 
molecular weight of the polymer was either 10 kDa or 20 kDa (8armPEG10k-hydrogel / 
8armPEG20k-hydrogels). Aliquots of the prepared protein-polymer mixture (375 µL) 
were cast into glass cylinders (Ø 7 mm) and allowed to gel for 24 h at 37 °C. The total 
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polymer content was 10 % (w/v) in all experiments. For protein release, each gel 
cylinder was incubated in 5 mL of PBS in a shaking water bath at 37 °C. At defined 
time points, samples of 500 µL in volume were drawn and replaced by fresh PBS. The 
samples were stored at 4 °C until quantification. For calibration, stock solutions were 
diluted with PBS, and stored at 4 °C until measurement. Protein concentrations were 
determined using a method described by Bradford [69]. The measurements were 
performed on a Kontron UVIKON® 941 spectrophotometer (Kontron Instruments 
S.p.A, Milan, Italy). The obtained data was normalized to the initial protein amount 
(0.5 mg) per gel cylinder. All release experiments were done in triplicate and the results 
are presented as means ± standard deviations. 
 
The enzymatic activity of lysozyme was determined as described in Chap. 3 [35]. In 
brief: all samples were diluted to a protein concentration of maximal 0.01 mg/mL. 
100 µL of each protein sample were mixed with 2.5 mL of a 0.015 % Micrococcus 
lysodeikticus cell suspension in 66 mM phosphate buffer pH 6.2. The measurement was 
immediately started and the decrease in the absorption was recorded over 4.8 min at 
450 nm on a Kontron UVIKON® 941 spectrophotometer (Kontron Instruments S.p.A, 
Milan, Italy). During the measurement, all solutions were kept at a constant temperature 
of 25 °C. The slope of the linear part of the curve was used to determine the lytic 
activity of lysozyme.  
 α
The enzymatic activity of α-CT was determined following a procedure published by 
Solá and Griebenow [154]. For this purpose, a substrate solution of 0.4 mM N-succinyl-
Ala-Ala-Pro-Phe-p-nitroanilide was prepared in PBS (pH 7.0 – 7.2) and diluted 1 : 3.9 
with PBS before measurement. All protein samples were diluted to a protein 
concentration of maximal 0.02 mg/mL. In a cuvette, 25 µL of the protein sample and 
975 µL of the substrate dilution were mixed and the increasing amount of p-nitroaniline 
was followed over 4.8 min in 0.8 min intervals at 410 nm on a Kontron UVIKON® 941 
spectrophotometer (Kontron Instruments S.p.A, Milan, Italy). The lytic activity of α-CT 
was determined from the slope of the curve.  
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α
Protein stock solutions of lysozyme and α-CT, respectively, with a concentration of 
1.33 mg/mL were prepared in water and different buffers (25 mM acetate buffer pH 4.0, 
25 mM acetate buffer pH 5.0, 25 mM phosphate buffer pH 6.0, PBS (pH 7.0 – 7.2), 
50 mM borate buffer pH 9.0). To determine the effect of maleimide on the enzymatic 
activity, the stock solutions were incubated with 0.91 µmol, 1.83 µmol and 3.66 µmol 
of mPEG5k-maleimide at 37 °C for 24 h in a shaking water bath. Afterwards, the 
enzymatic activity of each sample was determined as described above. In case of 
lysozyme, reference solutions were prepared for comparison. For this purpose, non-
reactive mPEG5k-NH2 (0.91 µmol, 1.83 µmol, 3.66 µmol) was dissolved in each stock 
solution and incubated at 37 °C for 24 h. Due to the influence of PEG on the lytic 
activity each sample activity was normalized to the corresponding activity of the 
reference. In case of α-CT, all stock solutions were incubated at 37 °C for 24 h for 
comparison. Due to the pH dependence of α-CT activity, the obtained sample activities 
were normalized to the stock solution showing the highest activity after incubation 
(stock solution prepared at pH 4). All activities were determined in triplicate. The 
results are presented as means ± standard deviation. 
 
Protein stock solutions of lysozyme and α-CT, respectively, with a concentration of 
1.33 mg/mL were prepared in 25 mM acetate buffer pH 4. Hydrogel cylinders were 
prepared in the same way as described for the release experiments. After cross-linking 
the gels were incubated in 5 mL of PBS (pH 7.0 – 7.2) at 37 °C. After 24 h, the activity 
of the proteins released in the incubation medium was determined as described above. 
For this, all lysozyme samples were diluted 1:10 and all α-CT samples were diluted 1:5 
with PBS. Stock solutions were diluted with PBS and incubated at 37 °C for 24 h to 
serve as a reference. Additionally, the protein amount released in the incubation 
medium and the protein amount of the reference was quantified using the Bradford 
assay [69]. This allowed standardization of the obtained protein activities to activity per 
mg protein. The standardized sample activities were normalized to the standardized 
reference activity. All release experiments were performed in triplicate. The results are 
presented as means ± standard deviation. 
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In the previous chapters, lysozyme was used as a model protein to determine 
PEGylation and PEG chain elimination of carbamate linkers, or side reactions during 
cross-linking of different, selected gel precursors. Lysozyme consists of 129 amino 
acids arranged in a three-dimensional structure with a molecular weight (MW) of about 
14 kDa and a hydrodynamic radius (Rh) of about 2.1 nm [124, 155]. It is found in body 
fluids, tissues and macrophages of humans, and in many further vertebrate and 
invertebrate animals [156]. Due to its antibacterial activity, lysozyme is part of the 
innate immune defense of many species [156]. In different fields, such as protein 
chemistry, enzymology, crystallography, or molecular biology, lysozyme is used as a 
model system [156]. In this chapter, two further model proteins, α-chymotrypsin (α-CT) 
and γ-globulin, were used in addition to lysozyme.  
 
In Chap. 5, side reactions of Diels-Alder hydrogel precursors with surface exposed 
nucleophilic amino acids of lysozyme were reported. In case of lysozyme, Michael-type 
addition reactions of nucleophilic amino acids to the maleimide group were observed. 
Especially amino acid residues located on the protein surface are susceptible for side 
reactions. The highest nucleophilicity is described for cysteine residues [131]. However, 
cysteine residues are mostly bound in disulfide bonds inside the secondary protein 
structure and show, therefore, low accessibility for modifications by macromolecules 
[131, 132]. The next lower nucleophilicity is exhibited by lysine residues and the N-
terminus. The lowest reactivity in this series is described for secondary amines 
(histidine, tryptophan) and the guanidino group of arginine [131]. Here, side reactions 
of the cross-linking agents with two further model proteins, α-CT and γ-globulin, were 
investigated. In line with the published data obtained for lysozyme, the extent of protein 
modification with maleimide and furan groups and mixtures of both polymers was 
determined by SDS-PAGE using linear mono-functionalized PEG derivatives 
(mPEG5k-maleimide, mPEG5k-furan). 
α-Chymotrypsin (α-CT) has a MW of 25 kDa and an Rh of about 2.9 nm [157]. α-CT is 
a serine protease formed in the digestive tract from the inactive pancreas storage form, 
chymotrypsinogen, in order to hydrolyze polypeptides [158, 159]. It is used as a 
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biocatalyst in organic synthesis [158, 160]. α-CT has a number of nucleophilic amino 
acid residues exposed to the protein surface which are vulnerable to side reactions 
during cross-linking. These are 14 of the 28 lysine residues, both histidine residues, 6 of 
the 8 tryptophan residues, and all three arginine residues [158, 159, 161, 162]. The 10 
cysteine residues are bound in disulfide bridges and are, therefore, less accessible for 
modifications [158]. 
Figure 6.1 exemplarily shows the modification of α-CT after incubation with mPEG5k-
maleimide, mPEG5k-furan, and mixtures of both polymers in water and PBS in 
comparison to the corresponding stock solution. α-CT stock solutions were separated in 
more than one band per lane by electrophoresis, indicating the existence of different α-
CT derivatives. α-CT is known for autolysis as well as self-association which might 
explain the appearance of different molecular weight species in the stock solution [163, 
164]. This complicates the interpretation of the SDS-PAGE data compared to lysozyme.  
 
Figure 6.1: Modification of α-CT in water (lane 1 - 4) and PBS (lane 5 – 8) analyzed by 
SDS-PAGE. α-CT stock solutions prepared in water (lane 1) and in PBS (lane 5) 
served as a reference. The stock solutions were incubated with mPEG5k-furan 
(lane 2 and lane 6), with mPEG5k-maleimide (lane 3 and lane 7) and with a mixture 
of both polymers (lane 4 and lane 8) for 24 h. 
For quantification, all modified species and all unmodified species were grouped and 
the results are presented in Figure 6.2. Incubation with mPEG5k-furan resulted in 
minor unspecific binding of less than 20 ± 0.9 % of the used amount of α-CT (pH6) 
(Figure 6.2 A). At pH 9, α-CT remained unaffected during incubation with mPEG5k-
furan. During incubation with mPEG5k-maleimide, the amount of free α-CT decreased 
with increasing pH from 90 ± 2.5 % (pH 4) to 21 ± 4.3 % (pH 9). (Figure 6.2 B). This 
can be explained by Michael-type addition reactions of nucleophilic, surface-exposed 
amino acids to maleimide as already described for lysozyme.  
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Figure 6.2: Modification of α-Chymotrypsin at different pH values. α-CT was 
incubated with mPEG5k-furan (A), mPEG5k-maleimide (B), and a mixture of both 
polymers (C) at 37 °C for 24 h. The results are shown as means ± standard deviation. 
An exception was the incubation in PBS, which resulted in only 22.4 ± 2.3 % 
modification of α-CT, compared to 44.7 ± 8.1 % and 79.4 ± 4.3 % modification of α-
CT, respectively, during incubation at pH 6 and pH 9.  
Incubation with a stoichiometric mixture of both polymers also resulted in pH-
dependent modifications (Figure 6.2 C). At pH 4, 85 ± 6.6 % of the total α-CT amount 
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remained unaffected; at pH 9, only 41 ± 8.5 % of free α-CT was detected. Incubation at 
pH 5, pH 6 and in PBS resulted in similar extent of modification (57 % to 61 % of free 
α-CT). Incubation in water resulted in a higher degree of modification (57 ± 3.4 % of 
modified α-CT) than expected. Due to the slightly acidic pH of ultrapure water, a degree 
of modification similar to that detected after incubation at pH 4 was expected. However, 
in contrast to a buffer the pH of ultrapure water is not exactly adjusted to a certain pH 
and might vary with each use. Furthermore, the pH of ultrapure water might change 
during the experiment due to the absence of buffer capacity. For these reasons, the 
detected reactivity in water might be different for each experiment. The stoichiometric 
mixture of mPEG5k-maleimide and mPEG5k-furan was used to mimic the conditions 
during hydrogel formation. Side reactions of mPEG5k-maleimide should be suppressed 
by the availability of a reaction partner. However, only at pH 9, a decreased extent of 
modification was observed after incubation with both polymers compared to mPEG5k-
maleimide alone. As already observed for incubation with lysozyme (see Chap. 5), 
Michael-type addition reactions are preferred over Diels-Alder reactions due to the 
lower energy barrier of Michael additions [144].  
As antibodies are of particular relevance for the clinical treatment of diseases, such as 
cancer, hepatitis, or rheumatoid arthritis, the compatibility of Diels-Alder hydrogels 
with a model antibody, γ-globulin, was investigated using SDS-PAGE. γ-Globulin is a 
mixture of 80 % IgG (MW: 150 kDa; Rh: 5.3nm), 10 % IgM (MW: 950 kDa; Rh: 
12.7 nm), and less than 10 % IgA (MW: 162 kDa; Rh: 6.5 nm) as declared by the 
manufacturer [124, 165]. IgA is primarily part of the mucosal immunity and only to a 
small extent part of the serum [166]. IgM is the first antibody secreted in case of an 
upcoming infection [166]. IgM monomers are associated to pentamers, making IgM the 
largest antibody in human circulation [166]. IgG covers the largest part of serum 
antibodies [166]. Due to the high specificity, long serum-half lives and the possibility of 
routine production of IgG, some of the most potent drugs are based on IgG [166]. 
However, IgG shows a large number of surface exposed amino acids, which are prone 
to side reactions. For example, about half of the over 80 lysine residues of IgG are 
located on the protein surface [167, 168]. The more nucleophilic cysteine residues are 
on the other hand combined to four pairs of disulfide bonds resulting in less 
accessibility for modifications [167].  
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In Figure 6.3, an acrylamide gel loaded with γ-globulin after incubation with mPEG5k-
maleimide, mPEG5k-furan and mixtures of both polymers in water and PBS is shown 
exemplarily. Protein stock solutions in water and PBS served as a reference. The 
individual components of γ-globulin were separated during electrophoresis. IgM 
migrated least and was detected near to the loading pocket due to its large size. IgG and 
IgA ran almost to the bottom of the gel because of their smaller size. Due to their 
similar size they were not clearly separated in this experimental set up.  
 
Figure 6.3: SDS-PAGE of γ-globulin after incubation in water (lane 1 - 4) and PBS 
(lane 5 - 8). γ-Globulin stock solutions prepared in water (lane 1) and in PBS (lane 5) 
served as a reference. The stock solutions were incubated with mPEG5k-furan 
(lane 2 and lane 6), with mPEG5k-maleimide (lane 3 and lane 7), and with a mixture 
of both polymers (lane 4 and lane 8) at 37 °C for 24 h.  
The quantification of free and modified γ-globulin is shown in Figure 6.4. Free γ-
globulin was defined as the sum of the detected amount of IgG, IgA, and IgM. Modified 
γ-globulin was the sum of all species with higher molecular weight than IgG or IgA 
(except IgM). Modification with mPEG5k-furan depended on the pH of the incubation 
medium (Figure 6.4 A). The amount of free γ-globulin decreased from 97 ± 0.6 % at pH 
4 to 42 ± 2.3 % at pH 9. In pure water 87 ± 2.2 % of γ-globulin was unmodified after 
incubation with mPEG5k-furan. In vivo, furan is metabolized by cytochrome P450 to 
cis-2-butene-1,4-dial, which reacts to pyrrolin-2-one with lysine residues [169]. Under 
certain conditions, ring opening oxidation of furan was also observed in vitro [170, 
171]. This ring opening might have occurred to a certain extent with the used mPEG5k-
furan resulting in the detected side reactions with lysine residues of the protein. After 
incubation with mPEG5k-maleimide, pH dependent modifications were observed 
(Figure 6.4 B). After incubation at pH 4, γ-globulin was completely unaffected, while 
an increasing pH decreased the amount of free γ-globulin to 20 ± 11.8 % at pH 9. This 
can be explained by Michael-type addition reactions of the surface exposed nucleophilic 
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amino acids to the maleimide group of PEG, as already described for lysozyme and α-
CT. The extent of modification after incubation in water (71 ± 5.4 % of free γ-globulin) 
was similar to that at pH 6 (68 ± 3.3 % of free γ-globulin). Incubation with a 
stoichiometric mixture of both polymers also resulted in pH-dependent modifications 
(Figure 6.4 C).  
 
Figure 6.4: Modification of γ-globulin at different pH values analyzed by SDS-PAGE. 
γ-Globulin was incubated with mPEG5k-furan(A), mPEG5k-maleimide (B), and a 
mixture of both polymers (C). The results are shown as means ± standard deviation. 
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At pH 4, no modification was detected; an increasing pH resulted in an increasing 
degree of modification up to almost complete modification at pH 9 (6 ± 6.0 % of free γ-
globulin). A suppression of side reactions by the availability of a reaction partner was 
not observed since Michael-type addition reactions are favored over Diels-Alder 
reactions as already mentioned above. A similar behavior in water and at pH 6 was 
observed in all three cases. Carbon dioxide dissolved in ultrapure water results in 
slightly acidic, but varying pH due to the absence of buffer capacity.  
 
Protein mobility inside the Diels-Alder hydrogels was determined by FRAP in order to 
understand the release behavior of the used proteins [172]. FRAP is a method to 
investigate the diffusion of fluorescently labeled molecules in different tissues and 
materials [173]. For this purpose, the fluorophores are bleached in a defined area of the 
material by a laser. Afterwards the recovery of the fluorescence intensity in the 
photobleached area by diffusion of bleached molecules out of the defined area and 
fluorescent molecules into this area is followed by fluorescence microscopy (Figure 
6.5) [173].  
 
Figure 6.5: Fluorescence recovery after photobleaching. The flash symbolizes the 
process of photobleaching. Example of fluorescence microscope images during a 
typical experiment (A) and schematic diagram of the monitored intensity during an 
experiment (B). The initial intensity before photobleaching is represented by the blue 
line. The decreasing intensity during photobleaching is shown as blue dotted line. 
The green line represents the subsequent fluorescence recovery.  
The fraction of not recovered fluorescence intensity corresponds to the immobile 
fraction, indicating binding of the protein to the hydrogel network [172]. The diffusion 
coefficient is a measure for protein mobility inside the hydrogel.  
Chapter 6 
 
110 
For the following experiments, proteins were labeled with Py1. Py1 is a chameleon 
label, which is blue and almost non-fluorescent in its free form; conjugation to primary 
amines of proteins (in particular ε-amino groups of lysine residues) results in red Py1-
proteins with an excitation wavelength between 470 to 530 nm [174–176]. Dye, which 
is not bound during conjugation or cleaved of during the experiment, was non-
fluorescent and cannot be detected during the measurement. This ensures that the higher 
mobility of the unbound dye is not included in the calculation of mobile fraction and 
diffusion coefficient of the protein.  
The mobile fractions detected in these experiments depended on the pH during cross-
linking (Figure 6.6 A and B).  
 
Figure 6.6: Fluorescence recovery after photobleaching. The mobility of Py1-
lysozyme, Py1-α-CT and Py1-γ-globulin in Diels-Alder hydrogels (10 % polymer 
content) was determined after cross-linking at pH 4 and at pH 7.4. The diagrams 
show the mobile fraction of each protein in hydrogel preparations of 10 kDa (A) and 
20 kDa (B) eight-armed PEG and the diffusion coefficients in hydrogel preparations 
of 10 kDa (C) and 20 kDa (D) eight-armed PEG. The results are shown as 
means ± standard deviation. 
Cross-linking at pH 7.4 resulted in low mobile fractions of 0.16 ± 0.01 (α-CT, 
8armPEG10k-hydrogel) to 0.27 ± 0.03 (lysozyme, 8armPEG20k-hydrogel). After cross-
linking at pH 4, higher mobile fractions of up to 0.84 ± 0.01 (α-CT, 8armPEG20k-
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hydrogel) were detected. As already discussed before, neutral or basic pH conditions 
promote Michael-type addition reactions between proteins and maleimide. These 
Michael-type addition reactions resulted in covalent protein attachment to the hydrogel 
backbone at pH 7.4. In this way, the fraction of mobile proteins was reduced under 
these conditions. Due to less pronounced Michael-type addition reactions at lower pH 
values, less side reactions and a higher mobile fraction were observed at pH 4. The 
molecular weight of PEG (10 kDa or 20 kDa) used for hydrogel preparation did not 
influence the mobile fraction of the incorporated proteins in the conducted experiments.  
As expected, the diffusion coefficients depended on the size of the protein and the mesh 
size of the hydrogel (Figure 6.6 C and D) [177]. Due to the higher molecular weight of 
the macromonomers, the mesh size in 8armPEG20k-hydrogels (12.9 ± 0.6 nm) is larger 
compared to 8armPEG10k-hydrogels (5.5 ± 0.0 nm) [46]. The diffusion coefficients 
calculated for both types of hydrogels and literature values of diffusion coefficients in 
water at 20 °C are shown in Table 6.1.  
Lysozyme is the smallest protein (Rh 2.1 nm) used in this experiment and showed the 
largest diffusion coefficients in all cases. Its hydrodynamic dynamic diameter is smaller 
than the mesh size of the used hydrogels; it was freely moving with almost equal 
diffusion coefficients in 8armPEG10k-hydrogels (D = 18.0 ± 1.6 µm2/s) and 
8armPEG20k-hydrogels (D = 20.8 ± 3.6 µm2/s) after cross-linking at pH 4. After 
crosslinking at pH 7.4, higher diffusion coefficients were determined in 8armPEG20k-
hydrogels (D = 27.2 ± 9.2 µm2/s) compared to 8armPEG10k-hydrogels (D = 12.5 ± 5.7 
µm2/s). The diffusion coefficient of lysozyme in water at 20 °C is about 4-8 times 
higher (~107 µm2/s) compared to the values measured in these experiments [178, 179]. 
Steric and hydrodynamic effects of the cross-linked polymer lower the diffusion 
coefficients of macromolecules incorporated in hydrogels compared to water [177].  
The diffusion of α-CT is limited in 8armPEG10k-hydrogels because the mesh size of 
the hydrogel network is smaller than the hydrodynamic diameter of the protein. In 
8armPEG20k-hydrogels, α-CT should be able to diffuse freely due to the larger mesh 
size. This is reflected by the increase of the diffusion coefficients from 13.4 ± 0.5 µm2/s 
(8armPEG10k-hydrogel) to 18.0 ± 0.6 µm2/s (8armPEG20k-hydrogel) at pH 4 and from 
9.8 ± 1.7 µm2/s (8armPEG10k-hydrogel) to 27.2 ± 3.5 µm2/s (8armPEG20k-hydrogel) 
at pH 7.4. In 8armPEG20k-hydrogels the diffusion coefficient of α-CT and lysozyme 
were nearly the same. This is in good agreement with the values published for 
unhindered diffusion of α-CT and lysozyme in water (Table 6.1). The diffusion 
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coefficient of α-CT in water at 20 °C was about 4 - 11 times higher than in hydrogels 
(~108 µm2/s) [180, 181].  
γ-Globulin moved slower compared to lysozyme and α-CT in all cases due to its larger 
hydrodynamic diameter. This lower mobility is also reflected by the published diffusion 
coefficients in water. The diffusion coefficient of IgG in water at 20 °C is about 
44 µm2/s [182–184]. The diffusion coefficient of IgM (~ 32 µm2/s) and IgA 
(~ 52 µm2/s) in water at 20 °C are slightly different [182]. In 8armPEG20k-hydrogel 
(16.4 ± 1.9 µm2/s at pH 4 and 15.6 ± 1.1 µm2/s at pH 7.4) higher diffusion coefficients 
were observed compared to 8armPEG10k-hydrogels (12.4 ± 2.1 µm2/s at pH 4 and 
5.0 ± 1.1 µm2/s at pH 7.4). The main component of γ-globulin, IgG, has a 
hydrodynamic diameter of about 10.6 nm and is, therefore, able to diffuse freely in 
8armPEG20k-hydrogels (mesh size: 12.9 nm), but not in 8armPEG10k-hydrogels 
(mesh size: 5.5 nm).  
Table 6.1: Diffusion coefficients determined by FRAP experiments. Diffusion 
coefficients of lysozyme, α-CT, and γ-globulin in 8armPEG10k-hydrogels and 
8armPEG20k-hydrogels in comparison to refecerence values and  the corresponding 
hydrodynamic diameter.  
Py1-
protein 
Hydrodynamic 
diameter (dh) 
(nm) 
D in water at 
20 °C 
(µm2/s) 
D in 8armPEG10k-
hydrogels [46] 
(mesh size: 
5.5 ± 0.0 nm)  
(µm2/s) 
D in 8armPEG20k-
hydrogels [46] 
(mesh size: 
12.9 ± 0.6 nm) 
(µm2/s) 
   pH 4 pH 7.4 pH 4 pH 7.4 
Lysozyme 4.2[124, 155] ~ 107[178, 179] 18.0 ± 1.6 12.5 ± 5.7 20.8 ± 3.6 27.2 ± 9.2 
α-CT 5.8[157] ~ 108[180, 181] 13.4 ± 0.5 9.8 ± 1.7 18.0 ± 0.6 27.2 ± 3.5 
γ-
Globulin 
10.6 (IgG) [165] 
25.4 (IgM) [165] 
13.0 (IgA) [165] 
 ~ 44[182–184] 
~ 32[182] 
~ 52[182] 
12.4 ± 2.1 5.0 ± 1.1 16.4 ± 1.9 15.6 ± 1.1 
 
The results of the FRAP experiments showed the dependence of protein mobility on the 
protein size, the mesh size of the hydrogel and the pH during cross-linking. However, 
the influence of swelling and degradation on the release behavior was not taken into 
account by FRAP experiments. It was not possible to study the changing mobility 
during hydrogel swelling using this set up. So, prediction of release kinetics based on 
FRAP experiments was not possible. 
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The suitability of Diels-Alder hydrogels for controlled protein release was investigated. 
To determine the influence of the pH during cross-linking, the hydrogels were prepared 
in PBS (pH 7.0 - 7.2) or ultrapure water, which shows a slightly acidic pH (pH 4 or 
pH 5) due to dissolved carbon dioxide. In order to study the influence of mesh size and 
cross-linking density, 8armPEG10k-hydrogels and 8armPEG20k-hydrogels were used 
in these experiments.  
As already shown by FRAP experiments, the pH during cross-linking influences protein 
mobility in hydrogels. After cross-linking in water, lysozyme was completely released 
from 8armPEG10k-hydrogels within 24 h (94.2 ± 3.4 %) (Figure 6.7 A). The 
hydrodynamic diameter of lysozyme is smaller than the mesh size of the hydrogel; thus, 
lysozyme was able to diffuse freely and was released very fast. SDS-PAGE showed low 
degrees of modification after incubation of lysozyme with the gel precursors in water. 
Consequently low amounts of protein are covalently bound to the hydrogel network as 
verified by high mobile fractions in FRAP experiments. This allowed almost complete 
protein release independent of hydrogel degradation. 
After cross-linking in PBS, lysozyme release proceeded in two steps. After 24 h, 
35.3 ± 4.0 % of the incorporated lysozyme was released in a first burst. Afterwards, no 
further release was observed until a second burst after about 38 d. On day 38 and 42, the 
released amount abruptly increased from 37.0 ± 5.7 % to 74.3 ± 17.6 %. The release 
was completed at the same time as hydrogel degradation after 49 d. This is in line with 
the results obtained by SDS-PAGE (see Chap. 5) and FRAP. In PBS, Michael-type 
addition reactions of nucleophilic amino acids of lysozyme to the maleimide group 
occur to a greater extent than at the slightly acid reaction conditions in water. This led to 
protein attachment to the hydrogel backbone during cross-linking resulting in a low 
mobile fraction, as shown by FRAP. As a consequence, after the first burst release of 
unbound protein, the remaining amount of incorporated lysozyme is released during 
hydrogel degradation. The protein modification by the gel precursors is irreversible, so 
parts of the degraded gel are covalently attached to the protein even after the release is 
completed.  
Similar results were obtained for the release of lysozyme from 8armPEG20k-hydrogels 
(Figure 6.7 B). Cross-linking in water limited side reactions with the gel precursors and 
the largest quantity of lysozyme was released within 24 h. Cross-linking in PBS resulted 
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in covalent attachment of lysozyme to the hydrogel network. During day 14 and 17, 
lysozyme release as well as hydrogel degradation were completed. It must be assumed 
that hydrogel fragments are irreversibly attached to lysozyme even after degradation as 
already mentioned above.   
The release of α-CT from 8armPEG10k-hydrogels after cross-linking in water occurred 
somewhat slower compared to lysozyme, as expected from the diffusion coefficient and 
the slightly higher hydrodynamic diameter (Figure 6.7 C). A large amount 
(54.2 ± 6.2 %) of the incorporated α-CT was released over the first 24 h. The remaining 
amount (79.9 ± 15.7 %) was released during hydrogel swelling and degradation. The 
release was completed after 14 d. The high extent of modification after incubation with 
the gel precursors, as detected by SDS-PAGE, could not be verified. An explanation 
might be the undefined pH of ultrapure water. Due to the absence of buffer capacity, the 
pH might be different in each experiment. After cross-linking in PBS, 14.1 ± 3.1 % of 
the total α-CT amount was released in a first burst within 24 h. Until day 35, the release 
occurred very slowly. Afterwards, a second burst occurred simultaneously with 
hydrogel degradation. During day 35 and day 45, the amount of released α-CT increased 
abruptly from 23.6 ± 1.9 % to 96.0 ± 2.0 %. As detected by SDS-PAGE, incubation of 
α-CT with the gel precursors in PBS resulted in protein modification. These side 
reactions lead to covalent protein binding to the hydrogel backbone, which was also 
reflected in the low mobile fraction determined by FRAP experiments. Parts of the 
hydrogel were probably attached to the protein after degradation controlled release, as 
already mentioned for lysozyme.  
The release profiles of α-CT from 8armPEG20k-hydrogels were similar for both cross-
linking conditions (water or PBS) (Figure 6.7 D). During the first 24 h, 38.1 ± 3.3 % 
(cross-linking in water) and 26.2 ± 6.2 % (cross-linking in PBS) of α-CT was released 
in a first burst. The remaining protein amount was released during hydrogel 
degradation. 8armPEG20k-hydrogels degraded within 17 d (cross-linking in water) and 
27 d (cross-linking in PBS), respectively. The incomplete recovery of α-CT may be 
caused by autolysis of the protein. The release from 8armPEG20k-hydrogels is in good 
agreement with the SDS-PAGE data, which showed almost the same extent of 
modification after incubation of α-CT with the gel precursors in water and PBS. The 
different results after incubation in water may be caused by the varying pH of ultrapure 
water due to the absence of buffer capacity as already mentioned above. In further 
studies, buffer should be used instead of water in all cases to standardize the conditions.  
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No influence of the cross-linking medium was observed for the release of γ-globulin 
from 8armPEG10k-hydrogels (Figure 6.7 E) and 8armPEG20k-hydrogels (Figure 6.7 
F). The hydrodynamic diameter of IgG is larger than the meshes of 8armPEG10k-
hydrogels and about the same size as the meshes of 8armPEG20k-hydrogels; the 
hydrodynamic diameter of IgA and IgM are larger than the meshes of both types of 
Diels-Alder hydrogels. For this reason, release is only possible during swelling and 
degradation, when the mesh size increases. Due to the slow degradation of 
8armPEG10k-hydrogels [46], γ-globulin was released in two steps. First, the release of 
γ-globulin occurred very slowly; 30.1 ± 2.5 % (water) and 38.9 ± 1.3 % (PBS) of the 
incorporated γ-globulin was released after 28 d. During this time, the gel cylinders were 
visually stable. The remaining amount was rapidly released during hydrogel 
degradation. The release was completed after 42 d. 8armPEG20k-hydrogels degrade 
faster [46]; so, γ-globulin was continuously released over 14 d from 8armPEG20k-
hydrogels. Due to the limited mobility of incorporated γ-globulin in all used hydrogel, 
covalent attachment to the hydrogel backbone would not have been detected in this 
experiment. However, irreversible modification of γ-globulin during cross-linking in 
PBS, as already mentioned for lysozyme and α-CT, is very likely. Even for the 
hydrogels prepared in water, the slightly acidic water inside the hydrogel is exchanged 
very fast by the neutral PBS surrounding the hydrogel during incubation. It should be 
kept in mind that Michael-type addition reactions might occur at a later time also after 
cross-linking in water, due to the long residence time of γ-globulin within the gel and 
the described increase of pH. This point should be part of further investigations. The 
release of proteins with attached hydrogel fragments might be problematic, because it 
may result in reduced bioactivity, decreased availability and increased immune 
responses [12, 51]. 
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Figure 6.7: Release of lysozyme (A, B), α-Chymotrypsin (C, D) and γ-globulin (E, F) 
from Diels-Alder hydrogels (10k, 20k).  The total polymer content of 8armPEG10k 
or 8armPEG20k, respectively, was 10 %. Crosslinking occurred in water (filled 
circle) or PBS (open circle). The results are shown as means ± standard deviation. 
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The protein activity after release from a carrier is an important factor in formulation 
development [12]. For this purpose, the activity of lysozyme and α-CT after incubation 
with mPEG5k-maleimide and after release from Diels-Alder hydrogels was 
investigated. For incubation with mPEG5k-maleimide, the same polymer amount was 
used as in SDS-PAGE experiments and, additionally, half and twice the quantity of 
polymer. 
The enzymatic activity of lysozyme decreased from fully retained activity in pure water 
and at pH 4 to 36.0 ± 1.2 % activity after incubation with 3.66 µmol of mPEG5k-
maleimide at pH 9 (Figure 6.8).  
 
Figure 6.8: Activity of lysozyme after incubation with different amounts of mPEG5k-
maleimide. The activity of the lysozyme stock solution was set to 100 %. The results 
are shown as means ± standard deviation.  
The activity after incubation with mPEG5k-maleimide at pH 5, pH 6 and in PBS clearly 
depended on the used polymer amount, i.e., the amount of functional groups. At pH 6, 
for example, the activity decreased from 93.0 ± 2.4 % after incubation with 0.91 µmol 
of mPEG5k-maleimide to 82.5 ± 0.5 % after incubation with 1.83 µmol of mPEG5k-
maleimide and 62.2 ± 1.1 % after incubation with 3.66 µmol of mPEG5k-maleimide, 
respectively. Lysozyme is known for loss of activity after covalent attachment of PEG 
chains [35, 84]. The observed decrease in activity after incubation with mPEG5k-
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maleimide is caused by attachment of PEG chains due to Michael-type addition 
reactions of nucleophilic amino acids with maleimide as already described.  
On the basis of all results obtained before, pH 4 was used during hydrogel preparation 
for the following release experiments (Figure 6.9). After incorporation in 
8armPEG20k-hydrogels, the amount released after 24 h showed an activity of 
97.1 ± 3.3 % compared to stock solution. The activity of lysozyme after incorporation in 
8armPEG10k-hydrogels was somewhat lower (70.8 ± 4.6 %). This might be due to the 
double amount of functional groups in 8armPEG10k-hydrogels at equal polymer 
content and the resulting higher risk for side reactions [46]. Altogether, using pH 4 
during cross-linking resulted in restricted side reactions and mostly retained activity of 
lysozyme after release.  
 
Figure 6.9: Activity of lysozyme after release from 8armPEG10k-/8armPEG20k-Diels-
Alder hydrogels (10k and 20k). The results are shown as means ± standard deviation. 
α-CT was more sensitive to varying pH conditions than lysozyme. Incubation of α-
CT at different pH values resulted in different activities (Figure 6.10). Therefore, all 
activities were normalized to the highest activity detected (pH 4). With increasing pH, 
the activity of the stock solution decreased to only 3.8 ± 0.1 % at pH 9. α-CT is known 
for low enzymatic activity at basic pH conditions (≥ pH 8.5) [158]. The conjugation of 
PEG chains by Michael-type addition reactions during incubation, on the other hand, 
resulted in increased activity compared to the stock solution. After incubation in PBS, 
for example, the stock solution showed an activity of 27.9 ± 2.2 %, while the activity of 
the protein polymer mixture varied between 87.5 ± 2.3 % - 91.4 ± 5.1 %. Rodríguez-
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Martínez et al. described the protection of α-CT by attached PEG chains against thermal 
inactivation during incubation at 45 °C [185]. This might explain the higher activity of 
α-CT after modification with mPEG5k-maleimide compared to the unmodified 
reference.  
 
Figure 6.10: Activity of α-CT after 24h of incubation with different amounts of 
mPEG5k-maleimide. The activity of the stock solution with the highest activity after 
incubation (pH 4) was set to 100%. The results are shown as means ± standard 
deviation. 
Similar results were obtained for α-CT released from Diels-Alder hydrogels (Figure 
6.11). The amount released after 24 h showed an activity of 136.6 ± 4.4 % 
(8armPEG10k-hydrogels) and 168.9 ± 6.0 % (8armPEG20k-hydrogels), respectively. 
Free α-CT in solution shows autolysis resulting in decreased activity. PEGylation or 
immobilization in hydrogels or polymer matrices has successfully been used to improve 
the stability of α-CT and retain the activity [185–187]. The higher activity of α-CT 
released from Diels-Alder hydrogels might be explained by stabilization of proteins in 
hydrogels compared to proteins stored in solution [188].  
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Figure 6.11: Activity of α-CT after release form Diels-Alder hydrogels related to a 
reference solution. The results are shown as means ± standard deviation. 
 
The aim of this chapter was to investigate the suitability of Diels-Alder hydrogels as 
carrier for controlled delivery of protein drugs. The release kinetics could be modified 
by varying the network mesh size relative to the protein size. The enzymatic activity of 
the proteins after release could be almost completely retained or even increased by 
incorporating in the hydrogel compared to the reference solution. A slightly acidic pH 
was essential to prevent protein immobilization and inactivation during cross-linking. 
As already shown in Chap. 5, the pH during cross-linking of Diels-Alder hydrogels 
plays an important role with regard to side reactions with incorporated proteins. 
Especially at neutral or basic pH, Michael-type addition reactions of nucleophilic amino 
acids of the incorporated protein to maleimide are favored over Diels-Alder reactions. 
In line with the results obtained after incubation of lysozyme with mPEG5k-maleimide, 
α-CT and γ-globulin were modified depending on the pH conditions during incubation 
with mPEG5k-maleimide. The detected side reactions resulted in covalent protein 
attachment to the hydrogel backbone during cross-linking and influenced the protein 
mobility in the hydrogel, release profiles and activity of the released protein. Decreasing 
the pH during cross-linking prevented covalent protein binding via Michael-type 
addition reactions. This led to higher protein mobility inside the hydrogel and 
unhindered protein release, and helped to retain protein activity after release. However, 
protein integrity and stability should be kept in mind and investigated during 
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formulation development for each protein and pH value. Furthermore, there may be 
further strategies besides choosing the “right” pH value during cross-linking to prevent 
irreversible covalent protein binding. Removing the protein from the reaction site, for 
example by protein precipitation before cross-linking, could be one possibility. Further 
studies focusing on these strategies should be taken into consideration. 
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The goal of this thesis was the development of suitable hydrogel formulations for the 
controlled delivery of protein drugs. In particular, consideration was given to protein 
integrity and activity during cross-linking and after release. For this purpose, two 
different strategies to tailor protein release were investigated; on the one hand, the 
reversible covalent attachment of proteins to the hydrogel backbone, on the other hand, 
the tailoring of the mesh size relative to the protein size.   
The reversible linking of the model protein, lysozyme, was realized using hydrolytically 
cleavable carbamates. First, the suitability of click hydrogels as model systems for 
linker incorporation and release experiments was investigated. As expected, the 
incorporation of protein and linker caused defects in the hydrogel structure resulting in 
significant lower absolute values of complex shear modulus and increased swelling 
compared to the reference gels without linker (Chap. 2). However, working with linkers 
would cause network defects in every hydrogel formulation. So, due to their still low 
swelling, high stiffness, fast gelation and non-degradability, click hydrogels were 
ideally suitable as model system to determine release kinetics without the influence of 
swelling or degradation. Nevertheless, the influence of the linker on gel properties 
should be kept in mind for formulation development for clinical applications. 
In Chapter 3 the suitability of carbamate linkers to control protein release was studied. 
SDS-PAGE experiments demonstrated that the kinetics of linker hydrolysis could 
successfully be controlled by the substitution pattern of the aromatic group. Depending 
on the used linker, linker hydrolysis took between 24 h and 28 d. This was in good 
agreement with the obtained release data; depending on the used linker, lysozyme 
release from click hydrogels lasted up to 21 d.  
CD spectroscopy indicated structural integrity of the secondary structure of lysozyme 
after PEGylation and De-PEGylation. As verified by SDS-PAGE only the three surface 
lysine residues were modified due to the mild PEGylation conditions preventing 
structural damage. After PEG chain elimination the activity of lysozyme was restored to 
73.4 % - 92.5 %, once more indicating structural integrity after cleaving off the linker 
group. However, PEGylation with the used carbamate linkers was not fully reversible. 
A maximum of 60 % of the initial dose was recovered during release. SDS-PAGE 
experiments provided similar results; here a recovery of maximal 63 % of free lysozyme 
was detected. This irreversible PEGylation may be caused by aliphatic non-degradable 
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site products of linker synthesis. In clinical application of degradable hydrogel systems 
this might cause release of protein irreversibly modified with polymer chains of the 
degraded hydrogel. Undefined limited activity would be the consequence. Another 
possible explanation might be the formation of protein aggregates due to reactions of 
the isocyanate formed during linker hydrolysis. In fact, lysozyme aggregates were 
identified by SDS-PAGE during PEG chain elimination. The presence of aggregates 
may result in immune response and would prevent application in humans. Further 
investigations should focus on the reason for incomplete PEG chain elimination and 
protein release and possibilities to prevent this phenomenon.  
For additional analytics of PEG chain elimination a SEC method was established 
allowing automated sampling and standardized data evaluation and quantification 
(Chap. 4). A special manufactured heating device permitted real-time sampling. This 
method confirmed the elimination kinetics determined by SDS-PAGE. Elimination of 
Linker 2a was completed after about 26 h. As already described above, PEGylation as 
well as PEG chain elimination were incomplete. In contrast to SDS-PAGE experiments, 
no lysozyme aggregates during PEGylation and PEG chain elimination were observed 
using SEC. The drawback of this experimental setup was the column degradation after 
about 160 injections. For future experiments, sample purification would be a possibility 
to overcome this issue.  
 
The second strategy, tailoring release kinetics via the hydrodynamic diameter of the 
drug and hydrogel mesh size was realized using Diels-Alder hydrogels. In order to vary 
the mesh size and hydrogel degradation, PEG derivatives with two different molecular 
weights (10 kDa and 20 kDa) were used. With regard to protein integrity, the Diels-
Alder precursor maleimide and furan were compared to other common cross-linking 
mechanisms (Chap. 5). The study showed side reactions of all tested gel precursors. 
Nucleophilic amino acids, especially lysine, were modified pH-dependent in Michael-
type addition reactions by maleimide, vinyl sulfone and acrylamide groups. Especially 
increased pH values promoted these unintended side reactions. mPEG6k-thiol resulted 
in pH-independent thiol-disulfide exchange reactions with cysteine residues. The 
incubation with mixtures of cross-linking partners only partially reduced protein 
modification. In some cases even higher degree of modification was observed. The 
degree of lysozyme modification ranged between slight PEGylation with 2 polymer 
chains and 88 ± 1.9 % lysozyme remaining unmodified (after incubation with a mixture 
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of mPEG5k-acrylamide and mPEG6k-thiol at pH4) to complete modification with up to 
seven PEG chains (after incubation with a mixture of mPEG5k-vinyl sulfone and 
mPEG6k-thiol at pH 9).  
The extent of modification not only depends on the pH and the used functionalization 
but also on the protein. Incubation of α-CT and γ-globulin with the Diels-Alder 
precursors, mPEG5k-furan and mPEG5k-maleimide, resulted in modifications varying 
between 0 % and 89 ± 5.5 % depending on the pH and polymer functionalization 
(Chap. 6). The degree of modification would be different for each formulation and each 
incorporated drug and would require individual investigations. However, especially the 
modification of amino acids located inside the tertiary structure would result in 
structural breakdown associated with loss of activity, decreased availability and 
unintended immune response. Furthermore, modifications lead to covalent protein 
attachment to the hydrogel backbone limiting protein mobility and subsequent release. 
This was verified by FRAP and release experiments using Diels-Alder hydrogels 
(Chap. 6). For lysozyme for example, covalent attachment at pH 7.4 resulted in low 
mobile fractions of 0.21 ± 0.01 (8armPEG10k-hydrogel), while pH 4 prevented side 
reactions resulting in higher mobile fractions of 0.71 ± 0.02 (8armPEG10k-hydrogel). 
Release experiments showed similar results; cross-linking in slightly acidic water 
resulted in almost complete lysozyme release within 24 h with almost retained protein 
activity. Using PBS, release occurred in two steps associated with ongoing hydrogel 
degradation. However, one has to keep in mind that there is a very fast exchange of 
medium between the hydrogel and the surrounding resulting in pH shifts. For this 
reason, reactions between the protein and the polymer might also be possible to a later 
point of time. However, protein mobility and release were successfully controlled by the 
mesh size of the Diels-Alder hydrogel. For example, γ-globulin was released in two 
steps over 42 d from 8armPEG10k-hydrogels. The release from 8armPEG20k-
hydrogels occurred continuously within 28 d.  
 
Overall, two different strategies, reversible covalent protein attachment via carbamate 
linkers and tailoring the hydrogel mesh size relative to the protein size, were 
investigated and successfully used to control the release of proteins; each one with 
individual benefits and drawbacks. For both strategies discussed here, irreversible 
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protein modifications represent the risk of immune reactions and restricted activity. 
However, on the other hand Diels-Alder hydrogels offered protection and stabilization 
to the protein as indicated by increasing activity of α-CT after release.  
Complete prevention of side reactions between protein and polymer, complete absence 
of protein aggregation and the maintenance of therapeutic activity is the key challenge 
for the development of protein formulations. These points should be addressed in 
further studies in order to optimize the presented hydrogel formulation and to remove 
the remaining concerns. 
For this purpose, careful evaluation of the formulation using reliable protein analytic is 
of great importance. Establishing suitable assays addressing protein quantification, 
activity and integrity of the protein can be tricky, but is essential for successful 
formulation development and should be one of the key aspects of further investigations.  
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